PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 2566907-3 1989 We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Agar 291-295 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 2565034-10 1989 Using oligonucleotides as probes, the neu gene in the foci was found to carry a single-point mutation identical to the one previously found in the rat neuroblastoma and glioblastoma induced by the ethylnitrosourea. Oligonucleotides 6-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-41 2565034-10 1989 Using oligonucleotides as probes, the neu gene in the foci was found to carry a single-point mutation identical to the one previously found in the rat neuroblastoma and glioblastoma induced by the ethylnitrosourea. Ethylnitrosourea 197-213 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-41 2566907-3 1989 We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Agar 291-295 erb-b2 receptor tyrosine kinase 2 Mus musculus 181-185 3476947-0 1987 Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. Ethylnitrosourea 130-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-13 2565807-1 1989 The neu oncogene, characterized by Weinberg and colleagues, is a transforming gene found in ethylnitrosourea-induced rat neuro/glioblastomas; its human proto-oncogene homologue has been termed erbB2 or HER2 because of its close homology with the epidermal growth factor receptor (EGF-R) gene (c-erbB1). Ethylnitrosourea 92-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-7 3072904-0 1988 Amino acid and sugar transport in mouse 3T3 cells expressing activated ras and neu oncogenes. Sugars 15-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-82 3476947-8 1987 The normal cellular neu sequence for the transmembrane region, but not the mutated sequence, was identified in DNA from all 11 gliomas surveyed by oligonucleotide hybridization. Oligonucleotides 147-162 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-23 2860972-5 1985 Anchorage-independent growth of cells from the ethylnitrosourea-induced rat neuroblastoma line in which neu was originally detected by DNA transfection is also inhibited in the presence of anti-p185 monoclonal antibodies. Ethylnitrosourea 47-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-79 3001730-4 1986 Amplification of the proto-neu gene in NIH 3T3 cells by means of cotransfection with a dihydrofolate reductase gene resulted in methotrexate-resistant colonies that produce high levels of normal neu-encoded p185 protein. Methotrexate 128-140 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-30 3001730-4 1986 Amplification of the proto-neu gene in NIH 3T3 cells by means of cotransfection with a dihydrofolate reductase gene resulted in methotrexate-resistant colonies that produce high levels of normal neu-encoded p185 protein. Methotrexate 128-140 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-198 3945311-1 1986 The neu oncogene is repeatedly activated in neuro- and glioblastomas derived by transplacental mutagenesis of the BDIX strain of rat with ethylnitrosourea. Ethylnitrosourea 138-154 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-16 33980613-0 2021 Visualization of intra-tumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. [fam-] trastuzumab deruxtecan 49-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-97 34039018-10 2021 RIPC-induced Nrg1beta interacts with endothelial ErbB2 and thereby prevents its degradation. ripc 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-54 33980613-0 2021 Visualization of intra-tumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. trastuzumab deruxtecan 80-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-97 33936816-0 2021 Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer. Sunitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 34003256-4 2021 Here, we use a CRE-activated HER2 orthologue to specifically target HER2/ERBB2 oncogenic activity to basal or luminal ER- mammary epithelial cells and perform a detailed analysis of the tumours that develop. Phenobarbital 110-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 34003256-4 2021 Here, we use a CRE-activated HER2 orthologue to specifically target HER2/ERBB2 oncogenic activity to basal or luminal ER- mammary epithelial cells and perform a detailed analysis of the tumours that develop. Phenobarbital 110-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 34003256-4 2021 Here, we use a CRE-activated HER2 orthologue to specifically target HER2/ERBB2 oncogenic activity to basal or luminal ER- mammary epithelial cells and perform a detailed analysis of the tumours that develop. Phenobarbital 110-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-78 33663521-0 2021 Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Losartan 10-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 33742099-5 2021 Modifications to the tumor immune microenvironment contributed to the antitumor activity of our combination immunotherapy, as intratumoral CAdTrio treatment induced chemotaxis to enable HER2.CART migration to the tumor site. cadtrio 139-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 186-190 33859761-10 2021 Subsequently, the in vivo distribution was evaluated by optical molecular imaging and ex vivo by tissue biodistribution and tumor immunohistochemical analysis after intravenous injection of IRDye800-conjugated nanobodies in mice bearing HER2-positive subcutaneous xenografts. IRDye800 190-198 erb-b2 receptor tyrosine kinase 2 Mus musculus 237-241 33663521-0 2021 Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Losartan 10-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-105 33663521-5 2021 We therefore hypothesized that by modifying tumor stroma and increasing oxygenation, losartan will improve the outcome of radiotherapy and inhibit disease progression in a highly metastatic HER2/neu + murine BC model. Losartan 85-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 190-194 33663521-13 2021 Our findings suggest that combining losartan with radiotherapy is a potential new treatment strategy for local control and inhibiting metastasis in HER2 + BC. Losartan 36-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-152 33506582-0 2021 Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis. Propofol 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-74 33506582-12 2021 Propofol suppressed lung cancer cell progression by regulating circ-ERBB2. Propofol 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 33506582-15 2021 Moreover, circ-ERBB2 knockdown enhanced the suppressive effect of propofol on tumor growth in vivo. Propofol 66-74 erb-b2 receptor tyrosine kinase 2 Mus musculus 15-20 33506582-16 2021 CONCLUSIONS: Propofol inhibited lung cancer progression via mediating circ-ERBB2/miR-7-5p/FOXM1 axis, which might provide an effective therapeutic target for lung cancer therapy. Propofol 13-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 33295756-4 2021 Precise labeling of THIOMAB-TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. 1,2,3,4-tetrazine 67-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 151-155 33525578-8 2021 In vivo studies demonstrated HER2-specific uptake of all 177Lu-labeled probes in xenografts in a pretargeting setting. Lutetium-177 57-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 33479914-0 2021 Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex. (i)-tricarbonyl complex 129-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-15 33479914-2 2021 Our aim was to introduce hexahistidine (His6) peptides into pertuzumab Fab to enable labeling with the [99mTc(CO)3(H2O)3]+ complex and study these radioimmunoconjugates for microSPECT/CT imaging of HER2-positive tumor xenografts in mice. His-His-His-His-His-His 25-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 198-202 33479914-2 2021 Our aim was to introduce hexahistidine (His6) peptides into pertuzumab Fab to enable labeling with the [99mTc(CO)3(H2O)3]+ complex and study these radioimmunoconjugates for microSPECT/CT imaging of HER2-positive tumor xenografts in mice. His-His-His-His-His-His 40-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 198-202 33574346-6 2021 In a preclinical therapeutic study, mice (n = 4-7/group) bearing HER2+ xenografts exhibited a 67Cu-dose dependent tumor-growth inhibition from 67Cu-labeled-Pertuzumab co-administered with trastuzumab. Copper-67 94-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 33574346-6 2021 In a preclinical therapeutic study, mice (n = 4-7/group) bearing HER2+ xenografts exhibited a 67Cu-dose dependent tumor-growth inhibition from 67Cu-labeled-Pertuzumab co-administered with trastuzumab. Copper-67 143-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 33572976-7 2021 In a tumor cell line xenograft mouse model, therapeutic intervention with nanoscale complexes based on polyethylenimine (PEI) for siRNA delivery, again reveals HER3 upregulation upon HER2 single knockdown and a therapeutic benefit from combination therapy. Polyethyleneimine 103-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-187 33572976-7 2021 In a tumor cell line xenograft mouse model, therapeutic intervention with nanoscale complexes based on polyethylenimine (PEI) for siRNA delivery, again reveals HER3 upregulation upon HER2 single knockdown and a therapeutic benefit from combination therapy. Polyethyleneimine 121-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-187 33367431-5 2021 Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. 1,2,3,4-tetrazine 76-85 erb-b2 receptor tyrosine kinase 2 Mus musculus 222-226 33367431-5 2021 Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Boron 101-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 222-226 33367431-5 2021 Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Carbon 112-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 222-226 33295756-8 2021 Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of 111In-DOTA-Tz on HER2+ tumors. 111in-dota-tz 113-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 33436496-7 2022 HER2 targeting in combination with phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase kinase (MEK) inhibitors induces CR-CSC death and regression of tumour xenografts, including those carrying Kras and Pik3ca mutation. Chromium 141-143 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 33747866-0 2021 The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells. Curcumin 58-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-98 33188406-0 2021 Combined Broccoli Sprouts and Green Tea Polyphenols Contribute to the Prevention of Estrogen Receptor-Negative Mammary Cancer via Cell Cycle Arrest and Inducing Apoptosis in HER2/neu Mice. Polyphenols 40-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 33188406-13 2021 CONCLUSIONS: Collectively, lifelong BSp and GTP administration can prevent estrogen receptor-negative mammary tumorigenesis through cell cycle arrest and inducing apoptosis in HER2/neu mice. bsp 36-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-180 33188406-13 2021 CONCLUSIONS: Collectively, lifelong BSp and GTP administration can prevent estrogen receptor-negative mammary tumorigenesis through cell cycle arrest and inducing apoptosis in HER2/neu mice. Guanosine Triphosphate 44-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-180 33747866-5 2021 Results: Curcumin, PGV-0, and PGV-1 exhibited cytotoxic effect against HER2-overexpressing breast cancer cells. Curcumin 9-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 33747866-1 2021 Purpose: The current study aims to evaluate the in vitro cytotoxic and cell migration effects of synthetic curcumin and its analogues on HER2 and nuclear factor kappa B (NFkappaB) pathways, as well as the in vivo inhibitory effect on cancer growth of metastatic breast cancer. Curcumin 107-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-141 33747866-5 2021 Results: Curcumin, PGV-0, and PGV-1 exhibited cytotoxic effect against HER2-overexpressing breast cancer cells. pgv-0 19-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 33382695-3 2020 We evaluated the impact of broccoli sprouts (BSp), green tea polyphenols (GTPs) and their combination on the gut microbiota and SCFAs metabolism from the microbiota in Her2/neu transgenic mice that spontaneously develop estrogen receptor-negative [ER(-)] mammary tumors. Fatty Acids, Volatile 128-133 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-172 33747866-7 2021 Curcumin and PGV-0 inhibited membrane localization of HER2. Curcumin 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-58 33747866-7 2021 Curcumin and PGV-0 inhibited membrane localization of HER2. pgv-0 13-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-58 33842876-13 2021 Treatment of Neu+ mice with DMAPT significantly restored grip strength (205+-6 g force), rotarod performance (74+-8.5 seconds), reversed molecular alterations associated with skeletal muscle aging, reduced circulating Ccl11 (1083.26 +-478 pg/ml), and improved animal survival. LC-1 compound 28-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-16 33876707-6 2021 We showed that expression of EGFR, HER2 and HER3 was increased in these gemcitabine-resistant pancreatic cancer models, and that an antibody mixture against all three receptors inhibited tumor growth in mice and downregulated HER receptors. gemcitabine 72-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 33876707-8 2021 The mixture of anti-EGFR, HER2 and HER3 antibodies is a good candidate therapeutic approach for gemcitabine-sensitive and -resistant pancreatic cancer. gemcitabine 96-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 33376321-17 2020 Chemical-photothermal therapy of Her2-targeted NPs has a good antitumor effect in the BT474 nude mice model. bt474 86-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 33415001-2 2020 In NeuT mice, a preclinical model or Her2-positive breast cancer, we previously reported that p140Cap counteracts Her2-dependent breast cancer progression, associating with the specific Rac1 Guanine Nucleotide Exchange Factor, Tiam1, and limiting the activation of both Tiam1 and Rac1. Guanine Nucleotides 191-209 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-118 33378043-10 2020 HER2-overexpressed cell line SK-BR-3 proliferation was stronger when suppressed by RC48-ADC than by the naked antibody. rc48-adc 83-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 33261651-4 2020 RESULTS: The specific accumulation of H2.1MS1 spheres was demonstrated at the site of Her2-positive cancer. Deuterium 38-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 33261651-5 2020 Dox delivered only by functionalized H2.1MS1 particles selectively inhibited Her2-positive cancer growth in primary and metastatic models. Doxorubicin 0-3 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-81 33261651-3 2020 Herein, we examined in vivo models to determine the efficacy of Her2-targeting silk spheres (H2.1MS1) as DDSs for delivering doxorubicin (Dox) to Her2-positive and Her2-negative primary and metastatic mouse breast cancers. Doxorubicin 125-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-68 33261651-3 2020 Herein, we examined in vivo models to determine the efficacy of Her2-targeting silk spheres (H2.1MS1) as DDSs for delivering doxorubicin (Dox) to Her2-positive and Her2-negative primary and metastatic mouse breast cancers. Doxorubicin 138-141 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-68 32822867-4 2020 Acetylshikonin was identified as the main bioactive component in extracts and was responsible for the antitumor activity observed, being able to decrease BC cell viability and to interfere with autochthonous mammary carcinogenesis in Delta16HER2 transgenic mice. acetylshikonin 0-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 241-245 32822867-5 2020 Acetylshikonin anticancer effect depends on its ability to act as a potent inhibitor of Dihydrofolate Reductase (DHFR), to down-regulate key mediators governing cancer growth and progression, such as HER2, Src and STAT3, and to induce apoptosis by caspase-3 activation. acetylshikonin 0-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 200-204 32548701-10 2020 Studies at the cellular level revealed that high glucose potentiated EGFR/EGF receptor 2 (ErbB2)-induced stimulation of SRF activity, enhancing the graded signalling responses to EGF, via the EGFR/ErbB2-ROCK-actin-MRTF pathway and promoted mitochondrial dysfunction. Glucose 49-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-95 33019652-5 2020 The combination treatment of NER and CBZ significantly inhibited proliferation and migration in ERBB2+ cell lines and reduced the organoid growth in vitro. neratinib 29-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 33019652-5 2020 The combination treatment of NER and CBZ significantly inhibited proliferation and migration in ERBB2+ cell lines and reduced the organoid growth in vitro. cabozantinib 37-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 33046724-11 2020 HER2 receptors expression were markedly reduced in 5-FU-SLN4 treated mice compared with 5FU and liver and kidney tissues showed no toxicity at dose of 20 mg/kg. Fluorouracil 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 32548701-10 2020 Studies at the cellular level revealed that high glucose potentiated EGFR/EGF receptor 2 (ErbB2)-induced stimulation of SRF activity, enhancing the graded signalling responses to EGF, via the EGFR/ErbB2-ROCK-actin-MRTF pathway and promoted mitochondrial dysfunction. Glucose 49-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 197-202 32787284-3 2020 This study combines the cytotoxic alpha-particle emitter bismuth-213 (213Bi) and HER2-targeting sdAbs. sdabs 96-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-85 32929154-5 2020 Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. ruxolitinib 60-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-193 32929154-5 2020 Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 76-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-193 32929154-5 2020 Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. sonidegib 124-133 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-193 32306807-0 2020 Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Deruxtecan 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 32306807-0 2020 Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. t-dxd 44-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 32306807-0 2020 Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. t-dxd 44-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 32306807-1 2020 Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7-8 with the topoisomerase I inhibitor DXd. Deruxtecan 12-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 32787284-6 2020 Finally, the therapeutic efficacy and potential associated toxicity of [213Bi]Bi-DTPA-2Rs15d was evaluated in a HER2pos tumor model that manifests peritoneal metastasis. bi-dtpa-2rs15d 78-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-116 32898439-0 2020 The Potential Usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice. Serine 41-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-81 32898439-2 2020 The aim of this study was to evaluate the potential usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY peptide for detecting HER2 alteration after paclitaxel therapy of ovarian tumor xenografts in nude mice. Paclitaxel 136-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-118 32787284-7 2020 In vitro, [213Bi]Bi-DTPA-2Rs15d bound HER2pos cells in a HER2-specific way. bi-dtpa 17-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-42 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Paclitaxel 44-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Paclitaxel 44-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 32787284-7 2020 In vitro, [213Bi]Bi-DTPA-2Rs15d bound HER2pos cells in a HER2-specific way. bi-dtpa 17-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Paclitaxel 44-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 32787284-13 2020 These results indicate the potential of [213Bi]Bi-DTPA-sdAb as a new radioconjugate for TAT, alone and as an add-on to trastuzumab for the treatment of HER2pos metastatic cancer. bi-dtpa-sdab 47-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-156 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Serine 149-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 32463664-5 2020 Noteworthy, HApDC exhibited excellent in vivo tumor inhibition function with much lower healthy organ toxicity compared with the free drug, which might be explained by the persistently targeted DM1 delivery attributed to the remained HER2 levels on cells. cantuzumab mertansine 194-197 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-238 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Serine 149-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 32898439-11 2020 Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC. Serine 149-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 32792841-0 2020 Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. neratinib 26-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 32792841-0 2020 Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. neratinib 137-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 32792841-2 2020 Neratinib, an irreversible tyrosine kinase inhibitor is used to treat HER2 positive cancers. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 32792841-3 2020 Neratinib targets HER2 and blocks its signal transduction resulting in inhibition of cell proliferation and induction of apoptosis without any information about the molecular mechanism involved. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 32757877-4 2022 Using the same basic protocol as the control group, the specific ErbB2 inhibitor mubritinib (TAK 165) was added to block the neuregulin-1/ErbB pathway in the TAK 165 group, while HRG was not added in the HRG-off group. TAK-165 81-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-70 32898333-0 2020 Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. pyrotinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 32417267-6 2020 Importantly, HER2 x mPEG BsAb plus Lipo-Dox significantly suppressed tumor growth as compared to control BsAb plus Lipo-Dox in MCF7/HER2 tumor-bearing mice. monomethoxypolyethylene glycol 20-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 32417267-6 2020 Importantly, HER2 x mPEG BsAb plus Lipo-Dox significantly suppressed tumor growth as compared to control BsAb plus Lipo-Dox in MCF7/HER2 tumor-bearing mice. Doxorubicin Hydrochloride 35-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 32417267-6 2020 Importantly, HER2 x mPEG BsAb plus Lipo-Dox significantly suppressed tumor growth as compared to control BsAb plus Lipo-Dox in MCF7/HER2 tumor-bearing mice. Doxorubicin Hydrochloride 115-123 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 32417267-7 2020 These results indicate that HER2 x mPEG BsAb can enhance tumor accumulation of mPEG-liposomes to improve the therapeutic efficacy of combination treatment. monomethoxypolyethylene glycol 35-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-32 32417267-7 2020 These results indicate that HER2 x mPEG BsAb can enhance tumor accumulation of mPEG-liposomes to improve the therapeutic efficacy of combination treatment. monomethoxypolyethylene glycol 79-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-32 31919745-2 2020 METHODS: In animal studies, micro-PET imaging and bio-distribution were performed to examine the specificity of 124I-trastuzumab in HER2-positive and HER2-negative mouse models. Nalpha-(2-naphthylsulfonyl)-3-amidinophenylalanine-carboxymethylpiperazide 112-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-136 32330574-11 2020 RESULTS: The selected nanobodies remained functional after conjugation to the PS, binding specifically and with high affinity to HER2-positive cells. ps 78-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 32330574-12 2020 Both nanobody-PS conjugates potently and selectively induced cell death of HER2 overexpressing cells, either sensitive or resistant to trastuzumab, with low nanomolar LD50 values. ps 14-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 32651443-0 2020 Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model. Doxorubicin 32-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-136 32651443-2 2020 The standard of care in the neoadjuvant setting for HER2-positive breast cancer is a combination of highly cytotoxic drugs such as anthracyclines and the anti-HER2 monoclonal antibody. Anthracyclines 131-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-56 32764923-11 2020 These results set the stage for preclinical studies of cardio and hepatoprotection in HER2+ breast cancer-bearing mice treated with Doxorubicin and Trastuzumab. Doxorubicin 132-143 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 32592121-24 2020 CONCLUSIONS: This protocol can provide high contrast images of tumors expressing ER or HER2 within 3 days from injection of 4FMFES to final scan of 89Zr-T and, hence, provides a basis for future dual-tracer combinations that include antibodies. 4fmfes 124-130 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 32636633-2 2020 For HER2 breast cancer, melatonin, estrogen, and progesterone delayed tumor onset and reduced tumor incidence in neu female mice. Melatonin 24-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-8 32636633-2 2020 For HER2 breast cancer, melatonin, estrogen, and progesterone delayed tumor onset and reduced tumor incidence in neu female mice. Progesterone 49-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-8 32034078-9 2020 The combination of neratinib and trastuzumab in vivo was more effective compared with single-agent neratinib or trastuzumab and was associated with more robust inhibition of HER2 and downstream signaling. neratinib 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 32276005-1 2020 Here, we report rationally engineered peptide-targeted liposomal doxorubicin nanoparticles that have an enhanced selectivity for HER2-positive breast tumor cells with high purity, reproducibility, and precision in controlling stoichiometry of targeting peptides. Doxorubicin 65-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 32276005-6 2020 These results were consistent with in vivo efficacy outcomes that ~90% tumor growth inhibition was achieved by Dox-loaded HER2 receptor targeted nanoparticles, TNPHER2pep, over control while all nanoparticle formulations minimized overall systemic toxicity relative to free Dox. Doxorubicin 111-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-126 32279037-0 2020 In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Quinazolines 34-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 32423101-0 2020 Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells. Curcumin 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-80 32392822-7 2020 The Oli-neu secretome regulates astrocyte genes known to modulate neuronal synaptic transmission and remodels calcium, chemokine, NOD-like receptor, PI3K-Akt, and thyroid hormone signaling, as well as actin-cytoskeleton, autophagy, cell cycle, and circadian rhythm pathways. Calcium 110-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 8-11 32329582-3 2020 We show here that the anti-HER3 antibody-drug conjugate EV20/MMAF exerted potent anti-tumoral properties against several models of primary resistance and secondary resistance to common anti-HER2 available therapies, including trastuzumab, lapatinib, neratinib, and trastuzumab-emtansine. ev20 56-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 190-194 32329582-3 2020 We show here that the anti-HER3 antibody-drug conjugate EV20/MMAF exerted potent anti-tumoral properties against several models of primary resistance and secondary resistance to common anti-HER2 available therapies, including trastuzumab, lapatinib, neratinib, and trastuzumab-emtansine. MMAF 61-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 190-194 32329582-5 2020 In mice injected with trastuzumab-resistant HER2+ cells, a single dose of EV20/MMAF caused complete and long-lasting tumor regression. ev20/mmaf 74-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 32267710-4 2020 In the synthesis, photosensitive pyropheophorbide a (Pyro) is modified with a PEG linker (molecular weight of 727 Da) and then site-specifically coupled to the anti-HER2 ZHER2:2891 affibody protein to provide a homogeneous protein-coupled photosensitizer via a convenient process. pyropheophorbide a 33-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 32267710-4 2020 In the synthesis, photosensitive pyropheophorbide a (Pyro) is modified with a PEG linker (molecular weight of 727 Da) and then site-specifically coupled to the anti-HER2 ZHER2:2891 affibody protein to provide a homogeneous protein-coupled photosensitizer via a convenient process. pyropheophorbide a 53-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 32267710-4 2020 In the synthesis, photosensitive pyropheophorbide a (Pyro) is modified with a PEG linker (molecular weight of 727 Da) and then site-specifically coupled to the anti-HER2 ZHER2:2891 affibody protein to provide a homogeneous protein-coupled photosensitizer via a convenient process. Polyethylene Glycols 78-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 32381043-9 2020 Consequently, the association between SH3BGRL and HER2 contributed to the prolonged HER2 phosphorylation at specific tyrosine sites, especially at Y1196, and their downstream signaling activation. Tyrosine 117-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 32381043-9 2020 Consequently, the association between SH3BGRL and HER2 contributed to the prolonged HER2 phosphorylation at specific tyrosine sites, especially at Y1196, and their downstream signaling activation. Tyrosine 117-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 32381043-9 2020 Consequently, the association between SH3BGRL and HER2 contributed to the prolonged HER2 phosphorylation at specific tyrosine sites, especially at Y1196, and their downstream signaling activation. decyl 4-hydroxybenzoate 147-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 32381043-9 2020 Consequently, the association between SH3BGRL and HER2 contributed to the prolonged HER2 phosphorylation at specific tyrosine sites, especially at Y1196, and their downstream signaling activation. decyl 4-hydroxybenzoate 147-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 32353937-0 2020 In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk. bisphenol A 21-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-124 32061845-0 2020 HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer. capecitabine 83-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 32061845-3 2020 Liposomal formulation of CAP was prepared by film hydration method using cholesterol-THP conjugate (CTHP-CAP-LPs) to achieve active targeting through HER2 receptors. capecitabine 25-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 32061845-3 2020 Liposomal formulation of CAP was prepared by film hydration method using cholesterol-THP conjugate (CTHP-CAP-LPs) to achieve active targeting through HER2 receptors. capecitabine 105-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 32345308-6 2020 In this study, AGO2 protein-conjugated, anti-HER2 antibody-linked and fluorophore-tagged SPION nanoparticles were developed (SP-AH nanoparticles) and used as a carrier for an autophagy inhibitory microRNA, MIR376B. sp-ah 125-130 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-49 32353937-8 2020 Molecular analysis of mammary tissues at PND 70 showed that in utero exposure to low doses of BPA induced upregulation of ERalpha, p-ERalpha, cyclin D1, and c-myc, concurrent activation of erbB2, EGFR, erbB-3, Erk1/2, and Akt, and upregulation of growth factors/ligands. bisphenol A 94-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-194 32353937-9 2020 Our results demonstrate that in utero exposure to low dose BPA promotes mammary tumorigenesis in MMTV-erbB2 mice through induction of ER-erbB2 crosstalk and mammary epithelial reprogramming, which advance our understanding of the mechanism associated with in utero exposure to BPA-induced breast cancer risk. bisphenol A 59-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-142 31941722-0 2020 Extracellular vesicle-mediated in vitro transcribed mRNA delivery for treatment of HER2+ breast cancer xenografts in mice by prodrug CB1954 without general toxicity. tretazicar 133-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-87 31228185-10 2020 In the mice receiving Auranofin before reperfusion, myocardial PTP activity was suppressed, leading to restored phosphorylation of PTP-PEST substrates, including ErbB-2 that maintains the survival signalling of the heart. Auranofin 22-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 162-168 31228185-13 2020 The drug Auranofin, potentially acting through the PTP-PEST-ErbB-2 signalling axis, reduces myocardial I/R injury. Auranofin 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-66 32143669-11 2020 CONCLUSION: Dual inhibition of radiation-activated EGFR and HER2 signaling by afatinib suppressed the proliferation and invasion of irradiated LLC cells. Afatinib 78-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 32490320-12 2020 The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-136 32490320-12 2020 The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 32216377-1 2021 Herein, we present the syntheses and characterization of a new undecadendate chelator, H4py4pa, and its bifunctional analog H4py4pa-phenyl-NCS, conjugated to the monoclonal antibody, Trastuzumab, which targets the HER2+ cancer. h4py4pa 87-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 214-218 32006673-2 2020 The aim of this study was to evaluate 99mTc-HYNIC-(Ser)3-LTVPWY (99mTc-HYNIC-LY) peptide as a novel HER2-targeted radiolabeled peptide in healthy mice to examine the applicability of this imaging agent in a first-in-human clinical trial. Serine 51-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 32143669-8 2020 RESULTS: Afatinib more effectively sensitized LLC cells to radiation and decreased invasiveness by inhibiting phosphorylation of EGFR, HER2, Akt, ERK, and p38, and down-regulating MMP-9 when compared to erlotinib. Afatinib 9-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 135-139 31931230-3 2020 For this purpose, a liposomal formulation of P5 peptide and PEGylated liposomal doxorubicin (Doxil ) was utilized to treat mice bearing HER2+ tumor model. Doxorubicin 80-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 31931230-3 2020 For this purpose, a liposomal formulation of P5 peptide and PEGylated liposomal doxorubicin (Doxil ) was utilized to treat mice bearing HER2+ tumor model. liposomal doxorubicin 93-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 32772021-0 2020 Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 32593254-8 2020 Under conditions of HER2/neu overexpression after the Cytoflavin treatment, an improvement in motor functions occurs. cytoflavin 54-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-28 32772021-0 2020 Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-112 31857845-3 2019 Preliminary studies were performed using proprietary Eg5 inhibitors which were conjugated onto a HER2-targeting antibody using maleimido caproyl valine-citrulline para-amino benzocarbamate, or MC-VC-PABC cleavable linker. Z-valine-citrulline-p-aminobenzylalcohol 127-188 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 33176309-2 2020 Lapatinib simultaneously inhibits EGFR and HER2, leading to apoptosis. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 31597712-0 2020 Precision Chemo-Radiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. auristatin 77-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 31597712-4 2020 To achieve tumor selective radiosensitization, we synthesized and tested anti-HER2 antibody drug conjugates of two auristatin derivatives with ionizing radiation. auristatin 115-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 31597712-5 2020 Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. monomethyl auristatin E 0-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-96 31597712-5 2020 Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. monomethyl auristatin E 25-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-96 31597712-5 2020 Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. monomethyl auristatin E 35-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-96 31597712-5 2020 Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. monomethyl auristatin E 60-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-96 31597712-7 2020 However when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2 expressing tumor cells in G2/M. monomethyl auristatin E 52-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 31597712-7 2020 However when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2 expressing tumor cells in G2/M. monomethyl auristatin E 79-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 31597712-8 2020 Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. monomethyl auristatin E 10-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 31597712-8 2020 Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. monomethyl auristatin E 10-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 31597712-10 2020 In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulate in the normal tissue surrounding tumors compared to MMAE. monomethyl auristatin E 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-42 31597712-11 2020 Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts. monomethyl auristatin E 39-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 30829072-0 2019 P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. dioleoyl phosphatidylethanolamine 65-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 5-9 30829072-0 2019 P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. dioleoyl phosphatidylethanolamine 65-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-13 30829072-1 2019 The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. maleimide 139-148 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 30829072-1 2019 The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. maleimide 139-148 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-108 31550733-2 2019 The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Toremifene 109-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 170-174 31376137-11 2019 We also found that PEITC hampered the in vivo growth of MI6 nodules by inducing hemorrhagic and necrotic intra-tumor areas and, in combination with trastuzumab, by significantly reducing spontaneous tumor development in d16HER2 transgenic mice. phenethyl isothiocyanate 19-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 223-227 31550733-2 2019 The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Toremifene 109-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 213-222 31550733-2 2019 The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Biguanides 141-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 170-174 31550733-2 2019 The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Metformin 152-161 erb-b2 receptor tyrosine kinase 2 Mus musculus 170-174 32245294-9 2019 Based on these findings, the idarubicin-ZHER2 conjugate can be considered as a candidate for the development of new therapeutics against HER2-overexpressing cancers although further in vivo studies are needed. Idarubicin 29-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-45 31570753-6 2019 However, we found that the infusion of CAR-147 macrophages significantly inhibited HER2-4T1 tumour growth in BALB/c mice. car-147 39-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-87 31720502-2 2019 We characterized the small molecule MBQ-167 as an effective dual Rac/Cdc42 inhibitor that reduces HER2-type tumor growth and metastasis in mice by ~90%. 18-O-demethylcervinomycin A2 36-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 31772236-6 2019 The co-administration of foretinib and lapatinib effectively inhibited both MET and HER2 phosphorylation, enhanced inhibition of cell proliferation and xenograft tumor growth by inducing apoptosis, and significantly enhanced mouse overall survival, overcoming single agent resistance. GSK 1363089 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 31772236-6 2019 The co-administration of foretinib and lapatinib effectively inhibited both MET and HER2 phosphorylation, enhanced inhibition of cell proliferation and xenograft tumor growth by inducing apoptosis, and significantly enhanced mouse overall survival, overcoming single agent resistance. lapatinib 39-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 31394419-16 2019 We successfully developed detectable HER2-targeting boron-containing AuNPs with high RCP and an acceptable yield. Boron 52-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-41 31251311-9 2019 Our results indicate that the one-step formulation of PLD by mPEG x HER2 is a simple method to confer tumor specificity, increase drug internalization and enhance the anticancer activity of PLD against HER2-overexpressing and doxorubicin-resistant breast cancer. Doxorubicin 226-237 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 31513391-9 2019 These HER2-specific reduction-sensitive immunopolymersomes with high loading of epirubicin emerge as an attractive treatment for HER2-positive tumors. Epirubicin 80-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-10 31513391-9 2019 These HER2-specific reduction-sensitive immunopolymersomes with high loading of epirubicin emerge as an attractive treatment for HER2-positive tumors. Epirubicin 80-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 31270151-9 2019 Tumors from atovaquone treated mice exhibited reduced HER2, beta-catenin and c-Myc levels alongside an increase in apoptosis in all the three tumor models when analyzed by western blotting, IHC and TUNEL assay. Atovaquone 12-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-58 31327474-5 2019 In vivo, the ectopic expression of HER2 in these cells was sufficient to activate the interstitial fibroblast and initiate interstitial fibrosis, whereas inhibiting HER2 reduced the accumulation of myofibroblasts and the extent of renal fibrosis in the mouse obstruction model and in streptozotocin (STZ)-induced diabetic mice. Streptozocin 284-298 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 31327474-5 2019 In vivo, the ectopic expression of HER2 in these cells was sufficient to activate the interstitial fibroblast and initiate interstitial fibrosis, whereas inhibiting HER2 reduced the accumulation of myofibroblasts and the extent of renal fibrosis in the mouse obstruction model and in streptozotocin (STZ)-induced diabetic mice. Streptozocin 300-303 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 31484456-6 2019 On 4T1 cells, siRNAs against AKT and ERBB2 plus paclitaxel or docetaxel resulted in the largest increase in anti-cancer effects compared to CA/paclitaxel or CA/docetaxel. Paclitaxel 143-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-42 31484456-6 2019 On 4T1 cells, siRNAs against AKT and ERBB2 plus paclitaxel or docetaxel resulted in the largest increase in anti-cancer effects compared to CA/paclitaxel or CA/docetaxel. Docetaxel 160-169 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-42 31484456-8 2019 Animals receiving injections of CA/paclitaxel or CA/docetaxel loaded with siRNAs against AKT and ERBB2 possessed significantly smaller tumors compared to CA/drug-treated mice. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-102 31268724-0 2019 Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. Astatine 38-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-21 31268724-3 2019 This research investigates a novel targeted therapy that combines the alpha-particle emitter astatine-211 (211At) and the anti-HER2 Nb 2Rs15d to selectively target HER2+ cancer cells. Astatine 93-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-168 31497357-5 2019 Here we demonstrate that methionine restriction induces eIF2alpha phosphorylation and enhances ATF4 gene expression and protein levels of ATF4 and Sestrin-2 in triple (ER/PR/HER2)-negative breast cancer (TNBC) cells. Methionine 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 30996140-9 2019 We next used the HER2dMAb single-chain variable fragment portion to engineer a DNA-encoded BiTE (DBiTE). dbite 97-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-21 31413568-0 2019 Targeted delivery of doxorubicin to HER2 positive tumor models. Doxorubicin 21-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 31355130-10 2019 Melatonin supplementation significantly decreased the incidence of grossly-detected lung metastases in MEL mice, suggesting that melatonin delays the formation of metastatic lesions and/or decreases aggressiveness in this model of HER2+ breast cancer. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 231-235 31355130-10 2019 Melatonin supplementation significantly decreased the incidence of grossly-detected lung metastases in MEL mice, suggesting that melatonin delays the formation of metastatic lesions and/or decreases aggressiveness in this model of HER2+ breast cancer. Melatonin 129-138 erb-b2 receptor tyrosine kinase 2 Mus musculus 231-235 31285769-0 2019 Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model. Deferoxamine 31-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-128 31285769-16 2019 Ex vivo biodistribution confirmed the data obtained by in vivo PET imaging, and site-specific 89Zr-DFO-trastuzumab successfully detected HER2-positive tumors in PDX mouse models. Deferoxamine 99-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-141 31285769-17 2019 Conclusion: 89Zr-DFO-trastuzumab is well-matched for specific immuno-PET imaging of HER2-positive tumors and site-specific labeling of trastuzumab by the SiteClickTM technology minimizes the impact of the DFO chelator on immuno-reactivity, stability and biodistribution. Deferoxamine 17-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 31209328-5 2019 RESULTS: Lapatinib increased intratumoral HER2 protein, which encouraged resistance to this treatment in mouse models. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 31222103-7 2019 We show that activation of the oncogene ErbB2 is associated with increased ROS and that high ROS sub-population of ErbB2 cancer cells show elevated SOD1. ros 75-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 31222103-7 2019 We show that activation of the oncogene ErbB2 is associated with increased ROS and that high ROS sub-population of ErbB2 cancer cells show elevated SOD1. ros 93-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 31222103-7 2019 We show that activation of the oncogene ErbB2 is associated with increased ROS and that high ROS sub-population of ErbB2 cancer cells show elevated SOD1. ros 93-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-120 31253840-11 2019 Overall, [99mTc]Tc(CO)3-(HE)3-G3 variant provided the highest tumor-to-lung, tumor-to-liver, tumor-to-bone and tumor-to-muscle ratios, which should improve sensitivity of HER2 imaging in these common metastatic sites. tc(co)3-(he) 16-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 171-175 30854738-5 2019 A cytotoxic molecule was then connected to the newly introduced thiol group, and both a surface plasmon resonance binding assay and in vivo xenograft mouse model results showed that the resulting ADC could selectively target and kill HER2-positive cells. Sulfhydryl Compounds 64-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-238 30881623-4 2019 Our one-pot three-component double-click labeling method was used to attach decaborate to trastuzumab (anti-HER2 antibody) using decaborate-tetrazine and TCO-aldehyde probes without reducing the antibody binding affinity. decaborate-tetrazine 129-149 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-112 30630630-0 2019 PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Afatinib 47-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-67 30630630-2 2019 Because scant information is currently available in the literature on the potential negative effect of PIK3CA mutations on the activity of afatinib, in this study we evaluate for the first time the role of oncogenic PIK3CA mutations as a potential mechanism of resistance to afatinib in HGSOC and USC overexpressing HER2/neu. Afatinib 139-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 316-324 30630630-5 2019 The effect of afatinib on HER2/PI3K/AKT/mTOR pathway was evaluated by immunoblotting. Afatinib 14-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 30630630-8 2019 By western-blot, afatinib effectively reduced total and phospho-HER2 proteins in all cell-lines. Afatinib 17-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-68 30911062-9 2019 In addition, tumors from paclitaxel and PFL-treated mice showed reduced HER2 and beta-catenin expression, along with increased apoptosis. Paclitaxel 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-76 30911062-9 2019 In addition, tumors from paclitaxel and PFL-treated mice showed reduced HER2 and beta-catenin expression, along with increased apoptosis. Penfluridol 40-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-76 30786890-0 2019 Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cholesterol 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-70 30786890-0 2019 Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cholesterol 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-119 30786890-3 2019 The present study aims to investigate the influence of membrane cholesterol contents on ErbB2 status and cellular responses to its tyrosine kinase inhibitors. Cholesterol 64-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-93 30786890-4 2019 METHODS: The cholesterol abundance was examined in ErbB2-positive breast cancer cells using filipin staining. Cholesterol 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-56 30786890-5 2019 Cellular ErbB2 localizations were investigated by immunofluorescence with altered membrane cholesterol contents. Cholesterol 91-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-14 30786890-7 2019 The synergistic effects of lovastatin with the ErbB2 inhibitor lapatinib were evaluated using an ErbB2-positive breast cancer xenograft mouse model. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-52 30786890-8 2019 RESULTS: Membrane cholesterol contents positively correlated with cell surface distribution of ErbB2 through increasing the rigidity and decreasing the fluidity of cell membranes. Cholesterol 18-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-100 30786890-9 2019 Reduction in cholesterol abundance assisted the internalization and degradation of ErbB2. Cholesterol 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-88 30786890-10 2019 The cholesterol-lowering drug lovastatin significantly potentiated the inhibitory effects of ErbB2 kinase inhibitors, accompanied with enhanced ErbB2 endocytosis. Cholesterol 4-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-98 30786890-10 2019 The cholesterol-lowering drug lovastatin significantly potentiated the inhibitory effects of ErbB2 kinase inhibitors, accompanied with enhanced ErbB2 endocytosis. Cholesterol 4-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 144-149 30786890-10 2019 The cholesterol-lowering drug lovastatin significantly potentiated the inhibitory effects of ErbB2 kinase inhibitors, accompanied with enhanced ErbB2 endocytosis. Lovastatin 30-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-98 30786890-10 2019 The cholesterol-lowering drug lovastatin significantly potentiated the inhibitory effects of ErbB2 kinase inhibitors, accompanied with enhanced ErbB2 endocytosis. Lovastatin 30-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 144-149 30786890-11 2019 Lovastatin also synergized with lapatinib to strongly suppress the in vivo growth of ErbB2-positive breast cancer xenografts. Lovastatin 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 30786890-11 2019 Lovastatin also synergized with lapatinib to strongly suppress the in vivo growth of ErbB2-positive breast cancer xenografts. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 30786890-12 2019 CONCLUSION: The cell surface distribution of ErbB2 was closely regulated by membrane physical properties governed by cholesterol contents. Cholesterol 117-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-50 30786890-13 2019 The cholesterol-lowering medications can hence be exploited for potential combinatorial therapies with ErbB2 kinase inhibitors in the clinical treatment of ErbB2-positive breast cancer. Cholesterol 4-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-108 30786890-13 2019 The cholesterol-lowering medications can hence be exploited for potential combinatorial therapies with ErbB2 kinase inhibitors in the clinical treatment of ErbB2-positive breast cancer. Cholesterol 4-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 156-161 30551875-3 2019 To answer these questions, we prepared AuNPs conjugated with anti-human epidermal growth factor receptor type 2 (HER2) antibody via polyethylene glycol (PEG) chains (AuNP-PEG-HER2ab). Polyethylene Glycols 132-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-117 30551875-3 2019 To answer these questions, we prepared AuNPs conjugated with anti-human epidermal growth factor receptor type 2 (HER2) antibody via polyethylene glycol (PEG) chains (AuNP-PEG-HER2ab). Polyethylene Glycols 153-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-117 30551875-4 2019 AuNP-PEG-HER2ab specifically bound to the HER2-expressing cancer cells and entered the cells via endocytosis. aunp-peg 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 30551875-4 2019 AuNP-PEG-HER2ab specifically bound to the HER2-expressing cancer cells and entered the cells via endocytosis. aunp-peg 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 30787176-0 2019 TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. TAS0728 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 30787176-3 2019 Here, we report a novel compound TAS0728 that covalently binds to HER2 at C805 and selectively inhibits its kinase activity. TAS0728 33-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-70 30787176-8 2019 TAS0728 induced tumor regression in mouse xenograft models bearing HER2 signal-dependent tumors and exhibited a survival benefit without any evident toxicity in a peritoneal dissemination mouse model bearing HER2-driven cancer cells. TAS0728 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-71 30787176-8 2019 TAS0728 induced tumor regression in mouse xenograft models bearing HER2 signal-dependent tumors and exhibited a survival benefit without any evident toxicity in a peritoneal dissemination mouse model bearing HER2-driven cancer cells. TAS0728 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 208-212 30787176-9 2019 Taken together, our results demonstrated that TAS0728 may offer a promising therapeutic option with improved efficacy as compared with current HER2 inhibitors for HER2-activated cancers. TAS0728 46-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 163-167 30705430-2 2019 The sentence should read "In mouse mammary tumour models, increased collagen levels and increased beta1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies164." NVP-BKM120 321-331 erb-b2 receptor tyrosine kinase 2 Mus musculus 250-254 30867840-6 2019 Results: We found that miR-4306 is transcriptionally regulated by ER-alpha, HER2 and PR, and the downregulation of miR-4306 in TNBC is caused by the loss of ER-alpha, HER2 and PR. mir-4306 23-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-80 30800128-9 2019 In addition, DS-437 significantly enhanced the anti-tumor effects of anti-erbB2/neu monoclonal antibody targeted therapy in Balb/c mice bearing CT26Her2 tumors by inhibiting Treg function and induction of tumor immunity. DS-437 13-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-79 30800128-9 2019 In addition, DS-437 significantly enhanced the anti-tumor effects of anti-erbB2/neu monoclonal antibody targeted therapy in Balb/c mice bearing CT26Her2 tumors by inhibiting Treg function and induction of tumor immunity. DS-437 13-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-83 30809308-5 2019 Results: We found that systemic delivery of HER2-targeted magnetic iron oxide nanoparticles carrying cisplatin significantly inhibited the growth of primary tumor and peritoneal and lung metastases in the ovarian cancer xenograft model in nude mice. ferric oxide 67-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 30809308-5 2019 Results: We found that systemic delivery of HER2-targeted magnetic iron oxide nanoparticles carrying cisplatin significantly inhibited the growth of primary tumor and peritoneal and lung metastases in the ovarian cancer xenograft model in nude mice. Cisplatin 101-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 29992881-0 2019 Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. linc01638 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 29992881-3 2019 OBJECTIVE: To investigate the effect of linc01638 on tumorigenesis in HER2-positive breast cancer. linc01638 40-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 29992881-5 2019 Then we analyzed the effects of linc01638 expression in HER2-positive breast cancer cells through cell apoptosis assay, cell proliferation assay, colony formation assay, and cell invasion assay. linc01638 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-60 29992881-6 2019 We conducted mouse xenograft model to further confirm the role of linc01638 in HER2-positive breast cancer. linc01638 66-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 29992881-8 2019 RESULTS: Linc01638 was found to be remarkably overexpressed in HER2-positive breast cancer cells and tissues. linc01638 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-67 29992881-9 2019 Suppression of linc01638 enhanced cell apoptosis, as well as inhibited the growth and invasiveness of HER2-positive breast cancer cells in vitro and tumor progression and metastasis in vivo. linc01638 15-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-106 29992881-10 2019 Furthermore, inhibition of linc01638 by shRNA attenuated expression of DNMT1, DNMT3a, and DNMT3b, and promoted expression of BRCA1 and PTEN in HER2-positive breast cancer cells and mouse xenograft models. linc01638 27-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 29992881-11 2019 CONCLUSION: Linc01638 might be a promising biomarker and therapeutic target for treatment of HER2-positive breast cancer. linc01638 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-97 30488805-0 2019 Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer. Docetaxel 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-71 30881623-4 2019 Our one-pot three-component double-click labeling method was used to attach decaborate to trastuzumab (anti-HER2 antibody) using decaborate-tetrazine and TCO-aldehyde probes without reducing the antibody binding affinity. tco-aldehyde 154-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-112 30384599-2 2018 Earlier, we evaluated two residualizing prosthetic agents for 18F-labeling of anti-HER2 sdAbs; however, these methods resulted in poor labeling yields and high uptake of 18F activity in the kidneys. sdabs 88-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-87 30881623-6 2019 Intratumor injection of the 211At-labeled trastuzumab in BALB/c nude mice implanted with HER2-expressing epidermoid cancer cells yielded efficient accumulation at the targeted tumor site as well as effective suppression of tumor growth. 211at 28-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 29069935-3 2018 METHODS: A system of novel nanoparticles (NPs) DM1-NPs-trastuzumab (DM1-NPs-Tmab) of DM1 combined with (anti-HER2 antibody, Herceptin , Trastuzumab) was developed for HER2+ breast cancer treatment, and its physical characterization and antitumor biological activity were investigated. Tetramethylammonium bromide 76-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 167-171 30384599-11 2018 Uptake of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d in HER2-expressing SKOV-3 ovarian carcinoma xenografts implanted in athymic mice was about 80% of that seen for coinjected [125I]SGMIB-2Rs15d. 1,4,7-triazacyclononane-N,N',N''-triacetic acid 19-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 30384599-11 2018 Uptake of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d in HER2-expressing SKOV-3 ovarian carcinoma xenografts implanted in athymic mice was about 80% of that seen for coinjected [125I]SGMIB-2Rs15d. Thiazoles 24-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 29069935-4 2018 RESULTS: DM1-NPs-Tmab-targeted HER2+ breast cancer cells specifically were developed. Tetramethylammonium bromide 17-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 29069935-5 2018 Compared with naked DM1 and Herceptin, DM1-NPs-Tmab showed greater toxicity on HER2+ cancer cells and blocked the HER2-PI3K/Akt cell activation pathway. Tetramethylammonium bromide 47-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 29069935-5 2018 Compared with naked DM1 and Herceptin, DM1-NPs-Tmab showed greater toxicity on HER2+ cancer cells and blocked the HER2-PI3K/Akt cell activation pathway. Tetramethylammonium bromide 47-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-118 29069935-8 2018 DM1-NPs-Tmab is a potential promising formulation for targeting biotherapy of HER2+ tumors. Tetramethylammonium bromide 8-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 29405790-6 2018 For HER2, a similar potency has been observed for a 12-amino-acid anti-HER2 peptide mimetic YCDGFYACYMDV-NH2 (AHNP, disulfide-bridged) and full-length trastuzumab. 12-amino-acid 52-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 29405790-6 2018 For HER2, a similar potency has been observed for a 12-amino-acid anti-HER2 peptide mimetic YCDGFYACYMDV-NH2 (AHNP, disulfide-bridged) and full-length trastuzumab. ycdgfyacymdv-nh2 92-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 29405790-6 2018 For HER2, a similar potency has been observed for a 12-amino-acid anti-HER2 peptide mimetic YCDGFYACYMDV-NH2 (AHNP, disulfide-bridged) and full-length trastuzumab. Disulfides 116-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 29967252-5 2018 In FVB mice bearing a syngeneic HER2-driven model of mammary adenocarcinoma (NDL), 64Cu-169cDb PET imaging accurately visualized and quantified changes in tumor-infiltrating CD8+ T cells in response to immunotherapy. 64cu-169cdb 83-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-36 30279968-4 2018 Furthermore, capns1 knockout in a tumor derived cell line correlated with enhanced sensitivity to the chemotherapeutic doxorubicin and the HER2/EGFR tyrosine kinase inhibitor lapatinib. Lapatinib 175-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-143 30217443-0 2018 SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin. 125i-herceptin 76-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 30217443-2 2018 In this study, we investigated the feasibility of detecting HER2 expression in colon cancer by SPECT imaging using 125I-Herceptin, which showed high labeling rate, good in vitro stability and high binding specificity for HER2. 125i-herceptin 115-129 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 30217443-2 2018 In this study, we investigated the feasibility of detecting HER2 expression in colon cancer by SPECT imaging using 125I-Herceptin, which showed high labeling rate, good in vitro stability and high binding specificity for HER2. 125i-herceptin 115-129 erb-b2 receptor tyrosine kinase 2 Mus musculus 221-225 30217443-5 2018 These results indicates that 125I-Herceptin can be considered as an effective SPECT probe for the non-invasive detection of HER2 expression in colon cancer. 125i-herceptin 29-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-128 30429889-3 2018 In this study, we tested the hypothesis that DOTA-PRIT can be performed successfully to target HER2, an internalizing membrane antigen widely expressed in breast, ovarian, and gastroesophageal junction cancers. dota-prit 45-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-99 29907770-8 2018 In conclusion, NBCn1 regulates intracellular pH in ErbB2-induced breast cancer tissue by providing a pathway for cellular uptake of HCO3-, which can neutralize metabolic acidic waste products. Bicarbonates 132-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-56 30229394-2 2018 An anti-HER2 aptamer-modified magnetic nanosensitizer (AptHER2-MNS) was prepared by conjugation with 5"-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). 5"-thiol 101-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 8-12 30015966-6 2018 Molecular analyses of premalignant mammary tissues further indicated that DMBA exposure enhanced epidermal growth factor receptor (EGFR)/ErbB2 and estrogen receptor (ER) signaling, which was associated with increased mRNA levels of EGFR/ErbB2 family members and ER-targeted genes. 9,10-Dimethyl-1,2-benzanthracene 74-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-142 30015966-6 2018 Molecular analyses of premalignant mammary tissues further indicated that DMBA exposure enhanced epidermal growth factor receptor (EGFR)/ErbB2 and estrogen receptor (ER) signaling, which was associated with increased mRNA levels of EGFR/ErbB2 family members and ER-targeted genes. 9,10-Dimethyl-1,2-benzanthracene 74-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 237-242 30015966-0 2018 DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. 9,10-Dimethyl-1,2-benzanthracene 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 30015966-8 2018 Together, the data suggested that DMBA-induced deregulation of EGFR/ErbB2-ER pathways plays a critical role in the enhanced chromosomal instability and promotion of ErbB2-mediated mammary tumorigenesis. 9,10-Dimethyl-1,2-benzanthracene 34-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 30015966-0 2018 DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. 9,10-Dimethyl-1,2-benzanthracene 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 30015966-3 2018 Therefore, the present study aimed to investigate the effect of DMBA exposure on ErbB2-mediated mammary tumorigenesis. 9,10-Dimethyl-1,2-benzanthracene 64-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-86 30015966-8 2018 Together, the data suggested that DMBA-induced deregulation of EGFR/ErbB2-ER pathways plays a critical role in the enhanced chromosomal instability and promotion of ErbB2-mediated mammary tumorigenesis. 9,10-Dimethyl-1,2-benzanthracene 34-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-170 30015966-4 2018 MMTV-ErbB2 transgenic mice exposed to DMBA (1 mg) via weekly oral gavage for 6 weeks exhibited significantly enhanced mammary tumor development, as indicated by reduced tumor latency and increased tumor multiplicity compared with control mice. 9,10-Dimethyl-1,2-benzanthracene 38-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 5-10 30139028-4 2018 The uptake ability of SK-BR-3, a HER-2 positive breast cancer cell, was observed by transmission electron microscopy. sk-br-3 22-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 29957952-13 2018 The tumor uptake of 89Zr-DFO-T-DM1 was 4.1-fold significantly higher than 89Zr-DFO-trastuzumab in mice with s.c. BT-474 (HER2 3+) xenografts (43.5 +- 4.3%ID/g vs 10.6 +- 5.4%ID/g, respectively; P < 0.001). Deferoxamine 25-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 121-125 30125265-0 2018 Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 30125265-1 2018 BACKGROUND The aim of this study was to evaluate the effect of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, on the radiosensitivity of murine bladder tumor line-2 (MBT-2) cells in vitro and in vivo. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 30125265-6 2018 RESULTS Lapatinib pretreatment, combined with radiation, decreased MBT-2 cell survival, and suppressed radiation-activated levels of p-EGFR and p-HER-2. Lapatinib 8-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 30125265-10 2018 CONCLUSIONS Lapatinib treatment enhanced the radiation sensitivity in an in vitro and in vivo murine bladder cancer model by decreasing radiation-mediated EGFR and HER-2 activation, and by causing DNA damage leading to cell apoptosis. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-169 29957952-14 2018 Tumor uptake of 89Zr-DFO-T-DM1 in MDA-MB-231/H2N xenografts (HER2 2+) was 3.7-fold significantly higher than 89Zr-DFO-trastuzumab (10.1 +- 3.6%ID/g vs 2.7 +- 0.5%ID/g; P < 0.001). Deferoxamine 21-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-65 29579155-1 2018 The propeptide (LOX-PP) domain of the lysyl oxidase proenzyme was shown to inhibit the transformed phenotype of breast, lung and pancreatic cells in culture and the formation of Her2/neu-driven breast cancer in a xenograft model. propeptide 4-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-186 29770537-0 2018 Dietary intake of iodine-enriched eggs decreases the incidence of mouse mammary tumors caused by the activated ErbB2 oncogene. Iodine 18-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 29770537-2 2018 In this study, we evaluated the efficacy of dietary intake of iodine-enriched eggs on mammary tumor incidence caused by the expression of activated type ErbB2. Iodine 62-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-158 29770537-6 2018 These results indicate that iodine intake through livestock-derived products can reduce the incidence of mammary cancers caused by the expression of activated type ErbB2. Iodine 28-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-169 29579155-1 2018 The propeptide (LOX-PP) domain of the lysyl oxidase proenzyme was shown to inhibit the transformed phenotype of breast, lung and pancreatic cells in culture and the formation of Her2/neu-driven breast cancer in a xenograft model. lox-pp 16-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-186 29940998-0 2018 ER-alpha36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Cisplatin 20-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-82 29703841-0 2018 A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Deruxtecan 54-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 2-6 29703841-0 2018 A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. trastuzumab deruxtecan 66-74 erb-b2 receptor tyrosine kinase 2 Mus musculus 2-6 29703841-1 2018 Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd), has been reported to exert potent antitumor effects in xenograft mouse models and clinical trials. Deruxtecan 12-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-41 29703841-1 2018 Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd), has been reported to exert potent antitumor effects in xenograft mouse models and clinical trials. trastuzumab deruxtecan 24-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-41 29864158-12 2018 Inhibiting epidermal growth factor receptor (EGFR) and ErbB2 with afatinib suppressed DSE-enhanced malignant phenotypes, establishing the critical role of the ErbB pathway in regulating the effects of DSE expression. Afatinib 66-74 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 29298799-5 2018 Interestingly, we further identified that combined treatment with osimertinib and the BET inhibitor JQ1 significantly increased the response rate in HER2-mutant NSCLC, whereas JQ1 single treatment did not show efficacy.Conclusions: Overall, our data indicated robust antitumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1. osimertinib 66-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 149-153 29298799-5 2018 Interestingly, we further identified that combined treatment with osimertinib and the BET inhibitor JQ1 significantly increased the response rate in HER2-mutant NSCLC, whereas JQ1 single treatment did not show efficacy.Conclusions: Overall, our data indicated robust antitumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1. osimertinib 66-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 318-322 28417445-0 2018 Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer. Curcumin 28-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-100 29501042-16 2018 rcdtB significantly reduced C-erbB-2 and Cox-2 in tumor tissues compared to Normal control group (P < 0.01). rcdtb 0-5 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-36 29501042-17 2018 In conclusion, rcdtB treatment inhibited tumor growth and induced apoptosis through inhibiting Bcl-2 expression, inflammatory responses, and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model. rcdtb 15-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-160 28417445-1 2018 Curcumin has shown promising inhibitory activity against HER-2-positive tumor cells in vitro but suffers from poor oral bioavailability in vivo. Curcumin 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-62 28417445-3 2018 The goal of this study was to examine the anticancer efficacy of curcumin-loaded polymeric microparticles in a transgenic mouse model of HER-2 cancer, Balb-neuT. Curcumin 65-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-142 29550255-4 2018 In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. Crizotinib 107-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 3-7 29540470-3 2018 Using pre-clinical human and murine mCRPC models, we show that SPRY2 deficiency leads to an androgen self-sufficient form of CRPC Mechanistically, HER2-IL6 signalling axis enhances the expression of androgen biosynthetic enzyme HSD3B1 and increases SRB1-mediated cholesterol uptake in SPRY2-deficient tumours. Cholesterol 263-274 erb-b2 receptor tyrosine kinase 2 Mus musculus 147-151 32254485-6 2018 Moreover, by using superparamagnetic iron oxide nanoparticles (SPIONs) as a probe in a clinically used magnetic resonance imaging (MRI) system, we found that HER2@NPs effectively deliver SPIONs into the brain. ferric oxide 37-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 158-162 29170110-0 2018 Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma. graphene oxide 39-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 29170110-3 2018 We established stable, non-covalent association of TRA with nanomaterial graphene oxide (GO) to generated multivalent TRA/GO complexes that demonstrated markedly enhanced HER2-binding activity and capacity to rapidly kill OS cells. graphene oxide 73-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 171-175 29170110-3 2018 We established stable, non-covalent association of TRA with nanomaterial graphene oxide (GO) to generated multivalent TRA/GO complexes that demonstrated markedly enhanced HER2-binding activity and capacity to rapidly kill OS cells. graphene oxide 89-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 171-175 29216514-3 2018 In this study, poly(D,L lactide-co-glycolide) (PLGA)-b-polyethylene glycol (PEG) NPs conjugated to different quantities of the commercial antibody Herceptin meant to target HER2-positive breast cancer cells were studied for their immune cell uptake and immunogenic properties (using murine macrophages and human dendritic cells). Polylactic Acid-Polyglycolic Acid Copolymer 15-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 29109274-5 2017 Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to MDA-MB-231 and SKBR3 (overexpressing HER2) breast cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-43 29352243-5 2018 The effect of the nucleolin-specific inhibitor GroA (AS1411) on ErbB2-positive breast cancer was tested in vivo, in a mouse xenograft model for breast cancer; as well as in vitro, alone and in combination with the ErbB2 kinase-inhibitor tyrphostin AG-825. AGRO 100 53-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-69 29305666-7 2018 In fact, more than 80% of 99mTc-DTPA-TZMB@Fe3O4 nanoparticles seems to be cleared by the renal pathway but the implanted tumor whose seems to increase the expression of HER2 receptors enhancing the uptake by all other organs. UNII-38IHL67R32 26-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-173 29305666-7 2018 In fact, more than 80% of 99mTc-DTPA-TZMB@Fe3O4 nanoparticles seems to be cleared by the renal pathway but the implanted tumor whose seems to increase the expression of HER2 receptors enhancing the uptake by all other organs. tzmb 37-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-173 29305666-7 2018 In fact, more than 80% of 99mTc-DTPA-TZMB@Fe3O4 nanoparticles seems to be cleared by the renal pathway but the implanted tumor whose seems to increase the expression of HER2 receptors enhancing the uptake by all other organs. ferryl iron 42-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-173 29464055-1 2018 The irreversible ERBB1/2/4 inhibitor neratinib has been shown in vitro to rapidly reduce the expression of ERBB1/2/4 and RAS proteins via autophagic/lysosomal degradation. neratinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-26 29464055-1 2018 The irreversible ERBB1/2/4 inhibitor neratinib has been shown in vitro to rapidly reduce the expression of ERBB1/2/4 and RAS proteins via autophagic/lysosomal degradation. neratinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-116 29721370-7 2018 Detection of IFN-gamma levels by enzyme-linked immunospot assay showed that the numbers of tumor-specific T cells against neu and non-neu tumor antigens were increased by combined PI3K inhibitor plus anti-neu antibody treatment, with A66 exhibiting more potent effects than GDC-0941. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 274-282 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-125 28982707-4 2017 We used male and female mice of a doxycycline-inducible transgenic line to induce expression of constitutively active ErbB2 (caErbB2) selectively in SCs after DR crush or transection. Doxycycline 34-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-123 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 38-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-0 2017 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. Iodine-131 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 28751451-0 2017 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. sdab 31-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 38-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. sdab 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 38-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. sdab 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. sdab 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 174-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 174-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 174-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 28751451-3 2017 Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental Design: Anti-HER2 sdAb 2Rs15d was labeled with 131I using [131I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2+ murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab. Iodine-131 174-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 140-144 29228623-5 2017 This was associated with diminished expression levels of the glucose transporter 1, reduced glucose uptake and reduced glycolytic activity in HER-2/neu-transfected cells with down-regulated CREB when compared to HER-2/neu+ cells. Glucose 61-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-147 29110836-11 2017 Ba/F3 cells harboring EGFR T263P/G719A mutation showed higher sensitivity to afatinib, compared to gefitinib due to inhibition of EGFR/HER2 heterodimerization. Afatinib 77-85 erb-b2 receptor tyrosine kinase 2 Mus musculus 135-139 29228623-5 2017 This was associated with diminished expression levels of the glucose transporter 1, reduced glucose uptake and reduced glycolytic activity in HER-2/neu-transfected cells with down-regulated CREB when compared to HER-2/neu+ cells. Glucose 61-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-151 28374157-10 2017 Interestingly, FKB-induced autophagy is associated with the suppression of HER-2 and PI3K/AKT/mTOR signaling cascades. flavokawain B 15-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 28961841-9 2017 Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. Afatinib 65-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-85 28777668-0 2017 Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model. gemcitabine 121-132 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 29075110-0 2017 Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. Polymers 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 29075110-0 2017 Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. Polymers 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 29075110-0 2017 Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. salinomycin 58-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 29075110-0 2017 Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. salinomycin 58-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 29075110-5 2017 We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells. salinomycin 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 58-62 29075110-5 2017 We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells. salinomycin 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 29075110-5 2017 We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells. salinomycin 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 29075110-6 2017 METHODS: The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo. Polymers 99-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 29075110-6 2017 METHODS: The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo. salinomycin 113-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 28777668-0 2017 Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model. gemcitabine 121-132 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 28777668-7 2017 Moreover, when tumor-bearing mice were treated with gemcitabine, they displayed HER2 vaccine-mediated antitumor activity, suggesting that cytotoxic drug treatment makes tumor cells susceptible to lysis by CTLs. gemcitabine 52-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 28777668-8 2017 Thus, these studies show that therapeutic control of HER2 DNA vaccines can be achieved by anti-Gr-1 Ab treatment through MDSC depletion and by gemcitabine treatment through sensitization of tumor cells to CTL-mediated killing in this model. gemcitabine 143-154 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 29088782-4 2017 The peptidomimetic (Cyclo(1,10)PpR (R) Anapa-FDDF-(R)-Anapa)R, compound 18) was shown to exhibit antiproliferative activity with an IC50 of 194 nM in HER2-expressing breast cancer cell lines and 18 nM in lung cancer cell lines. (r) anapa-fddf-(r)-anapa 35-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 28577439-4 2017 tumor xenografts was found to have greater therapeutic efficacy when directly compared with 212Pb-trastuzumab, which binds to HER2. Lead-212 92-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 29147611-0 2017 Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. Chloroquine 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-87 29147611-0 2017 Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. Curcumin 62-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-87 29147611-3 2017 In this study, we evaluated the in vitro and in vivo anti-cancer effect of curcumin (CUR) against Her2/neu overexpressing breast cancer cells (TUBO) in the presence or in the absence of the autophagy inhibitor chloroquine (CQ). Curcumin 75-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-106 28947975-6 2017 Reduced tumor size after phenformin treatment (30 mg/kg/day) was demonstrated in an MMTV-ErbB2 transgenic mouse syngeneic tumor model. Phenformin 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-94 28947975-7 2017 Phenformin also blocked epithelial-mesenchymal transition, decreased the invasive phenotype, and suppressed receptor tyrosine kinase signaling, including insulin receptor substrate 1 and IGF1R, in ErbB2-overexpressing breast cancer cells and mouse mammary tumor-derived tissues. Phenformin 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 197-202 28489607-1 2017 Trans-Scirpusin A (TSA) is a resveratrol oligomer found in Borassus flabellifer L. We found that TSA inhibited the growth of colorectal cancer Her2/CT26 cells in vivo in mice. trans-scirpusin a 0-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 28489607-1 2017 Trans-Scirpusin A (TSA) is a resveratrol oligomer found in Borassus flabellifer L. We found that TSA inhibited the growth of colorectal cancer Her2/CT26 cells in vivo in mice. trichostatin A 19-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 28489607-1 2017 Trans-Scirpusin A (TSA) is a resveratrol oligomer found in Borassus flabellifer L. We found that TSA inhibited the growth of colorectal cancer Her2/CT26 cells in vivo in mice. trichostatin A 97-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 28483787-2 2017 We examined to what extent preexisting antigen-specific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2+ breast tumors. chromium dinicotinate 160-163 erb-b2 receptor tyrosine kinase 2 Mus musculus 197-202 28396358-2 2017 We previously showed that HER2+/PIK3CAH1047R transgenic mammary tumors are resistant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib (TPB). NVP-BKM120 165-175 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 28396358-2 2017 We previously showed that HER2+/PIK3CAH1047R transgenic mammary tumors are resistant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib (TPB). tetraphenylbenzidine 177-180 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 28483787-3 2017 ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100% of nontolerant parental FVB/N mice. adu s-100 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-23 29367538-2 2017 In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-induced cell death. Doxorubicin 168-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 28288939-1 2017 Afatinib is a highly selective, irreversible inhibitor of EGFR and HER-2. Afatinib 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-72 28397106-0 2017 Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. neratinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-50 27565629-0 2017 Targeted tumor MRI with gadobutrol-loaded anti-HER2 immunoliposomes. gadobutrol 24-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-51 27565629-10 2017 Gd-ILs demonstrated superior tumor enhancement over control non target contrast agent and gadobutrol in HER2 overexpressing tumors at 60, 120 and 180 min post- injection. gadobutrol 90-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 28397106-4 2017 Neratinib"s efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 28397106-0 2017 Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. neratinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 28397106-4 2017 Neratinib"s efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-149 28397106-6 2017 Neratinib"s in vivo efficacy was evaluated in HER2-amplified epithelial ovarian carcinoma xenografts. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-50 28397106-8 2017 Neratinib showed significantly higher efficacy in treating HER2/neu-amplified cell lines when compared to the non-HER2/neu-amplified tumor cell lines (mean +- SEM IC50:0.010 muM +- 0.0003 vs. 0.076 muM +- 0.005 p < 0.0001). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-63 28397106-8 2017 Neratinib showed significantly higher efficacy in treating HER2/neu-amplified cell lines when compared to the non-HER2/neu-amplified tumor cell lines (mean +- SEM IC50:0.010 muM +- 0.0003 vs. 0.076 muM +- 0.005 p < 0.0001). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-67 28397106-10 2017 Neratinib prolonged survival in mice harboring HER2-amplified epithelial ovarian carcinoma xenografts (p = 0.003). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-51 28397106-11 2017 Neratinib inhibits proliferation, signaling, cell cycle progression and tumor growth of HER2-amplified epithelial ovarian carcinoma in vitro. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 28397106-12 2017 Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 28397106-12 2017 Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-77 28282145-5 2017 The modification of PGA-g-PEG-AHNP not only increased the serum stability of the nanodroplets but also improved the affinity between nanodroplets and Her2-overexpressing breast cells. pga-g-peg-ahnp 20-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 28394918-2 2017 Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. dacomitinib 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-158 28394918-2 2017 Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. dacomitinib 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-158 28245129-3 2017 IRDye800CW or IRdye680RD were conjugated either randomly (via lysines) or site-specifically (via C-terminal cysteine) to the anti-HER2 nanobody 2Rs15d. Cysteine 108-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 29515638-0 2017 The HER-2 as a Target Gene of Curcumin to Protect Hepatocytes Against the Arsenic-induced Carcinoma in Mice. Curcumin 30-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-9 27931797-5 2017 Compared with control littermates, Erbb2del mice remained free of papillomas for a longer time and had significantly reduced tumor burden after application of the 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate multistage chemical carcinogenesis protocol. 7,12-dimethylbenz 163-180 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-40 27931797-5 2017 Compared with control littermates, Erbb2del mice remained free of papillomas for a longer time and had significantly reduced tumor burden after application of the 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate multistage chemical carcinogenesis protocol. anthracene 183-193 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-40 27931797-5 2017 Compared with control littermates, Erbb2del mice remained free of papillomas for a longer time and had significantly reduced tumor burden after application of the 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate multistage chemical carcinogenesis protocol. Tetradecanoylphorbol Acetate 194-230 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-40 27931797-6 2017 Furthermore, tumor cell proliferation was substantially reduced in Erbb2del mice, and loss of ERBB2 also decreased keratinocyte proliferation after 12-O-tetradecanoylphorbol-13-acetate application. Tetradecanoylphorbol Acetate 148-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-99 29515638-0 2017 The HER-2 as a Target Gene of Curcumin to Protect Hepatocytes Against the Arsenic-induced Carcinoma in Mice. Arsenic 74-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-9 29515638-1 2017 Background & objective: The HER-2 gene is an important on co protein overexpressed in many types of cancers. Adenosine Monophosphate 12-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-37 29515638-2 2017 The current study hypothesized that curcumin downregulates HER-2 and inhibits the signal transduction pathway of PI3K/Akt, MAPK, and activation of NFkappaB, which could be useful to treat overexpressed-HER-2 hepatocellular carcinoma (HCC). Curcumin 36-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-64 29515638-2 2017 The current study hypothesized that curcumin downregulates HER-2 and inhibits the signal transduction pathway of PI3K/Akt, MAPK, and activation of NFkappaB, which could be useful to treat overexpressed-HER-2 hepatocellular carcinoma (HCC). Curcumin 36-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 202-207 29515638-6 2017 Results: Gene expression analysis showed that curcumin had significantly downregulated the activity of HER-2, in poisoned mice. Curcumin 46-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-108 29515638-7 2017 Conclusion: According to the current study results, it could be concluded that curcumin has the inhibitory potential toward HER-2-overexpressed HCC. Curcumin 79-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-129 28183282-5 2017 The formulation P467-CRM-Montanide induced higher serum IgG antibody titers, compared with P467-CRM-Alum, as examined by ELISA using recombinant Her-2/neu or Her-2/neu natively expressed on the tumor cell line SK-BR-3. crm-montanide 21-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-154 28423521-9 2017 EHT1864 suppressed growth of HER2+ tumors, and enhanced response to anti-estrogen treatment in ER+ tumors. EHT 1864 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-33 28110521-0 2017 From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. sb-443342 60-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-53 28056402-9 2017 In vivo studies confirmed positive uptake of ZHER2-DeltaHBc particles in HER2-expressing tumours, compared to non-targeted DeltaHBc particles in intraperitoneal tumour-bearing mice models. deltahbc 51-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-50 28238967-0 2017 Resveratrol fuels HER2 and ERalpha-positive breast cancer behaving as proteasome inhibitor. Resveratrol 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 28183282-5 2017 The formulation P467-CRM-Montanide induced higher serum IgG antibody titers, compared with P467-CRM-Alum, as examined by ELISA using recombinant Her-2/neu or Her-2/neu natively expressed on the tumor cell line SK-BR-3. crm-montanide 21-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 158-167 27506906-1 2017 PURPOSE: Evaluation of [18F]fluoromisonidazole ([18F]FMISO)-positron emission tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy with histological validation in a murine model of HER2+ breast cancer. fluoromisonidazole 23-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 218-222 28155894-0 2017 Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer. Porphyrins 54-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 28061785-0 2017 Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. Lapatinib 29-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-112 27872093-6 2017 To evaluate the in vivo stability of Lx and its effect on pharmacokinetics and tumor targeting of an ADC, Lx-DFO was conjugated to the HER2 mAb trastuzumab, followed by radiolabeling with 89Zr. lx-dfo 106-112 erb-b2 receptor tyrosine kinase 2 Mus musculus 135-139 28061785-2 2017 Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-69 28160858-13 2017 Finally, EA6 (20mg/kg/day) significantly reduced mammary tumor volume in 4T-1 bearing mice by down-regulating HER2/EGFR/integrin beta3 expression in tumor tissues. erythro-austrobailignan-6 9-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 27813707-10 2017 We conclude that PET/CT imaging with 64Cu-NOTA-pertuzumab F(ab")2 detected changes in HER2 expression in response to trastuzumab while delivering a lower total body radiation dose compared to 111In-labeled pertuzumab. 64cu-nota 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 27411392-0 2017 Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Phospholipids 143-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-50 27411392-0 2017 Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Phospholipids 143-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-54 28061785-2 2017 Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-104 28061785-8 2017 Then, we tested the efficacy of brief exposure to lapatinib (100 mg/kg/day for 8 weeks), beginning at 16 weeks of age, in the prevention of mammary tumor development in MMTV-erbB-2 mice. Lapatinib 50-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-180 28061785-12 2017 Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues. Lapatinib 34-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-108 28061785-16 2017 Our findings support further clinical testing to explore the benefit of shorter lapatinib exposure in the prevention of erbB-2-mediated carcinogenesis. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-126 27880046-7 2017 In vivo A549 xenograft analysis also demonstrated decreased expression levels of Hsp90-p23 association and diminished protein levels of ErbB2 and HIF-1alpha in mice supplemented with dietary DHA. Docosahexaenoic Acids 191-194 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-141 27563814-12 2016 Co-treatments with MTI-31 and etomoxir enhanced the suppression of cyclin D1, c-Myc and cell growth in HER2+/PIK3CAmut tumors. MTI-31 19-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-107 27974799-2 2016 Here, by studying metastasis in a HER2-driven mouse breast cancer model, we show that progesterone-induced signalling triggers migration of cancer cells from early lesions shortly after HER2 activation, but promotes proliferation in advanced primary tumour cells. Progesterone 86-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-38 27974799-2 2016 Here, by studying metastasis in a HER2-driven mouse breast cancer model, we show that progesterone-induced signalling triggers migration of cancer cells from early lesions shortly after HER2 activation, but promotes proliferation in advanced primary tumour cells. Progesterone 86-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 186-190 28138518-8 2016 zECM-treated groups exhibit proliferation of the remaining cardiomyocytes and multiple cardiac precursor cell populations and reactivation of ErbB2 expression in cardiomyocytes. zecm 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-147 28123895-0 2016 The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. C10Ph 29-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-48 27473824-3 2016 Here, we explored a dual-targeting strategy to incorporate tumor-tropic MSC delivery with HER2-specific killing by the immunoapoptotin e23sFv-Fdt-tBid generated in our previous studies. fdt-tbid 142-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-94 27998284-10 2016 In MCF10A-ERBB2 cells, glucose restriction or GLUT1 inhibition blocked transformation induced by activated ERBB2 through reduced cell proliferation. Glucose 23-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-15 27998284-10 2016 In MCF10A-ERBB2 cells, glucose restriction or GLUT1 inhibition blocked transformation induced by activated ERBB2 through reduced cell proliferation. Glucose 23-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-112 27831759-4 2016 In this research, AMF was introduced to evaluate therapeutic effects of magnetic hyperthermia on radionuclide-chemo therapy of HER2+ cells and tumor (HER2+)-bearing mice. Radioisotopes 97-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 127-131 27563814-12 2016 Co-treatments with MTI-31 and etomoxir enhanced the suppression of cyclin D1, c-Myc and cell growth in HER2+/PIK3CAmut tumors. etomoxir 30-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-107 27337051-5 2016 The mice treated with 2T-Dox-MNCs + multistage magnetic targeting (MT) (2 h d(-1) ) show 7.63-fold, 3.25-fold, and 2.7-fold reduction in HER2-positive tumor volume compared to Dox-MNCs, 2T-Dox-MNCs, and 2T-Dox-MNCs + single MT (12 h). 2t-dox 22-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-141 27711378-2 2016 The new conjugates were radiolabeled with zirconium-89 to give complexes that are more resistant to ligand exchange when compared to currently used H3DFO derivatives and result in high quality positron emission tomography images in mouse models of HER2 positive breast cancer. Zirconium 42-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 248-252 27486759-5 2016 The complete eradication of a significant number of tumor lesions occurred only in mice receiving cyclophosphamide shortly before immunotherapy, and was associated with increased serum anti HER-2/p185 antibodies and tumor leukocyte infiltration. Cyclophosphamide 98-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 190-195 27197158-7 2016 In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 3-7 27337051-5 2016 The mice treated with 2T-Dox-MNCs + multistage magnetic targeting (MT) (2 h d(-1) ) show 7.63-fold, 3.25-fold, and 2.7-fold reduction in HER2-positive tumor volume compared to Dox-MNCs, 2T-Dox-MNCs, and 2T-Dox-MNCs + single MT (12 h). Doxorubicin 25-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-141 27416801-6 2016 METHODS: We evaluated the effect of chronic alcohol exposure on mammary tumor development/metastasis in MMTV-neu transgenic mice and investigated the cell signaling in response to alcohol exposure in breast cancer cells overexpressing ErbB2/HER2. Alcohols 180-187 erb-b2 receptor tyrosine kinase 2 Mus musculus 235-240 27260485-0 2016 Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Poly I-C 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-68 27416801-6 2016 METHODS: We evaluated the effect of chronic alcohol exposure on mammary tumor development/metastasis in MMTV-neu transgenic mice and investigated the cell signaling in response to alcohol exposure in breast cancer cells overexpressing ErbB2/HER2. Alcohols 180-187 erb-b2 receptor tyrosine kinase 2 Mus musculus 241-245 27105499-5 2016 Here, we found that early DTC isolated from BM of 15-17 week-old Her2/neu transgenic (BALB-neuT) mice were not tumorigenic in immunodeficient mice. dtc 26-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-73 26429962-10 2016 Tumor growth was evaluated over a period of 49 d. RESULTS: (177)Lu-DOTA-Fab-PEG24-EGF bound specifically to HER2 and EGFR on tumor cells. lu-dota-fab 64-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-112 27039149-0 2016 Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Doxorubicin 117-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-85 26972276-0 2016 Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Doxorubicin 71-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 173-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 173-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-137 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 173-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 186-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 186-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 186-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-137 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Doxorubicin 186-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 26972276-4 2016 To establish efficient and reliable drug delivery to HER2-overexpressing cells, the authors of this study have developed anti-HER2 (ErbB2) peptide-liposomal formulations of doxorubicin (DOX) by an engineered breast tumor-targeting peptide ligand, AHNP, Anti-HER2/neu peptide, (FCDGFYACYADV) with three glycine amino acids as spacer before its original sequencing. Glycine 302-321 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-137 26972276-9 2016 Overall, the results showed that optimum AHNP density functionalization of PLD can significantly improve selectivity and the therapeutic index of liposomal DOX in the treatment of HER2 positive breast cancer and merits further investigation. Doxorubicin 156-159 erb-b2 receptor tyrosine kinase 2 Mus musculus 180-184 26429962-2 2016 We have developed (111)In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR on BC cells by linking trastuzumab Fab fragments through a polyethylene glycol (PEG24) spacer to epidermal growth factor (EGF). Polyethylene Glycols 159-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 27293993-7 2016 Furthermore, low-dose lapatinib treatment, starting at the early stages of mammary grand transformation in the MMTV-neu* mouse model, significantly delayed mammary tumor initiation and progression, extended tumor-free survival, which corresponded to effective inhibition of HER2/Akt signaling and downregulation of GLUT4 in vivo. Lapatinib 22-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 274-278 25691133-7 2016 In cell culture, the NBs-Her adhered to Her-2-positive cells significantly better than to Her-2-negative cells (p < 0.05). Niobium 21-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 25691133-7 2016 In cell culture, the NBs-Her adhered to Her-2-positive cells significantly better than to Her-2-negative cells (p < 0.05). Niobium 21-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-95 27067045-3 2016 METHODS: The GMP grade anti-HER2 nanobody was labeled with the prosthetic group, N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]-SFB), and its biodistribution, tumor targeting and specificity were evaluated in mouse and rat tumor models. N-succinimidyl-4-fluorobenzoate 81-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-32 26692570-1 2016 AIMS: Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Doxorubicin 79-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-40 26692570-2 2016 Since isoproterenol up-regulates ErbB2 in kidney and salivary glands and beta2AR and ErbB2 complex in brain and heart, we hypothesized that beta-adrenergic receptors (AR) modulate ErbB2 signalling status. Isoproterenol 6-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 26692570-4 2016 Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2(tg)) mice have amplified response to selective beta2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with beta2-antagonist ICI-118 551. zinterol 150-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-66 26692570-4 2016 Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2(tg)) mice have amplified response to selective beta2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with beta2-antagonist ICI-118 551. zinterol 150-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-88 26692570-5 2016 Consistently, receptor binding assays and western blotting demonstrate that beta2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Lapatinib 176-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 159-164 26692570-6 2016 Intriguingly, acute treatment of mice with beta1- and beta2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either beta1- or beta2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Isoproterenol 71-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-113 26692570-6 2016 Intriguingly, acute treatment of mice with beta1- and beta2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either beta1- or beta2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Isoproterenol 71-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 232-237 26712117-1 2016 Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2-positive metastatic breast cancer. t-dm1 0-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 26712117-1 2016 Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2-positive metastatic breast cancer. t-dm1 27-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 26785603-0 2016 Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER(-)/PR(-)/HER2(-)). ferric oxide 11-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 26941844-0 2016 Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice. 3-hydroxypyridin-2-one 16-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 26721874-4 2016 Here, we show the utility of a genetically engineered mouse model of HER2-driven breast cancer (MMTV-NIC) to define mechanisms of resistance to the pan-HER family inhibitor AZD8931. AZD 8931 173-180 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 26785603-0 2016 Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER(-)/PR(-)/HER2(-)). ferryl iron 23-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 26461116-4 2016 We show that these particulate PMVs can be easily modified within 4 h by a protein transfer process to stably incorporate a glycosylphosphatidylinositol (GPI)-anchored form of the breast cancer antigen HER-2 onto the PMV surface. Glycosylphosphatidylinositols 124-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 202-207 26461116-4 2016 We show that these particulate PMVs can be easily modified within 4 h by a protein transfer process to stably incorporate a glycosylphosphatidylinositol (GPI)-anchored form of the breast cancer antigen HER-2 onto the PMV surface. Glycosylphosphatidylinositols 154-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 202-207 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Paclitaxel 106-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26567138-3 2016 A comparison of the transcriptional profiles of murine Her2(+) breast tumor TUBO cells and their derived CSC-enriched tumorspheres has identified xCT, the functional subunit of the cystine/glutamate antiporter system xc(-), as a surface protein that is upregulated specifically in tumorspheres. Cystine 181-188 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-59 26567138-3 2016 A comparison of the transcriptional profiles of murine Her2(+) breast tumor TUBO cells and their derived CSC-enriched tumorspheres has identified xCT, the functional subunit of the cystine/glutamate antiporter system xc(-), as a surface protein that is upregulated specifically in tumorspheres. Glutamic Acid 189-198 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-59 26578208-0 2016 Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Cisplatin 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 26578208-0 2016 Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Cisplatin 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 26578208-1 2016 OBJECTIVES: The purpose of this study was to investigate whether the conjugation of anti-HER2-Affibody to cisplatin PEGylated liposome can efficiently enhance the therapeutic effectiveness of the targeted liposome. Cisplatin 106-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 26578208-6 2016 RESULTS: Anti-HER2 affisome demonstrated a higher amount of platinum intracellularly, and affected HER2(+)-SK-BR-3 cell death was at lower concentrations compared with its liposome counterparts. Platinum 60-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-18 26578208-7 2016 Further, cisplatin-affisome showed greater therapeutic efficiency than nontargeted liposome in HER2(+)-TUBO models. Cisplatin 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-99 26578208-9 2016 CONCLUSIONS: Affibody-targeting endowed cisplatin liposomes with significantly enhanced, albeit modest, therapeutic activity in HER2-overexpressing tumor model; however, further values are yet to be determined to advance clinical translation of these targeted nanoparticulates. Cisplatin 40-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 128-132 26722378-6 2016 In vivo MR imaging showed that MnMEIO-CyTE777-(Bis)-mPEG NPs could specifically and effectively target to HER2/neu- and EGFR-expressing tumors in mice; the relative contrast enhancements were 11.8 (at 2 hrs post-injection) and 61.5 (at 24 hrs post-injection) fold higher in SKBR-3 tumors as compared to Colo-205 tumors. monomethoxypolyethylene glycol 52-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-110 26722378-6 2016 In vivo MR imaging showed that MnMEIO-CyTE777-(Bis)-mPEG NPs could specifically and effectively target to HER2/neu- and EGFR-expressing tumors in mice; the relative contrast enhancements were 11.8 (at 2 hrs post-injection) and 61.5 (at 24 hrs post-injection) fold higher in SKBR-3 tumors as compared to Colo-205 tumors. monomethoxypolyethylene glycol 52-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-114 30444591-1 2016 In this study we established a HER2/neu expressing mouse tumor model using hepatoma MH-22a cell line tumorigenic in DBA mice. 1,2,5,6-dibenzanthracene 116-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 30444591-1 2016 In this study we established a HER2/neu expressing mouse tumor model using hepatoma MH-22a cell line tumorigenic in DBA mice. 1,2,5,6-dibenzanthracene 116-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-39 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 48-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26791520-8 2016 This study identifies and validates improved perfusion characteristics following trastuzumab therapy, resulting in an improvement in trastuzumab-doxorubicin combination therapy in a murine model of HER2+ breast cancer. Doxorubicin 145-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 198-202 28133539-4 2016 We recently reviewed different mouse models of BC overexpressing wild type or mutant neu driven by MMTV, neu, or doxycycline-inducible promoters. Doxycycline 113-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-88 26392569-4 2016 In the current study, the role of the CBM complex in HER2-mediated NF-kappaB activation and HER2-positive breast cancer was investigated. N-(4-chlorobenzoyl)melatonin 38-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Paclitaxel 118-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Lapatinib 46-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Paclitaxel 55-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Lapatinib 141-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Paclitaxel 211-214 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Paclitaxel 211-214 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-9 2015 To summarize, this localized co-delivery system with good synergistic effects between LAPA and PTX might offer a potential strategy for HER2 and P-gp positive breast cancer. Lapatinib 86-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 26474677-9 2015 To summarize, this localized co-delivery system with good synergistic effects between LAPA and PTX might offer a potential strategy for HER2 and P-gp positive breast cancer. Paclitaxel 95-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 26260909-0 2015 Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-49 26383165-4 2015 Src kinase blockade with the small-molecule inhibitor saracatinib prevented the disorganized three-dimensional growth of ER(-) mammary epithelial cells in vitro and delayed the development of premalignant lesions and tumors in vivo in mouse models developing HER2(+) and ER(-) mammary tumors, extending tumor-free and overall survival. saracatinib 54-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 259-263 26539808-8 2015 Furthermore, in vitro and in vivo data indicated that LHNPs presented the strong ability to induce apoptosis and superior anti-tumor efficacy in tumor-bearing mice to the commercial tablet Tykerb through the inhibition of HER2 phosphorylation. lhnps 54-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 222-226 26337386-0 2015 Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Lapatinib 93-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 26337386-3 2015 Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib. Lapatinib 259-268 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-181 26337386-6 2015 Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased. Lapatinib 137-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 26168818-0 2015 Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Berberine 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-116 26168818-0 2015 Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Berberine 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-120 26260909-3 2015 The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma. neratinib 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-95 26260909-4 2015 METHODS: The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. neratinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-59 26260909-4 2015 METHODS: The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. neratinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 187-195 26168818-0 2015 Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. 13-(4-chlorophenylethyl)berberine 64-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-116 26168818-0 2015 Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. 13-(4-chlorophenylethyl)berberine 64-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-120 26168818-2 2015 We recently demonstrated that BBR and its synthetic derivative 13-(4-chlorophenylethyl)berberine iodide, NAX014, exert antiproliferative activity against HER2-overexpressing breast cancer cells, inducing apoptosis, modulating the expression of cell cycle checkpoint molecules involved in cell senescence, and reducing both HER2 expression and phosphorylation on tumor cells. 13-(4-chlorophenylethyl)berberine 63-103 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 26168818-2 2015 We recently demonstrated that BBR and its synthetic derivative 13-(4-chlorophenylethyl)berberine iodide, NAX014, exert antiproliferative activity against HER2-overexpressing breast cancer cells, inducing apoptosis, modulating the expression of cell cycle checkpoint molecules involved in cell senescence, and reducing both HER2 expression and phosphorylation on tumor cells. 13-(4-chlorophenylethyl)berberine 63-103 erb-b2 receptor tyrosine kinase 2 Mus musculus 323-327 26168818-2 2015 We recently demonstrated that BBR and its synthetic derivative 13-(4-chlorophenylethyl)berberine iodide, NAX014, exert antiproliferative activity against HER2-overexpressing breast cancer cells, inducing apoptosis, modulating the expression of cell cycle checkpoint molecules involved in cell senescence, and reducing both HER2 expression and phosphorylation on tumor cells. 13-(4-chlorophenylethyl)berberine 105-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 26168818-2 2015 We recently demonstrated that BBR and its synthetic derivative 13-(4-chlorophenylethyl)berberine iodide, NAX014, exert antiproliferative activity against HER2-overexpressing breast cancer cells, inducing apoptosis, modulating the expression of cell cycle checkpoint molecules involved in cell senescence, and reducing both HER2 expression and phosphorylation on tumor cells. 13-(4-chlorophenylethyl)berberine 105-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 323-327 26168818-10 2015 The results of the present study indicate that NAX014 is more effective than BBR in exerting anticancer activity delaying the development of mammary tumors in mice transgenic for the HER-2/neu oncogene. 13-(4-chlorophenylethyl)berberine 47-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-192 26260909-6 2015 The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts. neratinib 16-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 26260909-8 2015 HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+-SEM IC50:0.014muM+-0.004vs.0.164muM+-0.019 p=0.0003). neratinib 87-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 26260909-8 2015 HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+-SEM IC50:0.014muM+-0.004vs.0.164muM+-0.019 p=0.0003). neratinib 87-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 5-8 26260909-9 2015 Neratinib treatment caused a significant build up in G0/G1 phase of the cell cycle, arrest auto phosphorylation of HER2/neu and activation of S6. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-123 26260909-10 2015 Neratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 26260909-11 2015 CONCLUSIONS: Neratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro. neratinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-36 26260909-12 2015 Neratinib inhibits HER2/neu amplified xenograft growth and improves overall survival. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 26260909-12 2015 Neratinib inhibits HER2/neu amplified xenograft growth and improves overall survival. neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-27 24798404-2 2015 UV radiation causes DNA damage leading to mutations and also activates the Erbb2/HER2 receptor through indirect mechanisms involving reactive oxygen species. Reactive Oxygen Species 133-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 24798404-2 2015 UV radiation causes DNA damage leading to mutations and also activates the Erbb2/HER2 receptor through indirect mechanisms involving reactive oxygen species. Reactive Oxygen Species 133-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-85 24798404-4 2015 Following the induction of benign squamous papillomas by UV exposure of v-ras(Ha) transgenic Tg.AC mice, mice were treated topically with the Erbb2 inhibitor AG825 and tumor progression monitored. tyrphostin AG825 158-163 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-147 25958246-1 2015 A (13)C-enriched phosphorylcholine polymer ((13)C-PMPC) as a self-traceable MR (magnetic resonance) tag was conjugated with a fragment (scFv) of Herceptin, a clinical antibody against antigen Her2. Phosphorylcholine 17-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-196 26086099-12 2015 Our findings indicate that TSA effectively inhibits Grg1-induced lung tumorigenesis through the down-regulation of ErbB1 and ErbB2, as well as reduced VEGF signaling. trichostatin A 27-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 125-130 25347743-6 2015 Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2(+) breast cancer. Lapatinib 84-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-126 26198000-1 2015 BACKGROUND: Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for breast cancer care but mostly focused on HER2-negative subtypes. Sunitinib 42-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 26198000-13 2015 CONCLUSIONS: [(18)F]FDG and [(18)F]FMISO PET were relevant approaches to study the response to sunitinib in this luminal B (HER2-positive) model. Sunitinib 95-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-128 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. Fatty Acids, Omega-3 30-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-156 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. Fatty Acids, Omega-3 30-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 201-205 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. alpha-Linolenic Acid 45-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-156 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. alpha-Linolenic Acid 45-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 201-205 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. alpha-Linolenic Acid 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-156 26282560-1 2015 BACKGROUND: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in mouse models. alpha-Linolenic Acid 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 201-205 26086099-8 2015 TSA did not affect overall Grg1 protein levels, but instead reduced ErbB1 and ErbB2 expression, which are upregulated by Grg1 in the absence of TSA. trichostatin A 0-3 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-83 26086099-10 2015 Furthermore, lapatinib, an inhibitor of both ErbB1 and ErbB2, effectively masked the effect of TSA on the inhibition of A549 cell proliferation and migration, suggesting TSA does work, at least in part, by downregulating ErbB receptors. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 26086099-10 2015 Furthermore, lapatinib, an inhibitor of both ErbB1 and ErbB2, effectively masked the effect of TSA on the inhibition of A549 cell proliferation and migration, suggesting TSA does work, at least in part, by downregulating ErbB receptors. trichostatin A 95-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 26086099-10 2015 Furthermore, lapatinib, an inhibitor of both ErbB1 and ErbB2, effectively masked the effect of TSA on the inhibition of A549 cell proliferation and migration, suggesting TSA does work, at least in part, by downregulating ErbB receptors. trichostatin A 170-173 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 25958246-1 2015 A (13)C-enriched phosphorylcholine polymer ((13)C-PMPC) as a self-traceable MR (magnetic resonance) tag was conjugated with a fragment (scFv) of Herceptin, a clinical antibody against antigen Her2. Carbon 6-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-196 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-56 26132162-9 2015 Further, when tested in vivo in a HER-2-overexpressing ovarian cancer xenograft mouse model, enzymatically generated trastuzumab-maytansine was found to lead to complete regression of established tumors, similar to Kadcyla. Maytansine 129-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 25689082-4 2015 We converted the breast cancer HER-2 antigen to a glycosylphosphatidylinositol (GPI)-anchored form and incorporated GPI-HER-2 onto VLPs by a rapid protein transfer process. Glycosylphosphatidylinositols 50-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36 25689082-4 2015 We converted the breast cancer HER-2 antigen to a glycosylphosphatidylinositol (GPI)-anchored form and incorporated GPI-HER-2 onto VLPs by a rapid protein transfer process. Glycosylphosphatidylinositols 80-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36 25689082-7 2015 The Soluble form of GPI-HER-2 induced only a weak Th2 response under similar conditions. th2 50-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-29 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 25700543-3 2015 Previous studies have indicated that lapatinib, a selective small-molecular dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in reducing cancer progression and metastasis, indicating that it might be a candidate for TNBC treatment. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. tc-gly 64-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. tc-gly 64-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. tc-gly 64-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. alanylglycine 74-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. alanylglycine 74-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. alanylglycine 74-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. Glycine 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. Glycine 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 25735223-3 2015 The purpose of this study was to evaluate SPECT imaging of (99m)Tc-Gly-(D)Ala-Gly-Gly-Z(HER2:342) ((99m)Tc-peptide-Z(HER2:342)) for monitoring therapeutic response to trastuzumab in nude mice bearing HER2-positive SKOV-3 xenografts. Glycine 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 26055175-8 2015 The mean volume of an MDA-MB-231-BR-HER2 tumor was significantly larger compared to other models (F2,12 = 5.845, P < .05); interestingly, this model also had a significantly higher proportion of Gd-impermeable tumors (F2,12 = 22.18, P < .0001). Gadolinium 198-200 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 26055175-9 2015 Ki67 staining indicated that Gd-impermeable tumors had significantly more proliferative nuclei compared to Gd-permeable tumors (t[24] = 2.389, P < .05) in the MDA-MB-231-BR-HER2 model. Gadolinium 29-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-180 25918676-0 2015 Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. Doxorubicin 110-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 25918676-0 2015 Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. Doxorubicin 110-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 25853264-0 2015 In Utero exposure to low-dose alcohol induces reprogramming of mammary development and tumor risk in MMTV-erbB-2 transgenic mice. Alcohols 30-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-112 25853264-8 2015 The results indicate that in utero exposure to low-dose alcohol induces the reprogramming of mammary development by mechanisms that include altered signaling in the estrogen receptor (ER) and erbB-2 pathways. Alcohols 56-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-198 25646013-3 2015 Breast cancer cell lines were exposed to multiple cycles of anti-Her2 trastuzumab-maytansinoid ADC (TM-ADC) at IC80 concentrations followed by recovery. trastuzumab-maytansinoid adc 70-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 25646013-3 2015 Breast cancer cell lines were exposed to multiple cycles of anti-Her2 trastuzumab-maytansinoid ADC (TM-ADC) at IC80 concentrations followed by recovery. tm-adc 100-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 25597638-1 2015 We fabricated a targeted delivery system for doxorubicin (Dox) using beta-1,3-glucan (Glu) as a carrier and decorated by trastuzumab antibody having the status of targeting agent against Her2+ breast tumors. Doxorubicin 45-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 187-191 25597638-1 2015 We fabricated a targeted delivery system for doxorubicin (Dox) using beta-1,3-glucan (Glu) as a carrier and decorated by trastuzumab antibody having the status of targeting agent against Her2+ breast tumors. Doxorubicin 58-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 187-191 25627551-0 2015 The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. imetelstat 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-146 25723091-4 2015 PA images demonstrated that INDs accumulate in tumors and completely delineated the entire tumor within 10 h. HER2 targeting significantly enhanced imaging of HER2-positive tumors. Protactinium 0-2 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 25723091-4 2015 PA images demonstrated that INDs accumulate in tumors and completely delineated the entire tumor within 10 h. HER2 targeting significantly enhanced imaging of HER2-positive tumors. inds 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 25949865-11 2015 Adv/GM treatment and they generated greater HER2-specific T-cell responses. gm 4-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 25196138-6 2015 In vivo, biguanides inhibited local and metastatic growth of triple negative and HER2+ BC in immune-competent and immune-deficient mice orthotopically injected with BC. Biguanides 9-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-85 25196138-7 2015 Biguanides inhibited local and metastatic BC growth in a genetically engineered murine model model of HER2+ BC. Biguanides 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-106 25627551-4 2015 The purpose of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat (GRN163L), on CSC and non-CSC populations of HER2(+) breast cancer cell lines. Oligonucleotides 86-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 159-163 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 25168102-0 2014 The effect of tamoxifen on expression of ER, PR, Cerb-B2, and ki-67 in C3H mice spontaneous breast cancer model and the relation with chemotherapeutic effect. Tamoxifen 14-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-56 25492620-7 2015 Overall, this study demonstrates that the incorporation of An2 to the anti-HER2 mAb confers properties of increased uptake in brain endothelial cells as well as BBB permeability. Angiopep-2 59-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 25168102-1 2014 To explore the effect of tamoxifen on expression of ER, PR, Cerb-B2, and ki-67 in C3H mice spontaneous breast cancer model and further explore its relation with chemotherapeutic effect. Tamoxifen 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-67 25168102-10 2014 After being treated with tamoxifen, expression levels of ER, PR, Cerb-B2 and ki-67 are changed, and change of ER, PR, Cerb-B2, and ki-67 can predict the therapeutical effect of tamoxifen. Tamoxifen 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-72 25168102-10 2014 After being treated with tamoxifen, expression levels of ER, PR, Cerb-B2 and ki-67 are changed, and change of ER, PR, Cerb-B2, and ki-67 can predict the therapeutical effect of tamoxifen. Tamoxifen 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-125 25168102-10 2014 After being treated with tamoxifen, expression levels of ER, PR, Cerb-B2 and ki-67 are changed, and change of ER, PR, Cerb-B2, and ki-67 can predict the therapeutical effect of tamoxifen. Tamoxifen 177-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-72 25168102-10 2014 After being treated with tamoxifen, expression levels of ER, PR, Cerb-B2 and ki-67 are changed, and change of ER, PR, Cerb-B2, and ki-67 can predict the therapeutical effect of tamoxifen. Tamoxifen 177-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-125 25217659-10 2014 The EGFR inhibitor, AG1478, decreased proliferation by 99, and the Erb-B2 inhibitor, AG825, decreased proliferation by ~66%. tyrphostin AG825 85-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-73 24723360-0 2014 Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. polymac 30-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 24723360-3 2014 We describe the first analysis of a tissue phosphoproteome using polymer-based metal ion affinity capture (PolyMAC), a nanopolymer that has excellent yield and specificity for phosphopeptide enrichment, on a transgenic mouse model of HER2-driven breast cancer. Metals 79-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-238 24723360-3 2014 We describe the first analysis of a tissue phosphoproteome using polymer-based metal ion affinity capture (PolyMAC), a nanopolymer that has excellent yield and specificity for phosphopeptide enrichment, on a transgenic mouse model of HER2-driven breast cancer. polymac 107-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-238 25303645-7 2014 A Fab fragment of the anti-Her2 antibody was thiolated with iminothiolane, and NOTA-MI-Mal was conjugated with the antibody fragment by maleimide-thiol chemistry. iminothiolane 60-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-31 25303645-7 2014 A Fab fragment of the anti-Her2 antibody was thiolated with iminothiolane, and NOTA-MI-Mal was conjugated with the antibody fragment by maleimide-thiol chemistry. nota-mi-mal 79-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-31 25303645-7 2014 A Fab fragment of the anti-Her2 antibody was thiolated with iminothiolane, and NOTA-MI-Mal was conjugated with the antibody fragment by maleimide-thiol chemistry. maleimide-thiol 136-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-31 25224570-2 2014 The aim of this study was to develop a simple and effective lipid-based vaccine delivery system using P5 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. maleimide 144-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-109 25224570-2 2014 The aim of this study was to develop a simple and effective lipid-based vaccine delivery system using P5 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. maleimide 144-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-113 25224570-2 2014 The aim of this study was to develop a simple and effective lipid-based vaccine delivery system using P5 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. diethylene glycol 154-161 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-113 25116755-4 2014 We hypothesized that cyclophosphamide-modulated vaccination with HER2-specific mAb safely induces relevant HER2-specific immunity in neu mice and patients with HER2+ metastatic breast cancer. Cyclophosphamide 21-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 24890382-2 2014 In this study, we evaluated for the first time Trastuzumab emtansine (T-DM1), a novel antibody-drug conjugate, against multiple epidermal growth factor receptor-2 (HER2)-positive USC cells in vitro followed by developing a supportive in vivo model. t-dm1 47-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-168 25426294-6 2014 METHODS: Activation and tumor targeting of iNKT cells via recombinant alpha-galactosylceramide (alphaGC)-loaded CD1d-anti-HER2 fusion protein (CD1d-antitumor) is combined or not with OVA peptide/CpG vaccine. alpha-galactosylceramide 70-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-126 25172762-8 2014 Taselisib was highly active at reducing tumor growth in vivo in USC mouse xenografts harboring PIK3CA mutation and overexpressing HER2/neu (P=0.007). 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-138 25105924-4 2014 Western blot assay indicated that 34 was more potent than 17-AAG in the down-regulation of Hsp90 client proteins CDK4, Her2, EGFR and Raf. tanespimycin 58-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-123 25092895-0 2014 Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. CPG-oligonucleotide 28-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 25092895-0 2014 Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. CPG-oligonucleotide 28-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-112 25116755-4 2014 We hypothesized that cyclophosphamide-modulated vaccination with HER2-specific mAb safely induces relevant HER2-specific immunity in neu mice and patients with HER2+ metastatic breast cancer. Cyclophosphamide 21-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-111 25116755-5 2014 Adding both cyclophosphamide and the HER2-specific mAb 7.16.4 to vaccination maximized HER2-specific CD8+ T-cell immunity and tumor-free survival in neu transgenic mice. Cyclophosphamide 12-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 24643779-2 2014 D-Dox-PGA or Tc-99 m labeled DTPA-succinyl-polylysine polymers (DSPL) were targeted to HER2-positive human mammary carcinoma (BT-474) in a double xenografted SCID mouse model also hosting HER2-negative human mammary carcinoma (BT-20). dtpa-succinyl-polylysine polymers 29-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 188-192 25124161-11 2014 Neratinib treated mice harboring xenografts of HER2/neu amplified USC showed delayed tumor growth and improved overall survival compared to vehicle (p=0.0019). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-51 25124161-11 2014 Neratinib treated mice harboring xenografts of HER2/neu amplified USC showed delayed tumor growth and improved overall survival compared to vehicle (p=0.0019). neratinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-55 25249538-8 2014 Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-36 24845231-6 2014 MSI-1436 antagonized HER2 signaling, inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2 mouse model of breast cancer, validating inhibition of PTP1B as a therapeutic strategy in breast cancer. 3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 21-25 24671949-3 2014 EXPERIMENTAL DESIGN: HER2-specific Affibody, conjugated to Alexafluor 750, was injected into nude mice bearing HER2-positive tumor xenograft. Alexa Fluor 750 59-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 21-25 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-16 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 25114718-4 2014 We hypothesized that anti-HER2 agents would cause increased sympathetic tone with changes in plasma catecholamines and NRG. Catecholamines 100-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 24807584-13 2014 The MMP-2/9-oriented combination strategy that employs the MMP-2/9-targeting antibody-based fusion protein and the small molecular inhibitor DOX as the basic composed agents may enhance antitumor efficacy in association with the EGFR/HER2-targeting fusion protein and GEM. Doxycycline 141-144 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-238 24556924-0 2014 Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Sirolimus 109-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-53 24463007-2 2014 The ErbB2(+) phenotype is associated with resistance to endocrine therapy, e.g. the selective estrogen receptor modulator Tamoxifen. Tamoxifen 122-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-9 24463007-6 2014 Knock-down of AKT3, but not of AKT1 or AKT2, led to reduced expression and tyrosine-phosphorylation of ErbB2 and ErbB3 in Balb-neuT-derived mammary tumor cells. Tyrosine 75-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-108 24714932-1 2014 B-cell translocation gene 1 (BTG1) is a member of the BTG/transducer of ERBB2 family, which regulates cell cycle progression in a variety of cell types and may have a role in inhibiting proliferation, promoting apoptosis and stimulating cellular differentiation in numerous cell types. beta-2'-deoxythioguanosine 29-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-77 24463007-12 2014 Our data indicate that AKT3 regulates the expression of ErbB2, ErbB3 and ERalpha and demonstrate that down-regulation of activated AKT3 can sensitize ErbB2(+) breast cancer cells for treatment with Tamoxifen. Tamoxifen 198-207 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-61 24463007-12 2014 Our data indicate that AKT3 regulates the expression of ErbB2, ErbB3 and ERalpha and demonstrate that down-regulation of activated AKT3 can sensitize ErbB2(+) breast cancer cells for treatment with Tamoxifen. Tamoxifen 198-207 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-155 24574803-5 2014 RESULTS: Orally and ip administered melatonin, Neu-P11, and Neu-P12 reduced pain responses in a dose-dependent manner. Oxacillin 64-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-63 24883121-8 2014 Similar findings were obtained with different 177Lu-DTPA-2Rs15d nanobody constructs in HER2pos tumor xenografted mice at 1 h p.i.. Kidney accumulation decreased 88% when comparing Myc-His-tagged to untagged 2Rs15d nanobody, and 95% with a coinfusion of Gelofusin, without affecting the tumor targeting capacity. 177lu-dtpa 46-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 24675532-8 2014 However, our p-RTK array analysis demonstrated that BEZ235 treatment led to increased ErbB2 expression and phosphorylation in genetically-engineered mouse tumors and in 3-D, but not 2-D, culture, leading to BEZ235 resistance. dactolisib 52-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-91 24675532-8 2014 However, our p-RTK array analysis demonstrated that BEZ235 treatment led to increased ErbB2 expression and phosphorylation in genetically-engineered mouse tumors and in 3-D, but not 2-D, culture, leading to BEZ235 resistance. dactolisib 207-213 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-91 24675532-9 2014 Mechanistically, we identified ErbB2 protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent treatment with lapatinib + BEZ235 combination. dactolisib 98-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36 24675532-9 2014 Mechanistically, we identified ErbB2 protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent treatment with lapatinib + BEZ235 combination. Lapatinib 165-174 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36 24675532-9 2014 Mechanistically, we identified ErbB2 protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent treatment with lapatinib + BEZ235 combination. dactolisib 177-183 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36 24729020-0 2014 Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. cucurbitacin B 41-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 23-27 24452693-0 2014 Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. triciribine 30-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-91 24452693-0 2014 Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. triciribine 30-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-95 24269306-3 2014 We found that the selective accumulation of the HER-2/neu targeted magnetic iron oxide nanoparticles (IONPs) led to about 5-fold contrast enhancements in the tumor for PAT, while near-infrared (NIR) dye labeled nanoparticles emitted strong optical signals for FMT. ferric oxide 76-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 24269306-3 2014 We found that the selective accumulation of the HER-2/neu targeted magnetic iron oxide nanoparticles (IONPs) led to about 5-fold contrast enhancements in the tumor for PAT, while near-infrared (NIR) dye labeled nanoparticles emitted strong optical signals for FMT. ferric oxide 76-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-57 24574803-7 2014 The antinociceptive effects of Neu-P11 or Neu-P12 were antagonized by ip or icv. icv 76-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-34 24574803-7 2014 The antinociceptive effects of Neu-P11 or Neu-P12 were antagonized by ip or icv. icv 76-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-45 24055142-6 2014 Importantly, microscopic analysis of JIMT-1 xenograft tumor tissue of archazolid treated mice confirms the defect in HER2-recycling which leads to reduced tumor growth. archazolid 70-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-121 24322659-4 2014 Previous studies demonstrated that metformin is a potent inhibitor of ErbB2-overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB2 transgenic mice in vivo. Metformin 35-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-75 24322659-4 2014 Previous studies demonstrated that metformin is a potent inhibitor of ErbB2-overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB2 transgenic mice in vivo. Metformin 35-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-200 24322659-4 2014 Previous studies demonstrated that metformin is a potent inhibitor of ErbB2-overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB2 transgenic mice in vivo. Metformin 112-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-75 24322659-4 2014 Previous studies demonstrated that metformin is a potent inhibitor of ErbB2-overexpressing breast cancer cells; metformin treatment extends the life span and impedes mammary tumor development in ErbB2 transgenic mice in vivo. Metformin 112-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-200 24292501-0 2014 Bispecific Her2 x cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. Cotinine 18-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-15 24292501-8 2014 In single-photon emission computed tomography (SPECT), the complex of tandem scFv Fc fusion protein and (125)I-cotinine peptide was localized to Her2-positive tumor xenografts in mice 4 h after the first injection. cotinine peptide 111-127 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-149 24451154-9 2014 RESULTS: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2 tyrosine kinase inhibitor lapatinib. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-115 24451154-12 2014 In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. Lapatinib 101-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-20 24451154-12 2014 In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. Lapatinib 101-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 24451154-14 2014 In a PIK3CA-mutant HER2+ xenograft, PI3K inhibition with BKM120 in combination with lapatinib and trastuzumab was required to achieve tumor regression. NVP-BKM120 57-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 24227890-8 2014 Bi-Ab more effectively inhibited cancer growth in SKOV-3 HER2- and IGF-IR-overexpressing cancer xenograft mouse model than m590 and trastuzumab alone or in combination. Antibodies, Bispecific 0-5 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 24344772-7 2014 To verify this, we have produced two variants of the HER2-targeting ZHER2:342 Affibody molecule by peptide synthesis: OA-PEP4313, where aminooxyacetic acid was conjugated directly to the N-terminal alanine, and OA-E3-PEP4313, where a triglutamyl spacer was introduced between the aminooxy moiety and the N-terminus. Aminooxyacetic Acid 136-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 24344772-7 2014 To verify this, we have produced two variants of the HER2-targeting ZHER2:342 Affibody molecule by peptide synthesis: OA-PEP4313, where aminooxyacetic acid was conjugated directly to the N-terminal alanine, and OA-E3-PEP4313, where a triglutamyl spacer was introduced between the aminooxy moiety and the N-terminus. Alanine 198-205 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 24384723-10 2014 In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway. Lapatinib 69-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-26 24384723-10 2014 In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway. Lapatinib 69-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-54 24227890-9 2014 Mice bearing SKOV-3 HER2- and IGF-IR-overexpressing xenografts showed extensive and sustainable tumor regression when treated with Bi-Ab. Antibodies, Bispecific 131-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 24092810-0 2013 HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Letrozole 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 25249017-3 2014 The synthetic anti-HER2 ZHER2:S1 Affibody molecule was conjugated with DOTA at the N-terminus, in the middle of helix 3, or at the C-terminus. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 71-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 24052576-0 2013 Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice. Fatty Acids, Omega-3 34-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 24092810-13 2013 Our results suggest that the HDAC inhibitor may reverse letrozole resistance in cells and tumors by modulating Her-2 expression and activity. Letrozole 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 23843024-1 2013 The dual erbB1/2 tyrosine kinase inhibitor lapatinib as well as the anthracycline doxorubicin are both used in the therapy of HER2-positive breast cancer. Lapatinib 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 24265712-5 2013 Surprisingly, we found that RCAS-mediated delivery of cDNA encoding a constitutively activated version of ErbB2 (HER2/Neu) into the small number of TVA+ mammary epithelial cells in TOP-tva mice failed to induce tumor, while the same virus readily induced mammary tumors after it was delivered into a comparable number of cells in our previously reported mouse line MMTV-tva, whose tva is broadly expressed in mammary epithelium. rcas 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-111 24265712-5 2013 Surprisingly, we found that RCAS-mediated delivery of cDNA encoding a constitutively activated version of ErbB2 (HER2/Neu) into the small number of TVA+ mammary epithelial cells in TOP-tva mice failed to induce tumor, while the same virus readily induced mammary tumors after it was delivered into a comparable number of cells in our previously reported mouse line MMTV-tva, whose tva is broadly expressed in mammary epithelium. rcas 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-121 24066900-0 2013 Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts. copolymer 26-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-172 24066900-4 2013 The current study aims to elucidate the in vivo fate of 31-nm-sized block copolymer micelles (BCMs) targeted to the nucleus of HER2-overexpressing breast cancer cells. copolymer 74-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 127-131 24066900-7 2013 Surface-grafted trastuzumab Fab fragments (TmAb-Fab) facilitated binding and internalization of BCMs by HER2-positive breast cancer cells, while synthetic 13-mer nuclear localization signal (NLS) peptides conjugated to the TmAb-Fab conferred nuclear translocation capability. Tetramethylammonium bromide 43-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 24066900-7 2013 Surface-grafted trastuzumab Fab fragments (TmAb-Fab) facilitated binding and internalization of BCMs by HER2-positive breast cancer cells, while synthetic 13-mer nuclear localization signal (NLS) peptides conjugated to the TmAb-Fab conferred nuclear translocation capability. tmab-fab 43-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 24308017-3 2013 The preclinical antitumor activity of trastuzumab emtansine was established in HER2-positive breast cancer cell lines and murine xenograft models. t-dm1 38-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 23843024-1 2013 The dual erbB1/2 tyrosine kinase inhibitor lapatinib as well as the anthracycline doxorubicin are both used in the therapy of HER2-positive breast cancer. anthracycline doxorubicin 68-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 23843024-2 2013 Using MMTV-neu mice as an animal model for HER2-positive breast cancer, we observed enhanced tumor infiltration by IFN-gamma-secreting T cells after treatment with doxorubicin and/or lapatinib. Doxorubicin 164-175 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 23843024-2 2013 Using MMTV-neu mice as an animal model for HER2-positive breast cancer, we observed enhanced tumor infiltration by IFN-gamma-secreting T cells after treatment with doxorubicin and/or lapatinib. Lapatinib 183-192 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 24325095-10 2013 CONCLUSION: The MR4 optimal time for MRI scanning of tumors in BALB/c mice using c-erbB2 antisense probe labeled with superparamagnetic iron oxide nanoparticles should be set at 360 min after injection. ferric oxide 136-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-88 32261200-4 2013 Next, we prepared HER2-specific-aptide-conjugated magneto-nanoclusters (APTHER2-MNCs) by a rehydration method using oleic acid-stabilized superparamagnetic iron oxide nanoparticles (SPIONs) and amphiphilic phospholipids, yielding nanoparticles with a hydrodynamic diameter of 47 +- 10 nm. Oleic Acid 116-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 32261200-4 2013 Next, we prepared HER2-specific-aptide-conjugated magneto-nanoclusters (APTHER2-MNCs) by a rehydration method using oleic acid-stabilized superparamagnetic iron oxide nanoparticles (SPIONs) and amphiphilic phospholipids, yielding nanoparticles with a hydrodynamic diameter of 47 +- 10 nm. ferric oxide 156-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 32261200-8 2013 Furthermore, after docetaxel loading, the drug-loaded APTHER2-MNCs remarkably inhibited the growth of HER2-overexpressing tumors (~50% relative to controls) with little apparent toxicity, measured as changes in body weight. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 25620857-3 2013 Because of the specific binding of the ligand conjugated NDs to the HER2-overexpressing murine breast cancer cells (4T1.2 neu), the tumor tissues are significantly delineated from the surrounding normal tissue at wavelength of 820 nm under the PA imaging modality. Protactinium 244-246 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 23403395-6 2013 The targeting effects of the HTCP NPs were demonstrated by a much lower IC50 value of 0.0201+0.00780+0.1629mug/mL of docetaxel+cisplatin+herceptin for SK-BR-3 cells, which are of high HER2 overexpression, than that of 0.225+0.0875+1.827mug/mL for NIH3T3 cells, which are of low HER2 overexpression, after 24h incubation. Docetaxel 117-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 278-282 23983820-0 2013 Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model. N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide 22-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 23940356-9 2013 Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in combination with lapatinib or pertuzumab. Lapatinib 91-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 23941509-5 2013 More importantly, in combination with temporary depletion of regulatory T cells (Treg) by low-dose cyclophosphamide, vaccination with scFvNLDC-145-HER2/neu induced the regression of established D2F2/E2 breast tumor and significantly retarded the development of spontaneous mammary carcinomas in transgenic BALB-neuT mice. Cyclophosphamide 99-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 134-155 23686858-9 2013 Both Neu-164 and Neu-107 significantly reduced the accumulation of inflammatory cells and the expression of inflammatory cytokines as effectively as dexamethasone. Dexamethasone 149-162 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-20 23616343-9 2013 This was accompanied by a dramatic up-regulation of both E-cadherin and beta-catenin and down-regulation of ErbB-2 in the dasatinib-treated tumours. Dasatinib 122-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-114 23743233-4 2013 CDBT blocks microtubule formation, decreases cancer-essential proteins CRAF-1, ERBB2 and phosphorylated AKT, and causes G2/M arrest and apoptosis. GNF-PF-62 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-84 23686858-11 2013 Neu-164 and Neu-107 inhibit acute cigarette smoke-induced inflammation by scavenging reactive oxygen species in cigarette smoke and by inhibiting further oxidative stress caused by inflammatory cells. Reactive Oxygen Species 85-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-3 23686858-11 2013 Neu-164 and Neu-107 inhibit acute cigarette smoke-induced inflammation by scavenging reactive oxygen species in cigarette smoke and by inhibiting further oxidative stress caused by inflammatory cells. Reactive Oxygen Species 85-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-15 23826254-11 2013 Furthermore as compared to controls, we observed reduced HER2, EGFR and VEGF expression in the brain sections of PEITC treated mice. phenethyl isothiocyanate 113-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 23613438-0 2013 Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding alphav beta3 integrins. DA364 94-99 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-65 23572162-4 2013 Hyperinsulinemic (MKR(+/+)) mice were crossed with doxycycline-inducible Neu-NT (MTB/TAN) mice to produce the MTB/TAN/MKR(+/+) mouse model. Doxycycline 51-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-76 23528382-0 2013 Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. aby-027 69-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 23528382-6 2013 METHODS: A novel Affibody-based construct, ZHER2:2891-ABD035-DOTA (ABY-027), was created by fusion of the reengineered HER2-binding Affibody molecule ZHER2:2891 to the N terminus of the high-affinity ABD035, and a maleimido-derivative of DOTA was conjugated at the C terminus of the construct. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 61-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 23528382-6 2013 METHODS: A novel Affibody-based construct, ZHER2:2891-ABD035-DOTA (ABY-027), was created by fusion of the reengineered HER2-binding Affibody molecule ZHER2:2891 to the N terminus of the high-affinity ABD035, and a maleimido-derivative of DOTA was conjugated at the C terminus of the construct. aby-027 67-74 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 23528382-6 2013 METHODS: A novel Affibody-based construct, ZHER2:2891-ABD035-DOTA (ABY-027), was created by fusion of the reengineered HER2-binding Affibody molecule ZHER2:2891 to the N terminus of the high-affinity ABD035, and a maleimido-derivative of DOTA was conjugated at the C terminus of the construct. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 238-242 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 23528382-10 2013 ABY-027 was stably labeled with (177)Lu and (111)In with preserved specific binding to HER2-expressing cells in vitro. aby-027 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 23572162-5 2013 Both MTB/TAN and MTB/TAN/MKR(+/+) mice were administered doxycycline in drinking water to induce Neu-NT mammary tumor formation. Doxycycline 57-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-100 22797066-3 2013 In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol. Doxorubicin 130-141 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 22797066-3 2013 In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol. Paclitaxel 145-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 23543055-4 2013 ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. Lapatinib 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 23569315-1 2013 PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed. Lapatinib 174-183 erb-b2 receptor tyrosine kinase 2 Mus musculus 156-160 23543055-4 2013 ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. Lapatinib 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-55 23644106-0 2013 [Optimal concentration of c-erbB2 antisense probe labeled with superparamagnetic iron oxide nanoparticles for magnetic resonance imaging in tumor-bearing nude mice]. ferric oxide 81-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-33 23153706-8 2013 Pre-treatment of irradiated cells with afatinib inhibited radiation-activated HER2 and EGFR phosphorylation. Afatinib 39-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 23378339-6 2013 Mechanistic investigations suggested that gemcitabine induces EGFR ligand expression and ERBB2 activation by increasing heterodimer formation with EGFR, thereby maintaining high levels of ERBB2 protein in PDAC cells. gemcitabine 42-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-94 23378339-6 2013 Mechanistic investigations suggested that gemcitabine induces EGFR ligand expression and ERBB2 activation by increasing heterodimer formation with EGFR, thereby maintaining high levels of ERBB2 protein in PDAC cells. gemcitabine 42-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 188-193 23644106-1 2013 OBJECTIVE: To determine the optimal concentration of c-erbB2 antisense probe labeled with superparamagnetic iron oxide (SPIO) nanoparticles for in vivo tumor imaging in mice using magnetic resonance imaging (MRI). ferric oxide 108-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-60 23644106-1 2013 OBJECTIVE: To determine the optimal concentration of c-erbB2 antisense probe labeled with superparamagnetic iron oxide (SPIO) nanoparticles for in vivo tumor imaging in mice using magnetic resonance imaging (MRI). ferumoxides 120-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-60 23644106-2 2013 METHODS: Thirty BALB/c mice bearing SK-Br-3 tumor were randomized into 5 groups to receive injections of different concentrations of SPIO-labeled c-erbB2 antisense probe (containing 6.0, 9.0, 12.0, 15.0, or 18.0 mg Fe/kg). ferumoxides 133-137 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-153 22614008-5 2013 In addition, we demonstrated that nicotine-mediated MUC4 upregulation promotes the PC cell migration through the activation of the downstream effectors, such as HER2, c-Src and FAK; this effect was attenuated by shRNA-mediated MUC4 abrogation, further implying that these nicotine-mediated pathological effects on PC cells are MUC4 dependent. Nicotine 34-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-165 23393332-2 2013 A fluorescent probe for detecting HER2/neu-expressing cells was generated by conjugation of the humanized anti-HER2/neu antibody trastuzumab with rhodamine. Rhodamines 146-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-38 23393332-2 2013 A fluorescent probe for detecting HER2/neu-expressing cells was generated by conjugation of the humanized anti-HER2/neu antibody trastuzumab with rhodamine. Rhodamines 146-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-42 23393332-2 2013 A fluorescent probe for detecting HER2/neu-expressing cells was generated by conjugation of the humanized anti-HER2/neu antibody trastuzumab with rhodamine. Rhodamines 146-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-115 23393332-2 2013 A fluorescent probe for detecting HER2/neu-expressing cells was generated by conjugation of the humanized anti-HER2/neu antibody trastuzumab with rhodamine. Rhodamines 146-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 116-119 23393332-4 2013 All tumor-bearing mice were given a single intravenous injection of either rhodamine-conjugated anti-HER2/neu probe, or conjugated control IgG antibody, when LN metastasis developed. Rhodamines 75-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 23393332-4 2013 All tumor-bearing mice were given a single intravenous injection of either rhodamine-conjugated anti-HER2/neu probe, or conjugated control IgG antibody, when LN metastasis developed. Rhodamines 75-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-109 23393332-5 2013 Each animal was imaged with both green and red fluorescence to assess in vivo binding of the rhodamine-conjugated anti-HER2/neu probe to the tumors and LN metastases. Rhodamines 93-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-123 23393332-5 2013 Each animal was imaged with both green and red fluorescence to assess in vivo binding of the rhodamine-conjugated anti-HER2/neu probe to the tumors and LN metastases. Rhodamines 93-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-127 23393332-8 2013 The primary tumors and LN metastases from the animals which were treated with rhodamine-conjugated anti-HER2/neu probe exhibited a visible red fluorescence signal. Rhodamines 78-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 23393332-8 2013 The primary tumors and LN metastases from the animals which were treated with rhodamine-conjugated anti-HER2/neu probe exhibited a visible red fluorescence signal. Rhodamines 78-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-112 23393332-10 2013 Sensitivity of 78% (14 out of 18) and specificity of 100% (20 out of 20) could be achieved with the rhodamine-conjugated anti-HER2/neu probe for the detection of LN metastasis. Rhodamines 100-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 23393332-10 2013 Sensitivity of 78% (14 out of 18) and specificity of 100% (20 out of 20) could be achieved with the rhodamine-conjugated anti-HER2/neu probe for the detection of LN metastasis. Rhodamines 100-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-134 23224399-1 2013 PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. Lapatinib 52-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 23224399-9 2013 Mice bearing HER2(+) xenografts treated with lapatinib, trastuzumab, and U3-1287 exhibited fewer recurrences and better survival than mice treated with lapatinib and trastuzumab. Lapatinib 45-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Fatty Acids, Omega-3 77-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-188 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Fatty Acids, Omega-3 77-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-192 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Docosahexaenoic Acids 101-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-188 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Docosahexaenoic Acids 101-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-192 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Docosahexaenoic Acids 123-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-188 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Docosahexaenoic Acids 123-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-192 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Eicosapentaenoic Acid 132-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-188 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Eicosapentaenoic Acid 132-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-192 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Eicosapentaenoic Acid 155-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-188 23213007-1 2013 SCOPE: We previously demonstrated that lifelong feeding of diets enriched in n-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly inhibits HER-2/neu-mediated mammary tumorigenesis in mice. Eicosapentaenoic Acid 155-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 189-192 22767445-0 2013 Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models. Lactic Acid 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-50 23125191-3 2013 Bioinformatics modeling of interactions for the sterol pathway genes in eukaryotes allowed us to hypothesize and then extensively validate an unexpected role for SC4MOL and NSDHL in controlling the signaling, vesicular trafficking, and degradation of EGFR and its dimerization partners, ERBB2 and ERBB3. Sterols 48-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 287-292 23489691-0 2013 Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. Curcumin 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-101 23055194-7 2013 Immunization with HSP65-HER2 had no significant influence on tumor weight or volume but significantly reduced tumor incidence (62.5 % in mice injected with 25 mug of HSP65-HER2 vs. 100 % in PBS-injected controls; P < 0.05). Lead 190-193 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-28 23055194-8 2013 Confocal microscopy and flow cytometry analyses revealed that HSP65-HER2 immunization significantly reduced the percentages of HER2(+) B16 cells in xenografted tumors (1.86 % vs. 30.56 % in PBS-injected controls; P = 0.01). Lead 190-193 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 23171545-2 2013 This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) via pipi-stacking, for functional imaging. in-benzyl-diethylenetriaminepentaacetic acid 103-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 23171545-2 2013 This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) via pipi-stacking, for functional imaging. bndtpa 149-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 23516601-6 2013 We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line. artemisinin 43-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-116 23516601-6 2013 We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line. Adenosine Diphosphate 64-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-116 23516601-6 2013 We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line. Adenosine Diphosphate 64-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 149-153 23961253-0 2013 Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer. (99m 38-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 125-129 23961253-15 2013 Based on the results it was concluded that (99m)Tc-HYNIC-Trastuzumab could be a promising radiopharmaceutical for in vivo diagnosis of the HER2 status in breast with impact on treatment planning. Technetium 48-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-143 22969147-3 2012 By tumor volume endpoint analysis, these mouse tumors respond to BIBW 2992 (an irreversible EGFR/HER2 TKI) and rapamycin combination therapy. Afatinib 65-74 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 23032741-7 2012 In immunocompetent mice, anti-FITC CAR T cells exhibited potent antitumor activity against syngeneic mouse breast cancer expressing Her2 and B-cell lymphoma expressing CD20 by combining with FITC-Her2 and FITC-Rtx, respectively. Fluorescein-5-isothiocyanate 30-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-136 23032741-7 2012 In immunocompetent mice, anti-FITC CAR T cells exhibited potent antitumor activity against syngeneic mouse breast cancer expressing Her2 and B-cell lymphoma expressing CD20 by combining with FITC-Her2 and FITC-Rtx, respectively. Fluorescein-5-isothiocyanate 30-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 196-200 22968785-10 2012 In contrast, tamoxifen (20 mg/1,800 kcal) significantly enhanced tumor prevention in ERDelta3/Neu versus MMTV-Neu mice (98% vs. 81% tumor free). Tamoxifen 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-97 22968785-10 2012 In contrast, tamoxifen (20 mg/1,800 kcal) significantly enhanced tumor prevention in ERDelta3/Neu versus MMTV-Neu mice (98% vs. 81% tumor free). Tamoxifen 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-113 23396851-1 2012 alpha-Mangostin is a xanthon derivative contained in the fruit hull of mangosteen (Garcinia mangostana L.), and the administration of alpha-Mangostin inhibited the growth of transplanted colon cancer, Her/CT26 cells which expressed Her-2/neu as tumor antigen. mangostin 0-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 232-241 23396851-1 2012 alpha-Mangostin is a xanthon derivative contained in the fruit hull of mangosteen (Garcinia mangostana L.), and the administration of alpha-Mangostin inhibited the growth of transplanted colon cancer, Her/CT26 cells which expressed Her-2/neu as tumor antigen. mangostin 134-149 erb-b2 receptor tyrosine kinase 2 Mus musculus 232-241 22872574-9 2012 This regimen even exhibited activity in lapatinib-resistant HER2(+) tumors. Lapatinib 40-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 22926341-1 2012 In pursuit of effective therapeutic agents for the estrogen receptor (ER)-negative breast cancer, we previously showed that bexarotene reduced mammary tumor development by 75% in ErbB2 mice. Bexarotene 124-134 erb-b2 receptor tyrosine kinase 2 Mus musculus 179-184 22806877-9 2012 Ganetespib also showed activity against mouse lung adenocarcinomas driven by oncogenic ERBB2 YVMA. STA 9090 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-92 23170249-8 2012 Tumor weights were significantly reduced in mice treated with HER-2 peptides alone, and even more in animals that received HER-2 peptide with low-dose paclitaxel, which alone had no significant effects on tumor growth in the transgenic model. Paclitaxel 151-161 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-128 23170249-9 2012 Specifically engineered native peptide sequences from HER-2 and VEGF used in combination with metronomic paclitaxel demonstrate enhanced anticancer efficacy and an encouraging safety profile. Paclitaxel 105-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-59 22806877-2 2012 EXPERIMENTAL DESIGN: The activity of ganetespib was compared with that of the geldanamycin 17-AAG in biochemical assays, cell lines, and xenografts, and evaluated in an ERBB2 YVMA-driven mouse lung adenocarcinoma model. STA 9090 37-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-174 22806877-5 2012 Ganetespib was also approximately 20-fold more potent in isogenic Ba/F3 pro-B cells rendered IL-3 independent by expression of EGFR and ERBB2 mutants. STA 9090 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-141 22806877-10 2012 CONCLUSIONS: Ganetespib has greater potency than 17-AAG and potential efficacy against several NSCLC subsets, including those harboring EGFR or ERBB2 mutation. STA 9090 13-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 144-149 22824293-16 2012 In agreement with our in vitro results, tumors from PEITC-treated mice demonstrated reduced HER2, EGFR and STAT3 expression and increased apoptosis as revealed by cleavage of caspase 3 and PARP. phenethyl isothiocyanate 52-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-96 22689915-6 2012 On the basis of this background, we tested whether Curaxin-137 could suppress tumorigenesis in MMTV-neu transgenic mice, which spontaneously develop mammary carcinoma due to steroid receptor-regulated expression of the Her2 proto-oncogene. CBLC137 51-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 219-223 22689915-7 2012 We found that chronic administration of Curaxin-137 in a preventive regimen to MMTV-neu mice did not cause any detectable changes in normal organs and tissues, yet inhibited tumor onset, delayed tumor progression, and prolonged survival of mice in a dose-dependent manner. CBLC137 40-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-87 22752247-1 2012 Previously, we have shown that the intraductal (i.duc) administration of pegylated liposomal doxorubicin (PLD) to Her2/neu transgenic mice is associated with mammary tumor regression and prevention. Doxorubicin 93-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-118 22752247-1 2012 Previously, we have shown that the intraductal (i.duc) administration of pegylated liposomal doxorubicin (PLD) to Her2/neu transgenic mice is associated with mammary tumor regression and prevention. Doxorubicin 93-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-122 22514210-0 2012 Accelerated mammary tumor onset in a HER2/Neu mouse model exposed to DDT metabolites locally delivered to the mammary gland. DDT 69-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-41 22514210-0 2012 Accelerated mammary tumor onset in a HER2/Neu mouse model exposed to DDT metabolites locally delivered to the mammary gland. DDT 69-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-45 22562558-2 2012 The authors have previously shown in mouse xenograft experiments that masking ErbB2 by hyaluronan leads to diminished binding of the antibody and consequent resistance. Hyaluronic Acid 87-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-83 22270933-5 2012 G129R reduced tyrosine phosphorylation of Neu (p-Neu) in a dose-dependent manner (IC50~10 mug/ml) in tumor chunks, but had no effect on primary tumor epithelial cells grown in monolayer. Tyrosine 14-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-52 22787684-12 2004 A setapeptide sequence consisting of Lys-Cys-Cys-Tyr-Ser-Leu (KCCYSL) was identified using phage display screening to bind specifically to the extracellular domain of HER2 (17). lys-cys-cys-tyr-ser-leu 37-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 167-171 22270933-5 2012 G129R reduced tyrosine phosphorylation of Neu (p-Neu) in a dose-dependent manner (IC50~10 mug/ml) in tumor chunks, but had no effect on primary tumor epithelial cells grown in monolayer. Tyrosine 14-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-45 22665489-0 2012 Transcriptional regulation of the protocadherin beta cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. n-glycan 133-141 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 22787682-12 2004 A setapeptide sequence consisting of Lys-Cys-Cys-Tyr-Ser-Leu (KCCYSL) was identified using phage display screening to bind specifically to the extracellular domain of HER2 (17). lys-cys-cys-tyr-ser-leu 37-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 167-171 22787683-12 2004 A setapeptide sequence consisting of Lys-Cys-Cys-Tyr-Ser-Leu (KCCYSL) was identified using phage display screening to bind specifically to the extracellular domain of HER2 (17). lys-cys-cys-tyr-ser-leu 37-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 167-171 22542611-4 2012 The thermosensitive poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)(118) (PID(118)) shell with volume phase transition temperature (VPTT: 39 C) and the anchored anti-Her2 Fab moiety contributed to the passive and active targeting, respectively. poly(IPAAm-co-DMAAm) 20-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 173-177 22542611-7 2012 The cytotoxicity assay against Her2 overexpression gastric cancer cells (N87s) showed that the IC50 of the FCIMs was 9 times lower than that of Doxil under cooperatively targeting by Fab at T > VPTT. liposomal doxorubicin 146-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 22644656-7 2012 The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam + LT) or estrogen deprivation (ED + LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tamoxifen 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 22644656-7 2012 The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam + LT) or estrogen deprivation (ED + LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tamoxifen 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-168 22644656-7 2012 The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam + LT) or estrogen deprivation (ED + LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. tam + lt 74-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 22249974-8 2012 (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC preserved specific binding to HER2-expressing cells. gggc 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 22644656-7 2012 The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam + LT) or estrogen deprivation (ED + LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. tam + lt 74-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-168 22326466-0 2012 The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. abexinostat 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-103 22326466-2 2012 In our current study, we examined the therapeutic effects of the histone deacetylase (HDAC) inhibitor PCI-24781 against GBCa that developed in BK5.erbB2 mice. abexinostat 102-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 147-152 22392499-3 2012 A fast and simple microwave-assisted method of generating N-succinimidyl-4-[(18)F]fluorobenzoate has been developed and employed for radiolabeling a small, rapidly targeting HER2-specific engineered antibody fragment, the cys-diabody. N-succinimidyl-4-fluorobenzoate 58-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 22392499-3 2012 A fast and simple microwave-assisted method of generating N-succinimidyl-4-[(18)F]fluorobenzoate has been developed and employed for radiolabeling a small, rapidly targeting HER2-specific engineered antibody fragment, the cys-diabody. Cysteine 222-225 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-178 22741041-7 2012 The growth rate for 231-BR-HER2 metastases was 67.5% compared with 54.4% for the 231-BR metastases. 231-br 20-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-31 22249974-8 2012 (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC preserved specific binding to HER2-expressing cells. gggc 28-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-67 22249974-9 2012 In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. Technetium 37-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 22249974-9 2012 In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. Technetium 37-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 22249974-9 2012 In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. Technetium 37-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 22249974-9 2012 In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. Technetium 131-133 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 22249974-9 2012 In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. tc-z 131-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 22249974-10 2012 At 1 and 4 h after injection, the renal uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was 2-3-fold lower than uptake of (99m)Tc-Z(HER2:2395)-VDC, but it was substantially higher than uptake of (99m)Tc-Z(HER2:342)-GGGC. Technetium 55-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 21981381-0 2012 Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice. Alcohols 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 22172396-2 2012 The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule. 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid 83-140 erb-b2 receptor tyrosine kinase 2 Mus musculus 185-189 22172396-2 2012 The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule. 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane 142-148 erb-b2 receptor tyrosine kinase 2 Mus musculus 185-189 22172396-3 2012 METHODS: The maleimidoethylmonoamide NODAGA (MMA-NODAGA) was synthesized and conjugated to Z(HER2:2395) Affibody molecule having a C-terminal cysteine. Cysteine 142-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-97 22172396-6 2012 RESULTS: The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. Cysteine 36-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-52 22172396-6 2012 RESULTS: The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. Cysteine 36-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 22172396-7 2012 The (111)In-labeling yield was 99.6%+-0.5% after 30 min at 60 C. [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. nodaga-cys 78-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 22172396-7 2012 The (111)In-labeling yield was 99.6%+-0.5% after 30 min at 60 C. [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. nodaga-cys 78-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 22172396-8 2012 Tumor uptake of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) in mice bearing DU-145 xenografts (4.7%+-0.8% ID/g) was lower than uptake of [(111)In-MMA-DOTA-Cys(61)]-Z(HER2:2395) (7.5%+-1.6% ID/g). nodaga-cys 29-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-168 22172396-9 2012 However, tumor-to-organ ratios were higher for [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) due to higher clearance rate from normal tissues. nodaga-cys 60-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 21981381-0 2012 Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice. Alcohols 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-112 22319204-0 2012 SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. SKLB1206 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-107 22170322-9 2012 In xenografts with high HER2 expression, the uptake of (111)In-ABY-002 was significantly higher than that of (111)In-PEP09239. aby-002 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-28 22319204-5 2012 In addition, SKLB1206 has also considerable inhibition potency against some other related oncokinases, including ErbB2, ErbB4, and VEGF receptor 2 (VEGFR2). SKLB1206 13-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-118 22319204-6 2012 SKLB1206 exhibited highly antiproliferative activity against a range of EGFR-mutant cell lines, including gefitinib-sensitive and -resistant cell lines, and EGFR or ErbB2-overexpressing cell lines. SKLB1206 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-170 22319204-8 2012 In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice. SKLB1206 32-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 234-239 22319204-10 2012 Collectively, these preclinical evaluations may support clinical development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed. SKLB1206 80-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 151-156 22266114-7 2012 We discovered that ErbB2/Neu levels were sensitive to nutrient availability, such that reduced glucose concentrations resulted in diminished ErbB2/Neu protein levels. Glucose 95-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-24 22266114-7 2012 We discovered that ErbB2/Neu levels were sensitive to nutrient availability, such that reduced glucose concentrations resulted in diminished ErbB2/Neu protein levels. Glucose 95-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-28 22266114-7 2012 We discovered that ErbB2/Neu levels were sensitive to nutrient availability, such that reduced glucose concentrations resulted in diminished ErbB2/Neu protein levels. Glucose 95-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 141-146 22266114-7 2012 We discovered that ErbB2/Neu levels were sensitive to nutrient availability, such that reduced glucose concentrations resulted in diminished ErbB2/Neu protein levels. Glucose 95-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 147-150 22266114-8 2012 Therefore, our data indicate that PGC-1alpha prevents the nutrient-mediated downregulation of ErbB2/Neu in tumors by increasing glucose supply. Glucose 128-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-99 22266114-9 2012 Mechanistic investigations revealed that the regulation of ErbB2/Neu levels by glucose was mediated by the unfolded protein response (UPR). Glucose 79-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-64 22266114-9 2012 Mechanistic investigations revealed that the regulation of ErbB2/Neu levels by glucose was mediated by the unfolded protein response (UPR). Glucose 79-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-68 22266114-10 2012 Incubation of ErbB2/Neu-induced breast cancer cells in limited glucose concentrations or with drugs that activate the UPR led to significant reductions in ErbB2/Neu protein levels. Glucose 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 22266114-10 2012 Incubation of ErbB2/Neu-induced breast cancer cells in limited glucose concentrations or with drugs that activate the UPR led to significant reductions in ErbB2/Neu protein levels. Glucose 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-23 22266114-10 2012 Incubation of ErbB2/Neu-induced breast cancer cells in limited glucose concentrations or with drugs that activate the UPR led to significant reductions in ErbB2/Neu protein levels. Glucose 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 155-160 22266114-10 2012 Incubation of ErbB2/Neu-induced breast cancer cells in limited glucose concentrations or with drugs that activate the UPR led to significant reductions in ErbB2/Neu protein levels. Glucose 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-164 22235098-2 2012 For this, we evaluated the known Her2 response to 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG) treatment, an Hsp90 inhibitor. 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride 50-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 22011930-0 2012 Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-98 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-98 22157714-0 2012 ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival. Dextran Sulfate 39-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 22157714-3 2012 In this study, mice bearing intestinal epithelial-specific deletion of ErbB2 or ErbB3 were treated with dextran sulfate sodium (DSS). Dextran Sulfate 104-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-76 22157714-6 2012 However, the roles of both receptors were more apparent during recovery from DSS colitis, in which ErbB2 or ErbB3 epithelial deletion resulted in greater inflammation and crypt damage during the early reparative period. Dextran Sulfate 77-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 22235098-2 2012 For this, we evaluated the known Her2 response to 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG) treatment, an Hsp90 inhibitor. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 117-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 22235098-5 2012 Optical images were obtained both pretreatment (day 0) and posttreatment (day 3, 6, and 9), always 5 hours postinjection of 500 pmol of anti-Her2 Affibody-AlexaFluor680 via tail vein (with preinjection background subtraction). alexafluor680 155-168 erb-b2 receptor tyrosine kinase 2 Mus musculus 141-145 22235098-7 2012 RESULTS: Her2 expression decreased with 17-DMAG dose in vitro. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 40-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 21934603-3 2012 We have shown for the first time that a water-soluble extract of taro (TE) potently inhibits lung-colonizing ability and spontaneous metastasis from mammary gland-implanted tumors, in a murine model of highly metastatic estrogen receptor, progesterone receptor and Her-2/neu-negative breast cancer. Water 40-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 265-270 22325452-2 2012 HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. Lapatinib 135-144 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 21934603-3 2012 We have shown for the first time that a water-soluble extract of taro (TE) potently inhibits lung-colonizing ability and spontaneous metastasis from mammary gland-implanted tumors, in a murine model of highly metastatic estrogen receptor, progesterone receptor and Her-2/neu-negative breast cancer. Water 40-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 271-274 22509306-3 2012 HerDox is comprised of doxorubicin non-covalently assembled in a viral-like particle targeted to HER2+ tumor cells, causing tumor cell death at over 10-fold lower dose compared to the untargeted drug, while sparing the heart. Doxorubicin 23-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 23346199-8 2012 In addition, TPL downregulates the activated (phosphorylated) forms of HER2, phosphoinositide-3 kinase (PI3K), and serine/threonine-specific protein kinase (Akt). triptolide 13-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 23028451-12 2012 Treatment of transgenic MMTV-ERBB2/neu mice with 100 mg/kg/day TMI-1 alone induced tumor apoptosis, inhibiting mammary gland tumor occurrence and development. apratastat 63-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-34 21793718-6 2012 Maturation promoting factor (MPF) inhibitor roscovitine did not affect the expression of c-erbB(2) mRNA and c-myb mRNA, but blocked the effects of recombinant c-erbB(2) and c-myb protein-induced oocyte maturation. Roscovitine 44-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 159-168 22222115-0 2012 A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice. Oligodeoxyribonucleotides 6-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 22222115-0 2012 A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice. Oligodeoxyribonucleotides 6-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 22267010-2 2012 To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge. Cysteine 60-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 22267010-2 2012 To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge. Cysteine 60-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-97 22101132-0 2012 Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases. 5-alkynyl-4-anilinopyrimidines 19-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-108 22101132-1 2012 5-Alkenyl or 5-alkynyl-4-anilinopyrimidines were prepared and evaluated for in vitro inhibition of EGFR/Her-2 kinase activity and the growth of tumor cell lines (BT474 and N87). 5-alkenyl 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-109 22101132-1 2012 5-Alkenyl or 5-alkynyl-4-anilinopyrimidines were prepared and evaluated for in vitro inhibition of EGFR/Her-2 kinase activity and the growth of tumor cell lines (BT474 and N87). 5-alkynyl-4-anilinopyrimidines 13-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-109 21933912-6 2012 We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice. bardoxolone methyl 150-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-37 21933912-6 2012 We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice. bardoxolone methyl 150-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-46 21933912-6 2012 We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice. bardoxolone methyl 150-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-46 21933912-7 2012 In BRCA1-deficient cell lines, the triterpenoids directly interacted with ErbB2, decreased constitutive phosphorylation of ErbB2, inhibited proliferation, and induced G(0)-G(1) arrest. triterpenoids 35-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-79 21933912-7 2012 In BRCA1-deficient cell lines, the triterpenoids directly interacted with ErbB2, decreased constitutive phosphorylation of ErbB2, inhibited proliferation, and induced G(0)-G(1) arrest. triterpenoids 35-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-128 22457761-11 2012 Furthermore, cytoplasmic ss-catenin was detected in HER2/neu-induced mouse mammary tumors. ss-catenin 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-56 22457761-11 2012 Furthermore, cytoplasmic ss-catenin was detected in HER2/neu-induced mouse mammary tumors. ss-catenin 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-60 22774532-7 2012 The cumulative neoplastic frequency curve for the experimental group was shifted to the right in comparison to the control group curve giving evidence to the inhibitory effect of SSH&H on the neoplastic rate in transgenic mice with HER-2/neu mutation. SSH 179-182 erb-b2 receptor tyrosine kinase 2 Mus musculus 236-241 22384017-1 2012 The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. diethoxyphosphoryloxymethyl butanoate 42-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 22384017-1 2012 The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. an-7 78-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 22774532-7 2012 The cumulative neoplastic frequency curve for the experimental group was shifted to the right in comparison to the control group curve giving evidence to the inhibitory effect of SSH&H on the neoplastic rate in transgenic mice with HER-2/neu mutation. SSH 179-182 erb-b2 receptor tyrosine kinase 2 Mus musculus 242-245 22774532-7 2012 The cumulative neoplastic frequency curve for the experimental group was shifted to the right in comparison to the control group curve giving evidence to the inhibitory effect of SSH&H on the neoplastic rate in transgenic mice with HER-2/neu mutation. Adenosine Monophosphate 183-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 236-241 22774532-7 2012 The cumulative neoplastic frequency curve for the experimental group was shifted to the right in comparison to the control group curve giving evidence to the inhibitory effect of SSH&H on the neoplastic rate in transgenic mice with HER-2/neu mutation. Adenosine Monophosphate 183-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 242-245 22007722-6 2011 In addition, the surface of PS-NPs was functionalized with polyethylene glycol (PEG) and the monoclonal antibody herceptin, and their binding to HER2/neu-overexpressing tumor cells was confirmed in vitro. Polyethylene Glycols 59-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-149 21803026-0 2011 Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Atorvastatin 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 22044845-7 2011 RESULTS: We show in vitro that alpha-TEA plus anti-HER2/neu antibody has an increased cytotoxic effect against murine mammary tumor cells and human breast cancer cells and that the anti-tumor effect of alpha-TEA is independent of HER2/neu status. 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 202-211 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-55 21772253-6 2011 Adoptive transfer of PB-modified HER2-CTLs resulted in tumor regression in a murine xenograft model. pladienolide B 21-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 21803026-7 2011 Unexpectedly Her2-positive cells were much more sensitive to the inhibition of RhoA-dependent pathways than to the suppression of Ras-dependent pathways elicited by atorvastatin. Atorvastatin 165-177 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 21803026-0 2011 Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Atorvastatin 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-83 21914943-8 2011 Moreover, plain NOBs were biocompatible whereas CPT-loaded NOBs exerted a strong cytotoxic effect on HER2/neu-positive cells in vitro. Camptothecin 48-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 21920766-1 2011 A series of novel metronidazole derivatives were recently reported as potent anticancer agents targeting EGFR and HER-2 by our group [Qian, Y.; Zhang, H. J.; Zhang, H.; Xu, C.; Zhao, J.; Zhu, H. L. Bioorg. Metronidazole 18-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-119 21920766-4 2011 Based on the previous results, we designed and synthesized a new series of metronidazole acid acyl sulfonamide derivatives and a new series of phenylacetyl benzenesulfonamide derivatives and their anticancer activities were evaluated as potential EGFR and HER-2 kinase inhibitors. phenylacetyl benzenesulfonamide 143-174 erb-b2 receptor tyrosine kinase 2 Mus musculus 256-261 21914943-8 2011 Moreover, plain NOBs were biocompatible whereas CPT-loaded NOBs exerted a strong cytotoxic effect on HER2/neu-positive cells in vitro. 2-(Morpholinothio)benzothiazole 59-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 22214307-14 2011 CONCLUSIONS: We conclude that 111In-DOTA-trastuzumab Fab was more specific than 64Cu-DOTA-trastuzumab Fab for imaging HER2-positive tumors, especially those with low receptor density. 64cu-dota-trastuzumab fab 80-105 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 21499296-8 2011 Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice. Lapatinib 28-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-157 21499296-8 2011 Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice. saracatinib 60-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-157 21899335-5 2011 The PEG-based vesicles, 117 nm in diameter, were functionalized with either folic acid or anti-HER2/neu affibodies as targeting ligands to confer specificity for cancer cells. Polyethylene Glycols 4-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-99 22214307-16 2011 Use of alternative chelators that more stably bind 64Cu may improve the association between T/B ratios and HER2 density for 64Cu-labeled trastuzumab Fab. Copper-64 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-111 21816844-5 2011 Clinical trials include a recent placebo-controlled phase IIb presurgical trial of the dual EGFR HER2 inhibitor lapatinib that suppressed growth of breast premalignancy [including atypical ductal hyperplasia (ADH) and DCIS] and invasive cancer in patients with early-stage, HER2-overexpressing or -amplified breast cancer. Lapatinib 112-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 21685235-1 2011 Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 21685235-1 2011 Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 21816844-6 2011 These results suggest that lapatinib can clinically suppress the progression of ADH and DCIS to invasive breast cancer, an effect previously observed in a mouse model of HER2-overexpressing, ER-negative mammary cancer. Lapatinib 27-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 170-174 21718945-8 2011 (111)In-ABY-003 bound specifically to HER2-expressing cells in vitro. aby-003 8-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-42 21499904-3 2011 In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185(neu) expressing tumor MBT-2 in mice. lz-8 46-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-64 21499904-3 2011 In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185(neu) expressing tumor MBT-2 in mice. lz-8 46-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-64 21673053-7 2011 Strikingly, in a genetically engineered mouse model of HER-2/neu-induced mammary cancer, tumor penetrance in mice on a Western diet was nearly 50% by the age of 1 year whereas no tumors were detected in mice on the low CHO diet. CAV protocol 219-222 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 21673053-7 2011 Strikingly, in a genetically engineered mouse model of HER-2/neu-induced mammary cancer, tumor penetrance in mice on a Western diet was nearly 50% by the age of 1 year whereas no tumors were detected in mice on the low CHO diet. CAV protocol 219-222 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-64 21496448-4 2011 Here we report the full characterization of CLI using the positron-emitting radiotracer 89Zr-DFO-trastuzumab for target-specific, quantitative imaging of HER2/neu-positive tumors in vivo. Deferoxamine 93-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 21770186-0 2011 Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. ferric oxide 75-85 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-21 21770186-4 2011 Iron oxide based magnetic nanoparticles conjugated to breast cancer monoclonal antibody (Her2) were used as a specific contrast agent for detection of the tumor cells in nude mice models. ferric oxide 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 21482676-2 2011 In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. Lapatinib 128-137 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 21482676-3 2011 In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Lapatinib 172-181 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 21721808-2 2011 We describe and characterize a ratiometric spectral imaging and analysis method and evaluate its performance for tumor detection and delineation by quantitatively monitoring the specific accumulation of targeted gallium corrole (HerGa) into HER2-positive (HER2 +) breast tumors. gallium corrole 212-227 erb-b2 receptor tyrosine kinase 2 Mus musculus 241-245 21721808-2 2011 We describe and characterize a ratiometric spectral imaging and analysis method and evaluate its performance for tumor detection and delineation by quantitatively monitoring the specific accumulation of targeted gallium corrole (HerGa) into HER2-positive (HER2 +) breast tumors. gallium corrole 212-227 erb-b2 receptor tyrosine kinase 2 Mus musculus 256-260 21496448-4 2011 Here we report the full characterization of CLI using the positron-emitting radiotracer 89Zr-DFO-trastuzumab for target-specific, quantitative imaging of HER2/neu-positive tumors in vivo. Deferoxamine 93-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 159-162 21496448-7 2011 CLI, PET, and biodistribution studies revealed target-specific uptake of 89Zr-DFO-trastuzumab in BT-474 (HER2/neu positive) versus MDA-MB-468 (HER2/neu negative) xenografts in the same mice. Deferoxamine 78-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-109 21496448-7 2011 CLI, PET, and biodistribution studies revealed target-specific uptake of 89Zr-DFO-trastuzumab in BT-474 (HER2/neu positive) versus MDA-MB-468 (HER2/neu negative) xenografts in the same mice. Deferoxamine 78-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-113 21496448-7 2011 CLI, PET, and biodistribution studies revealed target-specific uptake of 89Zr-DFO-trastuzumab in BT-474 (HER2/neu positive) versus MDA-MB-468 (HER2/neu negative) xenografts in the same mice. Deferoxamine 78-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 21496448-7 2011 CLI, PET, and biodistribution studies revealed target-specific uptake of 89Zr-DFO-trastuzumab in BT-474 (HER2/neu positive) versus MDA-MB-468 (HER2/neu negative) xenografts in the same mice. Deferoxamine 78-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-151 21496448-8 2011 Competitive inhibition (blocking) studies followed by CLI also confirmed the in vivo immunoreactivity and specificity of 89Zr-DFO-trastuzumab for HER2/neu. Deferoxamine 126-129 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 21496448-8 2011 Competitive inhibition (blocking) studies followed by CLI also confirmed the in vivo immunoreactivity and specificity of 89Zr-DFO-trastuzumab for HER2/neu. Deferoxamine 126-129 erb-b2 receptor tyrosine kinase 2 Mus musculus 151-154 21536547-8 2011 In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. triciribine 110-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-11 21443270-7 2011 In mice bearing prostate cancer DU-145 xenografts, the tumor uptake of [(111)In-MMA-NOTA-Cys(61)]-Z(HER2:2395) was 8.2 +- 0.9% IA/g and the tumor-to-blood ratio was 31 +- 1 (4 h postinjection). mma-nota-cys 80-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 21536547-8 2011 In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. tipifarnib 126-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-11 21109923-0 2011 Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Mus musculus 134-142 21086124-4 2011 Here, we report that chA21 combined with Paclitaxel or Trastuzumab significantly enhances the tumor-inhibition effects on ErbB2-overexpressing breast and ovarian cancer in xenograft mice. Paclitaxel 41-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-127 21303974-0 2011 Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. polymalic acid-based nanobiopolymer 0-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-115 21504091-0 2011 Beneft of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic effcacy and biodistribution in mice. Paclitaxel 27-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 15-19 21138857-7 2011 RESULTS: L + T was the most effective regimen in both MCF7/HER2-18 and BT-474 xenografts with complete regression (CR) of tumor observed in all mice. l + t 9-14 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-63 21109923-1 2011 We assessed the effects of direct injection of docetaxel-loaded immuno-(trastuzumab)-liposomes (IDL) on a xenograft mouse tumor model to determine potential clinical applications of intratumoral tailored chemotherapy against Her2/neu-overexpressing gastric cancer. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 225-229 21109923-1 2011 We assessed the effects of direct injection of docetaxel-loaded immuno-(trastuzumab)-liposomes (IDL) on a xenograft mouse tumor model to determine potential clinical applications of intratumoral tailored chemotherapy against Her2/neu-overexpressing gastric cancer. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 230-233 21109923-2 2011 The NCI-N87 Her2/neu overexpressing gastric cancer cell line xenograft mouse model was treated with IDL or docetaxel-loaded liposomes (DL). Docetaxel 107-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-20 21826239-2 2011 We hypothesized that reducing or eliminating the expression of the most prominently expressed glucose transporter(s) would decrease the amount of glucose available to breast cancer cells thereby decreasing their metabolic capacity and proliferative potential.Of the 12 GLUT family glucose transporters expressed in mice, GLUT1 was the most abundantly expressed at the RNA level in the mouse mammary tumors from MMTV-c-ErbB2 mice and cell lines examined. Glucose 94-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 418-423 22190871-6 2011 MPPS1 cells maintain high ErbB2 overexpression when propagated in DFCI-1 or related media, and their growth is ErbB2-dependent, as demonstrated by concentration-dependent inhibition of proliferation with the ErbB kinase inhibitor Lapatinib. Lapatinib 230-239 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 22190871-9 2011 Immunofluorescence staining of control vs. Lapatinib-treated acini for markers of epithelial polarity revealed that inhibition of ErbB2 signaling led to rapid resumption of normal mammary epithelium-like cell polarity. Lapatinib 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-135 21220136-2 2011 Preclinical studies have revealed high tumor/blood ratios (>27:1) for (111)In-labeled Fab fragments of the HER2 monoclonal antibody, trastuzumab (Herceptin) ((111)In-DTPA-trastuzumab Fab) at 72 h pi in athymic mice bearing subcutaneous human breast cancer xenografts. Pentetic Acid 169-173 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 21789172-8 2011 In vivo, AST1306 potently suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models, but weakly inhibited the growth of EGFR-overexpressing tumor xenografts. AST 1306 9-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-58 20925038-5 2010 This new EPL-click conjugation strategy is applied to create superparamagnetic iron oxide nanoparticles (SPIO) labeled with HER2/neu affibodies. ferric oxide 79-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-132 20964447-5 2010 Two variants of the HER2-binding Affibody molecule Z(HER)2(:)342 were made in an attempt to create a tagged tracer that could be purified by immobilized metal affinity chromatography, yet would not result in anomalous hepatic radioactivity accumulation following labeling with [99(m)Tc(CO)3](+). Metals 153-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 20964447-5 2010 Two variants of the HER2-binding Affibody molecule Z(HER)2(:)342 were made in an attempt to create a tagged tracer that could be purified by immobilized metal affinity chromatography, yet would not result in anomalous hepatic radioactivity accumulation following labeling with [99(m)Tc(CO)3](+). Technetium 283-285 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 20964447-5 2010 Two variants of the HER2-binding Affibody molecule Z(HER)2(:)342 were made in an attempt to create a tagged tracer that could be purified by immobilized metal affinity chromatography, yet would not result in anomalous hepatic radioactivity accumulation following labeling with [99(m)Tc(CO)3](+). co)3 286-290 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-24 21897861-7 2011 The proliferative effect was blocked by treatment with AG1478 or AG825, specific tyrosine kinase inhibitors of ErbB-1 and ErbB-2, respectively. RTKI cpd 55-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-128 21897861-7 2011 The proliferative effect was blocked by treatment with AG1478 or AG825, specific tyrosine kinase inhibitors of ErbB-1 and ErbB-2, respectively. tyrphostin AG825 65-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-128 21078982-8 2010 These results demonstrate that GnT-V expression and its branched glycan products effectively modulate her-2-mediated signaling pathways that, in turn, regulate the relative proportion of tumor initiating cells and the latency of her-2-driven tumor onset. Polysaccharides 65-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-107 20717927-2 2010 The 18 kDa propeptide domain of lysyl oxidase (LOX-PP) released from the secreted precursor protein (Pro-LOX) has been shown to inhibit RAS signaling and the transformed phenotype of breast, pancreatic, lung, and prostate cancer cells in culture, and formation of tumors by Her-2/neu-driven breast cancer cells in a mouse xenograft model. propeptide 11-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 274-283 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). maleimide 138-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 20811002-9 2010 Mice (n = 6 per group) bearing xenograft tumors originating from HER2-overexpressing BT474 cells showed statistically significantly reduced tumor volume on day 28 when treated with the drug combination (control vs trastuzumab and dasatinib combination; mean volume = 2.6 vs 0.5 cm(3), difference = 2.1 cm(3), 95% confidence interval = 0.76 to 3.51 cm(3), P = .01) and total regression of tumors by day 36 with no later relapse. Dasatinib 230-239 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 20682802-5 2010 GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice. GW2974 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 20682802-5 2010 GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice. GW2974 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-174 20682802-5 2010 GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice. Tetradecanoylphorbol Acetate 53-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 20682802-7 2010 GW2974 inhibited 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperproliferation, which correlated with reduced activation of both the EGFR and erbB2. GW2974 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-159 20682802-7 2010 GW2974 inhibited 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperproliferation, which correlated with reduced activation of both the EGFR and erbB2. Tetradecanoylphorbol Acetate 17-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-159 20682802-9 2010 Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process. GW2974 83-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-48 20682802-9 2010 Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process. GW2974 83-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-166 20553947-5 2010 RESULTS: Here we show that herceptin, AG1478 and CI-1033, inhibitors of two different members of the ErbB family of oncogenes (HER-2 and EGFR), reduce TF levels in epithelial cancer cells. RTKI cpd 38-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 127-132 20553947-5 2010 RESULTS: Here we show that herceptin, AG1478 and CI-1033, inhibitors of two different members of the ErbB family of oncogenes (HER-2 and EGFR), reduce TF levels in epithelial cancer cells. Canertinib 49-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 127-132 20552190-10 2010 By 40 h all three of the (64)Cu-BFC-trastuzumab conjugates allowed for clear visualization of the HER2/neu-positive tumors but not the negative control tumor. cu-bfc 29-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 20801634-6 2010 In vitro SERS screening was performed in cancer cell lines using B2LA containing nanotag conjugated with selective antibodies recognizing HER2 and EGFR cancer proteins. sers 9-13 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-142 20801634-7 2010 We found reasonably strong SERS signals from both HER2 and EGFR positive cells whereas no signal was measured from respective negative cells. sers 27-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 20801634-9 2010 Both SERS and cell-imaging study further confirmed the selective binding of antibody conjugated nanotag to cancer cells over-expressing HER2 and EGFR. sers 5-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 20130858-3 2010 Earlier, (111)In-DOTA-Z(HER2:342-pep2) (ABY-002) Affibody molecule demonstrated excellent imaging of HER2-expressing xenografts in mice shortly after injection. aby-002 40-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-28 20130858-3 2010 Earlier, (111)In-DOTA-Z(HER2:342-pep2) (ABY-002) Affibody molecule demonstrated excellent imaging of HER2-expressing xenografts in mice shortly after injection. aby-002 40-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 20533530-5 2010 CONCLUSIONS: The present study demonstrates that a single low dose of DCs modified with rLV containing a truncated neu oncogene can achieve a strong and long lasting effect on neu-overexpressing tumors, suggesting the possible clinical application of this strategy. rlv 88-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-118 20533530-5 2010 CONCLUSIONS: The present study demonstrates that a single low dose of DCs modified with rLV containing a truncated neu oncogene can achieve a strong and long lasting effect on neu-overexpressing tumors, suggesting the possible clinical application of this strategy. rlv 88-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-179 20610158-8 2010 CONCLUSIONS: Z(HER2:2395)-C labeled with (99m)Tc using the lyophilized kit was stable and resulted in a favorable biodistribution in an in vivo evaluation in normal Naval Medical Research Institute mice. Technetium 46-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 15-19 20219607-0 2010 Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Paclitaxel 28-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-20 19779897-0 2010 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Copper-64 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-51 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). maleimide 138-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). maleimide 138-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate 173-238 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). mono (n-ethylmaleimide amide) 239-268 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 19779897-3 2010 The anti-HER2 Affibody molecules in monomeric (Z(HER2:477)) and dimeric [(Z(HER2:477))(2)] forms were site specifically modified with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA). mal-dota 270-278 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 19779897-5 2010 Biodistribution experiments showed that tumor uptake values of (64)Cu-DOTA-Z(HER2:477) and (64)Cu-DOTA-(Z(HER2:477))(2) were 6.12 +/- 1.44% and 1.46 +/- 0.50% ID/g, respectively, in nude mice (n = 3 each) at 4 h postinjection. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 95-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-110 19779897-7 2010 MicroPET imaging of (64)Cu-DOTA-Z(HER2:477) in SKOV3 tumor mice clearly showed good and specific tumor localization. Copper 24-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-38 19779897-7 2010 MicroPET imaging of (64)Cu-DOTA-Z(HER2:477) in SKOV3 tumor mice clearly showed good and specific tumor localization. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 27-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-38 19779897-8 2010 This study demonstrates that (64)Cu-labeled Z(HER2:477) is a promising targeted molecular probe for imaging HER2 receptor expression in living mice. Copper 33-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-50 19779897-8 2010 This study demonstrates that (64)Cu-labeled Z(HER2:477) is a promising targeted molecular probe for imaging HER2 receptor expression in living mice. Copper 33-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-112 20350624-4 2010 co-immunization of pFl inhibits the production of anti-HER-2 antibody elicited by pECD vaccine, resulting in the development of spontaneous carcinomas in all co-immunized mice. pecd 82-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 20219072-7 2010 Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with (64)Cu-DOTA-trastuzumab PET and (64)Cu-DOTA-IgG. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 86-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-19 20459769-0 2010 Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Lapatinib 89-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-62 20459769-3 2010 Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-93 20459769-3 2010 Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-142 20459769-11 2010 We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels. Lapatinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 20459769-11 2010 We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels. Lapatinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-97 20219072-7 2010 Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with (64)Cu-DOTA-trastuzumab PET and (64)Cu-DOTA-IgG. Copper 86-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-19 20219072-7 2010 Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with (64)Cu-DOTA-trastuzumab PET and (64)Cu-DOTA-IgG. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 89-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-19 19771426-3 2010 When optimizing chelators for (99m)Tc-labelling, we have found that synthetic Z(HER2:342) conjugated with mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) and mercaptoacetyl-glycyl-seryl-glycyl (maGSG) chelators provides relatively low renal uptake of radioactivity and could be suitable for therapy. Technetium 35-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 20049896-0 2010 EGF and its related growth factors mediate sodium transport in mpkCCDc14 cells via ErbB2 (neu/HER-2) receptor. Sodium 43-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-88 20049896-0 2010 EGF and its related growth factors mediate sodium transport in mpkCCDc14 cells via ErbB2 (neu/HER-2) receptor. Sodium 43-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-93 20049896-11 2010 Both acute and long-term effects of EGF were abolished when cells were treated with tyrphostin AG-825 and ErbB2 inhibitor II, chemically dissimilar selective inhibitors of the ErbB2 receptor. tyrphostin AG825 84-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-181 20305377-2 2010 In the early 2000s, Anisimov s experiments revealed that chronic treatment of female transgenic HER2-/neu mice with metformin significantly reduced the incidence and size of mammary adenocarcinomas and increased the mean latency of the tumors. Metformin 116-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 20305377-6 2010 Our current perception is that metformin may constitute a novel "hybrid anti-cancer pill" physically combining both the long-lasting effects of antibodies -by persistently lowering levels of blood insulin and glucose- and the immediate potency of a cancer cell-targeting molecular agent -by suppressing the pivotal AMPK/mTOR/S6K1 axis and several protein kinases at once, including tyrosine kinase receptors such as HER1 and HER2-. Metformin 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 425-429 19942284-0 2010 Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Polyethyleneimine 21-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 19942284-0 2010 Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. (2-hydroxypropyl)-gamma-cyclodextrin 54-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 19771426-3 2010 When optimizing chelators for (99m)Tc-labelling, we have found that synthetic Z(HER2:342) conjugated with mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) and mercaptoacetyl-glycyl-seryl-glycyl (maGSG) chelators provides relatively low renal uptake of radioactivity and could be suitable for therapy. magsg 190-195 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 19771426-6 2010 RESULTS: Gluconate-mediated labelling of maGGG-Z(HER2:342) and maGSG-Z(HER2:342) with (186)Re provided a yield of more than 95% within 60 min. gluconic acid 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 19771426-6 2010 RESULTS: Gluconate-mediated labelling of maGGG-Z(HER2:342) and maGSG-Z(HER2:342) with (186)Re provided a yield of more than 95% within 60 min. gluconic acid 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 19801490-3 2009 It is, therefore, important to understand how NRG1, via erbB2, protects the heart against Dox cardiotoxicity. Doxorubicin 90-93 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-61 20111600-2 2010 In addition, pharmacodynamic studies on HER2/neu expression levels in response to therapeutic doses of PU-H71 (a specific inhibitor of heat-shock protein 90 [Hsp90]) were conducted. 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- 103-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-44 20111600-2 2010 In addition, pharmacodynamic studies on HER2/neu expression levels in response to therapeutic doses of PU-H71 (a specific inhibitor of heat-shock protein 90 [Hsp90]) were conducted. 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- 103-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-48 20016287-0 2010 Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-40 20016287-2 2010 In our animal studies, metformin delayed the onset of mammary adenocarcinoma (MAC) in transgenic HER-2/neu mice but not the onset of spontaneous mammary tumors in female SHR mice. Metformin 23-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-102 20016287-2 2010 In our animal studies, metformin delayed the onset of mammary adenocarcinoma (MAC) in transgenic HER-2/neu mice but not the onset of spontaneous mammary tumors in female SHR mice. Metformin 23-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-106 20016287-5 2010 Metformin (0.5 mg/ml in drinking water) increased mean life span by 8% and MAC latency by 13.2% (p < 0.05) in HER2/neu mice. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-117 20016287-5 2010 Metformin (0.5 mg/ml in drinking water) increased mean life span by 8% and MAC latency by 13.2% (p < 0.05) in HER2/neu mice. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-121 20016287-5 2010 Metformin (0.5 mg/ml in drinking water) increased mean life span by 8% and MAC latency by 13.2% (p < 0.05) in HER2/neu mice. Water 33-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 113-117 20016287-5 2010 Metformin (0.5 mg/ml in drinking water) increased mean life span by 8% and MAC latency by 13.2% (p < 0.05) in HER2/neu mice. Water 33-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-121 20016287-7 2010 The treatment metformin alone inhibited the growth of transplantable HER2 mammary carcinoma in FVB/N male mice by 46% at the 45(th) day after transplantation (p < 0.001). Metformin 14-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 20053764-1 2010 Using a hormone-dependent xenograft model, we established that loss of response to letrozole was accompanied by upregulation of the Her-2/mitogen-activated protein kinase (MAPK) pathway and downregulation of estrogen receptor alpha (ERalpha) and aromatase activity. Letrozole 83-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-137 20053764-9 2010 Our studies revealed that the adaptation of cells to a low-estrogen environment by upregulation of Her-2/MAPK and downregulation of ERalpha/aromatase was reversed on letrozole withdrawal. Letrozole 166-175 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 20524399-0 2010 In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. alpha-Bisabolol 18-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-124 20524399-0 2010 In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. alpha-Bisabolol 18-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 125-128 20524399-4 2010 The aim of the present study is to investigate the role played by two doses of BISA (via intramammary infusion) on the induction and development of mammary tumor in HER-2/neu transgenic mice as well as the BISA effect after tumor surgical resection. bisa 79-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-170 20111600-11 2010 CONCLUSIONS/SIGNIFICANCE: The results indicate that (89)Zr-DFO-trastuzumab provides quantitative and highly-specific delineation of HER2/neu positive tumors, and has potential to be used to measure the efficacy of long-term treatment with Hsp90 inhibitors, like PU-H71, which display extended pharmacodynamic profiles. Deferoxamine 59-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-136 20111600-11 2010 CONCLUSIONS/SIGNIFICANCE: The results indicate that (89)Zr-DFO-trastuzumab provides quantitative and highly-specific delineation of HER2/neu positive tumors, and has potential to be used to measure the efficacy of long-term treatment with Hsp90 inhibitors, like PU-H71, which display extended pharmacodynamic profiles. Deferoxamine 59-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-140 20346445-1 2010 Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice. Paclitaxel 21-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-69 20346445-1 2010 Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice. Paclitaxel 21-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-69 20346445-1 2010 Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice. Paclitaxel 21-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-74 20346445-1 2010 Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice. Paclitaxel 21-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-74 20346445-2 2010 We demonstrate that co-administration of PTX and Cyclophosphamide (CY) synergizes to slow tumor growth, and that in vitro, DC precursors exposed to PTX before LPS maturation results in greater co-stimulatory molecule expression, IL-12 production, and the ability to induce CD8(+) T cells with enhanced lytic activity against neu(+) tumors. Paclitaxel 148-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 325-328 20140973-4 2010 Here, we have demonstrated that the combined use of HER-2 targeting affibody, a small 7 kDa molecule that behaves similarly to antibodies, and superparamagnetic iron oxide (SPIO) can non-invasively image HER-2 expressing cells or tissues both in vitro and in vivo by MRI. ferric oxide 161-171 erb-b2 receptor tyrosine kinase 2 Mus musculus 204-209 20140973-4 2010 Here, we have demonstrated that the combined use of HER-2 targeting affibody, a small 7 kDa molecule that behaves similarly to antibodies, and superparamagnetic iron oxide (SPIO) can non-invasively image HER-2 expressing cells or tissues both in vitro and in vivo by MRI. ferumoxides 173-177 erb-b2 receptor tyrosine kinase 2 Mus musculus 204-209 19833232-0 2010 Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Sunitinib 24-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 38-42 19833232-0 2010 Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Sunitinib 24-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-46 19536776-0 2009 The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Lapatinib 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 19536776-0 2009 The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Irinotecan 105-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 19536776-0 2009 The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Irinotecan 134-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 19536776-2 2009 Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-109 19536776-5 2009 Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-50 19536776-5 2009 Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-181 19801490-17 2009 NRG1 maintains cardiac troponins by the erbB2-PI3K pathway, which may lessen Dox-induced cardiac dysfunction. Doxorubicin 77-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 19934283-0 2009 Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. tetrathiomolybdate 15-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-55 19920193-8 2009 These data suggest (225)Ac-labeled anti-HER-2/neu monoclonal antibody could significantly prolong survival in HER-2/neu-positive metastatic breast cancer patients. Actinium 24-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 116-119 19934283-0 2009 Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. tetrathiomolybdate 15-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-59 19934283-2 2009 EXPERIMENTAL DESIGN: Nulliparous Her2/neu transgenic mice were treated with water or TM for 180 days and observed for tumor development during treatment and for 180 days after treatment. Water 76-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-41 19934283-4 2009 RESULTS: At the 1-year follow-up, 86.7% of control and 40% of TM-treated Her2/neu mice had palpable mammary tumors with a median time to tumor development of 234 days (95% confidence interval, 202-279 days) for control and >460 days for TM-treated mice (P < 0.0005, n = 15). tetrathiomolybdate 62-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-77 19837760-8 2009 RESULTS: The treatment of mice with trastuzumab, compared with control mice treated with PBS, resulted in a significant decrease in tumor uptake of (18)F-FDG in HER2-overexpressing MDA-MB-361 xenografts after 16 d of treatment (2.6 +/- 0.8 %ID/g vs. 4.6 +/- 1.8 %ID/g, respectively; P < 0.03) but not after 2 or 9 d of treatment (P = 0.28-0.32). pbs 89-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-165 19675140-9 2009 Altered Erb B2 signaling is a novel mechanism that contributes to SC dysfunction in diabetes, and inhibiting Erb B2 may ameliorate deficits of tactile sensitivity in DPN. dpn 166-169 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-115 19625781-4 2009 BB selectively inhibited EGFR with a IC(50) value of 50 +/- 37 nM, at least 32-fold more potent than suppressed all other ten tested receptor tyrosine kinases including the same family member ErbB2 (IC(50) = 5.6 +/- 3.2 microM). boeravinone B 0-2 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-197 20641789-9 2004 In another study, SCID mice bearing xenograft tumors expressing the Her-2/neu receptor were pre-exposed to a biotinylated anti-Her-2/neu monoclonal antibody (MAb), and the animals were subsequently treated with an avidin-Gd-DTPA conjugate (8). avidin-gd-dtpa 214-228 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-86 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-96 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 19554571-10 2009 CONCLUSIONS: Lapatinib has little activity against the xenografts of the PPTP"s in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 188-193 19370475-5 2009 Neuregulin-1beta (NRG-1beta) induced Tyr-phosphorylation of both ErbB4 and ErbB2. Tyrosine 37-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. N-(2-amino-3-(para-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N,N',N',N'-pentaacetic acid 34-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-58 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. N-(2-amino-3-(para-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N,N',N',N'-pentaacetic acid 34-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. N-(2-amino-3-(para-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N,N',N',N'-pentaacetic acid 34-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. 4-aminobenzamidine 47-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-58 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. bz-dota-abd 72-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 19430786-9 2009 RESULTS: The apparent affinity of CHX-A""-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. bz-dota-abd 72-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-91 19440708-3 2009 In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 71-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-58 19690041-11 2009 The specificity of (68)Ga-DOTA-MUT-DS for SKOV3 tumors was confirmed by monitoring modulation of HER2 protein on treatment of tumor mice with heat shock protein 90 inhibitor 17-N,N-dimethyl ethylene diamine-geldanamycin in vivo. 17-n 174-178 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 19584156-3 2009 EXPERIMENTAL DESIGN: Induction of cellular and humoral immune responses and antitumoral activity of the fusion proteins admixed with DC-activating CpG oligonucleotides (scFv(CD11c)-HER2/neu(CpG)) were tested in transplantable HER2/neu-expressing murine tumor models and in transgenic BALB-neuT mice developing spontaneous neu-driven mammary carcinomas. Oligonucleotides 151-167 erb-b2 receptor tyrosine kinase 2 Mus musculus 181-189 19647173-9 2009 Tumor uptake of radioiodine activity in athymic mice bearing MCF7-HER2 xenografts in vivo was significantly higher for the [(125)I]IB-Mal-d-GEEEK-labeled scFv-Fc DM fragment compared with that of the [(131)I]SGMIB-labeled fragment, particularly at later time points. Iodine-131 16-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-70 19480464-5 2009 Rhodamine derivatives were conjugated to avidin and trastuzumab, which target D-galactose receptor and HER2/neu antigen, respectively. Rhodamines 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-111 19459856-0 2009 Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. MP 412 89-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-71 19459856-0 2009 Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. MP 412 97-103 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-71 19617342-0 2009 Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. 111in-dtpa 20-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-87 19617342-2 2009 Our objective was to determine whether SPECT with (111)In-diethylenetriaminepentaacetic acid-pertuzumab ((111)In-DTPA-pertuzumab) could sensitively detect an early molecular response to trastuzumab manifested by HER2 downregulation and a later tumor response revealed by a decreased number of HER2-positive viable tumor cells. Pentetic Acid 58-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 212-216 19617342-2 2009 Our objective was to determine whether SPECT with (111)In-diethylenetriaminepentaacetic acid-pertuzumab ((111)In-DTPA-pertuzumab) could sensitively detect an early molecular response to trastuzumab manifested by HER2 downregulation and a later tumor response revealed by a decreased number of HER2-positive viable tumor cells. Pentetic Acid 58-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 293-297 19617342-2 2009 Our objective was to determine whether SPECT with (111)In-diethylenetriaminepentaacetic acid-pertuzumab ((111)In-DTPA-pertuzumab) could sensitively detect an early molecular response to trastuzumab manifested by HER2 downregulation and a later tumor response revealed by a decreased number of HER2-positive viable tumor cells. Pentetic Acid 113-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 212-216 19617342-2 2009 Our objective was to determine whether SPECT with (111)In-diethylenetriaminepentaacetic acid-pertuzumab ((111)In-DTPA-pertuzumab) could sensitively detect an early molecular response to trastuzumab manifested by HER2 downregulation and a later tumor response revealed by a decreased number of HER2-positive viable tumor cells. Pentetic Acid 113-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 293-297 19617342-10 2009 There was also a 2-fold decreased tumor uptake in trastuzumab- versus PBS-treated mice by image volume-of-interest analysis (P = 0.05), suggesting trastuzumab-mediated HER2 downregulation. pbs 70-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-172 19617342-11 2009 After 3 wk of trastuzumab, tumor uptake of (111)In-DTPA-pertuzumab decreased 4.5-fold, compared with PBS-treated mice (7.6 +/- 0.4 vs. 34.6 +/- 9.9 %ID/g, respectively; P < 0.001); this decrease was associated with an almost-completed eradication of HER2-positive tumor cells determined immunohistochemically. Pentetic Acid 51-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 253-257 19584156-3 2009 EXPERIMENTAL DESIGN: Induction of cellular and humoral immune responses and antitumoral activity of the fusion proteins admixed with DC-activating CpG oligonucleotides (scFv(CD11c)-HER2/neu(CpG)) were tested in transplantable HER2/neu-expressing murine tumor models and in transgenic BALB-neuT mice developing spontaneous neu-driven mammary carcinomas. Oligonucleotides 151-167 erb-b2 receptor tyrosine kinase 2 Mus musculus 181-185 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. N-(2-(4-18F-fluorobenzamido)ethyl)maleimide 70-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-60 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. N-(2-(4-18F-fluorobenzamido)ethyl)maleimide 70-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. N-(2-(4-18F-fluorobenzamido)ethyl)maleimide 70-114 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. (dimethylaminoethylamino)-17-demethoxygeldanamycin 204-254 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-60 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. (dimethylaminoethylamino)-17-demethoxygeldanamycin 204-254 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. (dimethylaminoethylamino)-17-demethoxygeldanamycin 204-254 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 256-263 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-60 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 256-263 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-2 2009 This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 256-263 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 19525458-4 2009 To study the downregulation of HER2, we treated the mice with 4 doses (40 mg/kg) of 17-DMAG, an inhibitor of heat-shock protein 90, known to decrease HER2 expression. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 84-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 19525458-4 2009 To study the downregulation of HER2, we treated the mice with 4 doses (40 mg/kg) of 17-DMAG, an inhibitor of heat-shock protein 90, known to decrease HER2 expression. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 84-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 19331844-0 2009 Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. Doxorubicin 34-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 19331844-2 2009 The goal of this study was to assess whether Her2-targeted pegylated liposomal doxorubicin (PLD) retains its binding ability to Her2-expressing target cells through circulation in the blood and extravasation to tumor interstitial fluid. Doxorubicin 79-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-49 19331844-2 2009 The goal of this study was to assess whether Her2-targeted pegylated liposomal doxorubicin (PLD) retains its binding ability to Her2-expressing target cells through circulation in the blood and extravasation to tumor interstitial fluid. Doxorubicin 79-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 128-132 19372467-9 2009 RESULTS: (99m)Tc-His(6)-Z(HER2:342)-Cys was capable of targeting HER2-expressing SKOV-3 xenografts in SCID mice, but the liver radioactivity uptake was high. tc-his 14-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 19458057-6 2009 Using gefitinib, ERBB1 inhibition rapidly inhibits tumor cell motility and invasion but not intravasation, whereas ERBB2 inhibition by AG825 rapidly blocks intravasation. tyrphostin AG825 135-140 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-120 19302475-1 2009 Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoic acid 14-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-7 19302475-1 2009 Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. Sulfasalazine 109-122 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-7 19302475-1 2009 Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. Sulfasalazine 109-122 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-12 19302475-1 2009 Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. N-Methylaspartate 135-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-7 19302475-1 2009 Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. N-Methylaspartate 135-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-12 19302475-3 2009 NEU reversibly suppressed NMDA responses in an uncompetitive manner with fast binding kinetics. N-Methylaspartate 26-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-3 19302475-5 2009 NEU accelerated NMDA desensitization without affecting the binding affinity of NMDAR for its agonists and stabilized the closed state of NMDAR. N-Methylaspartate 16-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-3 19302475-6 2009 Therefore, NEU should effectively alleviate disorders that are a result of glutamate excitoxicity with fewer side effects because it is a low-affinity gating modifier that antagonizes NMDAR in an uncompetitive manner. Glutamic Acid 75-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-14 18989354-4 2009 Additionally, combination of SM360320 with plasmid encoding the extracellular and transmembrane domain of ratHER2/neu affected the spontaneous tumor progression in BALB-neuT mice treated in an advanced disease setting. SM360320 29-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-117 18989354-6 2009 These data demonstrate that SM360320 exerts significant antitumor effects and can act in association with DNA-EP for CEA-positive colon cancer and HER2-positive mammary carcinoma. SM360320 28-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 147-151 19372467-9 2009 RESULTS: (99m)Tc-His(6)-Z(HER2:342)-Cys was capable of targeting HER2-expressing SKOV-3 xenografts in SCID mice, but the liver radioactivity uptake was high. tc-his 14-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 19372467-9 2009 RESULTS: (99m)Tc-His(6)-Z(HER2:342)-Cys was capable of targeting HER2-expressing SKOV-3 xenografts in SCID mice, but the liver radioactivity uptake was high. Cysteine 36-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 19372467-9 2009 RESULTS: (99m)Tc-His(6)-Z(HER2:342)-Cys was capable of targeting HER2-expressing SKOV-3 xenografts in SCID mice, but the liver radioactivity uptake was high. Cysteine 36-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 19428831-2 2009 Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-gamma. Tamoxifen 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 23-32 19066886-3 2009 The goal of this study was to evaluate the use of ((4-hydroxyphenyl)ethyl)maleimide (HPEM) for radioiodination of Z(HER2:342) and to compare the targeting properties of monomeric and dimeric forms of Z(HER2:342). hpem 85-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 116-120 19428831-2 2009 Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-gamma. Tamoxifen 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 23-28 19428831-2 2009 Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-gamma. Tamoxifen 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-32 19240169-2 2009 In the present study, we have examined the ability of a novel agonist of TLR9, called immunomodulatory oligonucleotide (IMO), to enhance effects of a HER-2/neu plasmid DNA electroporation/adenovirus (DNA-EP/Ad) vaccine. Oligonucleotides 103-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-155 19299620-5 2009 An affinity-improved version of bH1 inhibits both HER2- and VEGF-mediated cell proliferation in vitro and tumor progression in mouse models. bh1 32-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 19240169-2 2009 In the present study, we have examined the ability of a novel agonist of TLR9, called immunomodulatory oligonucleotide (IMO), to enhance effects of a HER-2/neu plasmid DNA electroporation/adenovirus (DNA-EP/Ad) vaccine. Oligonucleotides 103-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 156-159 19240169-2 2009 In the present study, we have examined the ability of a novel agonist of TLR9, called immunomodulatory oligonucleotide (IMO), to enhance effects of a HER-2/neu plasmid DNA electroporation/adenovirus (DNA-EP/Ad) vaccine. 6-o-phosphoryl inosine monophosphate 120-123 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-155 19240169-2 2009 In the present study, we have examined the ability of a novel agonist of TLR9, called immunomodulatory oligonucleotide (IMO), to enhance effects of a HER-2/neu plasmid DNA electroporation/adenovirus (DNA-EP/Ad) vaccine. 6-o-phosphoryl inosine monophosphate 120-123 erb-b2 receptor tyrosine kinase 2 Mus musculus 156-159 19106626-2 2009 Animal studies have shown that metformin suppresses the development of mammary carcinomas in transgenic female mice carrying a HER2 oncogene, but not that of spontaneous tumors. Metformin 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 127-131 19028424-0 2009 Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors. pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines 40-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-107 19028424-1 2009 A novel class of pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines has been identified which potently inhibit the EGFR and ErbB-2 receptor tyrosine kinases. pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines 17-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-129 19409087-13 2009 In vivo studies focusing on low Her2-expressing breast cancer cells (LCC6) implanted orthotopically demonstrated that treatment with 267/Dt engendered improved therapeutic effects when compared with mice treated with either agent alone. Docetaxel 137-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-36 18975017-0 2009 Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. herceptin-dextran iron oxide 9-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 18975017-0 2009 Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. herceptin-dextran iron oxide 9-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-87 19141783-1 2009 Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-102 18712381-0 2009 Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. 111in-dtpa 35-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-63 19118039-9 2009 Treatment of Her2/Neu(+) mammary tumor cells with DPPE in vitro efficiently killed TICs, as determined by flow cytometry and transplantation assays; DPPE further cooperated with doxorubicin to completely eradicate tumorigenic cells. tesmilifene 50-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 19118039-9 2009 Treatment of Her2/Neu(+) mammary tumor cells with DPPE in vitro efficiently killed TICs, as determined by flow cytometry and transplantation assays; DPPE further cooperated with doxorubicin to completely eradicate tumorigenic cells. tesmilifene 149-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 19118039-9 2009 Treatment of Her2/Neu(+) mammary tumor cells with DPPE in vitro efficiently killed TICs, as determined by flow cytometry and transplantation assays; DPPE further cooperated with doxorubicin to completely eradicate tumorigenic cells. Doxorubicin 178-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 18712381-11 2009 CONCLUSION: HER2 expression (0 to 3+) can be differentiated using (111)In-DTPA-trastuzumab, but requires correction of tumour uptake for nonspecific IgG localization and circulating radioactivity. Pentetic Acid 74-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-16 18712381-2 2009 MATERIALS AND METHODS: The tumour uptake of (111)In-DTPA-trastuzumab in athymic mice bearing BC xenografts with increasing HER2 density (0 to 3+) was evaluated. Pentetic Acid 52-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-127 18712381-7 2009 RESULTS: Strong, nonlinear associations with HER2 density were obtained if the uptake of (111)In-DTPA-trastuzumab was corrected for nonspecific IgG localization (i.e., SUR; r (2) = 0.99) and circulating radioactivity (i.e., LI; r (2) = 0.87), but without these corrections, the association between HER2 density and tumour uptake was poor (r (2) = 0.22). Pentetic Acid 97-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-49 18712381-7 2009 RESULTS: Strong, nonlinear associations with HER2 density were obtained if the uptake of (111)In-DTPA-trastuzumab was corrected for nonspecific IgG localization (i.e., SUR; r (2) = 0.99) and circulating radioactivity (i.e., LI; r (2) = 0.87), but without these corrections, the association between HER2 density and tumour uptake was poor (r (2) = 0.22). Pentetic Acid 97-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 298-302 18594815-6 2008 MATERIALS AND METHODS: Anti-HER2 Z(HER2:342) Affibody molecules, carrying the mercaptoacetyl-glutamyl-seryl-glutamyl (maESE), mercaptoacetyl-glutamyl-glutamyl-seryl (maEES) and mercaptoacetyl-seryl-glutamyl-glutamyl (maSEE) chelators, were prepared by peptide synthesis and labelled with (99m)Tc. Technetium 293-295 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-32 19035668-0 2008 Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Lysine 11-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-109 19035668-0 2008 Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. mercaptoacetyl 29-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-109 19035668-1 2008 The effects of polar (mercaptoacetyl-triseryl) and negatively charged (mercaptoacetyl-triglumatyl) chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules were previously investigated. mercaptoacetyl-triglumatyl 71-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 19035668-12 2008 In conclusion, the substitution with one single lysine in the chelator results in better tumor imaging properties of the Affibody molecule Z(HER2:342) and is favorable for imaging of tumors and metastases in the abdominal area. Lysine 48-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 141-145 19139133-7 2009 Tra-Alexa680(SQ) produced specific enhancement in the 3T3/HER-2+ tumors but not in the HER-2- control tumors. tra-alexa680 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 58-63 19173004-0 2009 Developmental and lactational exposure to dieldrin alters mammary tumorigenesis in Her2/neu transgenic mice. Dieldrin 42-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-87 19173004-0 2009 Developmental and lactational exposure to dieldrin alters mammary tumorigenesis in Her2/neu transgenic mice. Dieldrin 42-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-91 19111799-14 2009 Analysis of breast tumors from mice treated with letrozole revealed up-regulation of HER-2 and MAP Kinase signaling proteins and down-regulation of the estrogen receptor. Letrozole 49-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 20641259-10 2004 The avidin-biotin system has been used to visualize HER2/neu-positive tumors in transgenic mice by some investigators with magnetic resonance imaging (MRI) (16, 17). avidin-biotin 4-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-56 19047120-2 2008 The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial. Lapatinib 138-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-127 18594815-6 2008 MATERIALS AND METHODS: Anti-HER2 Z(HER2:342) Affibody molecules, carrying the mercaptoacetyl-glutamyl-seryl-glutamyl (maESE), mercaptoacetyl-glutamyl-glutamyl-seryl (maEES) and mercaptoacetyl-seryl-glutamyl-glutamyl (maSEE) chelators, were prepared by peptide synthesis and labelled with (99m)Tc. Technetium 293-295 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 18594815-10 2008 The renal uptakes of serine-containing conjugates, 33 +/- 5, 68 +/- 21 and 71 +/- 10%IA/g, for(99m)Tc-maESE-Z(HER2:342), (99m)Tc-maEES-Z(HER2:342) and (99m)Tc-maSEE-Z(HER2:342), respectively, were significantly reduced in comparison with (99m)Tc-maEEE-Z(HER2:342) (102 +/- 13%IA/g). Serine 21-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 18842405-0 2008 Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines. pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines 39-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-16 18842405-1 2008 A novel class of substituted pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines has been identified that are potent and selective inhibitors of both EGFR/ErbB-2 receptor tyrosine kinases. pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines 29-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-158 18534779-2 2008 Millerenolide and thieleanin showed a similar pattern of cytotoxicity with the greatest effect on viability being evident with A549 human lung cancer cells (IC(50) - 40 and 32 microM respectively), and with the 3T3/HER2 cell line which are 3T3 mouse fibroblasts transfected with the HER2 oncogene (IC(50) - 16 and 28 microM respectively). millerenolide 0-13 erb-b2 receptor tyrosine kinase 2 Mus musculus 215-219 18794141-5 2008 To target the CpG-ODN to the tumor site anywhere within the body, we chemically conjugated an anti-Her-2/neu monoclonal antibody (mAb) with CpG-ODN. CPG-oligonucleotide 14-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 18534779-2 2008 Millerenolide and thieleanin showed a similar pattern of cytotoxicity with the greatest effect on viability being evident with A549 human lung cancer cells (IC(50) - 40 and 32 microM respectively), and with the 3T3/HER2 cell line which are 3T3 mouse fibroblasts transfected with the HER2 oncogene (IC(50) - 16 and 28 microM respectively). millerenolide 0-13 erb-b2 receptor tyrosine kinase 2 Mus musculus 283-287 18534779-2 2008 Millerenolide and thieleanin showed a similar pattern of cytotoxicity with the greatest effect on viability being evident with A549 human lung cancer cells (IC(50) - 40 and 32 microM respectively), and with the 3T3/HER2 cell line which are 3T3 mouse fibroblasts transfected with the HER2 oncogene (IC(50) - 16 and 28 microM respectively). thieleanin 18-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 215-219 18534779-2 2008 Millerenolide and thieleanin showed a similar pattern of cytotoxicity with the greatest effect on viability being evident with A549 human lung cancer cells (IC(50) - 40 and 32 microM respectively), and with the 3T3/HER2 cell line which are 3T3 mouse fibroblasts transfected with the HER2 oncogene (IC(50) - 16 and 28 microM respectively). thieleanin 18-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 283-287 18575520-5 2008 By linking LEQDs with anti-Her2 antibodies, the expression of Her2/neu receptors in live breast cancer cells could also be easily detected through THG. Thioguanine 147-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-70 18620447-5 2008 The recently developed maleimido-CHX-A"" DTPA was site-specifically conjugated at the C-terminal cysteine of Z HER2:2395-C, a variant of Z HER2:342, providing a homogeneous conjugate with a dissociation constant of 56 pM. maleimido-chx-a"" dtpa 23-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-115 18620447-5 2008 The recently developed maleimido-CHX-A"" DTPA was site-specifically conjugated at the C-terminal cysteine of Z HER2:2395-C, a variant of Z HER2:342, providing a homogeneous conjugate with a dissociation constant of 56 pM. maleimido-chx-a"" dtpa 23-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-143 18620447-5 2008 The recently developed maleimido-CHX-A"" DTPA was site-specifically conjugated at the C-terminal cysteine of Z HER2:2395-C, a variant of Z HER2:342, providing a homogeneous conjugate with a dissociation constant of 56 pM. Cysteine 97-105 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-115 18620447-5 2008 The recently developed maleimido-CHX-A"" DTPA was site-specifically conjugated at the C-terminal cysteine of Z HER2:2395-C, a variant of Z HER2:342, providing a homogeneous conjugate with a dissociation constant of 56 pM. Cysteine 97-105 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-143 18620447-7 2008 In vitro cell tests demonstrated specific binding of (111)In-CHX-A"" DTPA-Z 2395-C to HER2-expressing cell-line SKOV-3 and good cellular retention of radioactivity. Pentetic Acid 69-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 18686132-0 2008 Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. Doxorubicin 73-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-48 18686132-0 2008 Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. Doxorubicin 73-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-110 18686132-4 2008 We have examined, in a murine breast cancer model, the rate and the extent of bioavailability of doxorubicin (DXR) entrapped in liposomes targeted by a single-chain antibody fragment against the HER2/neu antigen, in comparison with free DXR and non-targeted liposomal DXR (DOXIL). Doxorubicin 97-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-203 18664652-3 2008 We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis. Lapatinib 28-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-107 18664652-7 2008 RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2). Lapatinib 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 18664652-7 2008 RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2). Lapatinib 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 182-186 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18664652-11 2008 CONCLUSIONS: Lapatinib is the first HER2-directed drug to be validated in a preclinical model for activity against brain metastases of breast cancer. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 18575520-5 2008 By linking LEQDs with anti-Her2 antibodies, the expression of Her2/neu receptors in live breast cancer cells could also be easily detected through THG. Thioguanine 147-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 27-31 18483270-4 2008 In vivo migration assays showed that approximately 40% injected CR-modified DC (scFv-CD40-DC) effectively migrated to ErbB2-positive tumors, where they were activated after ErbB2 antigen stimulation, and sequentially homed into the draining lymph nodes. Chromium 64-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-123 19138935-7 2008 In vivo AP-1 blockade by Tam67 expression started delayed mammary tumor formation in MMTV-erbB2 mice by more than 11 weeks. tam67 25-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-95 19138935-10 2008 Twenty-five percent of the doxycycline-treated MMTV-erbB2 mice survived more than 72 weeks of age without developing mammary tumors. Doxycycline 27-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-57 18483270-4 2008 In vivo migration assays showed that approximately 40% injected CR-modified DC (scFv-CD40-DC) effectively migrated to ErbB2-positive tumors, where they were activated after ErbB2 antigen stimulation, and sequentially homed into the draining lymph nodes. Chromium 64-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 173-178 18339686-0 2008 t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. Linoleic Acid 19-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-77 18454161-0 2008 Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Tetracycline 23-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-52 18454161-4 2008 We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. 4-epianhydrotetracycline 34-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-94 18454161-4 2008 We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. 4-epianhydrotetracycline 55-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-94 18339686-0 2008 t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. Linoleic Acid 19-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-83 18339686-2 2008 In the current study, we report that a 4-week supplementation of the diet with 0.5% trans-10, cis-12 conjugated linoleic acid (t10,c12-CLA) stimulated the growth of established ErbB2-overexpressing mammary tumors by 30% and increased the number of new tumors from 11% to 82%. trans-10 84-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-182 18339686-1 2008 The t10,c12 isomer of conjugated linoleic acid (CLA) inhibits rat mammary carcinogenesis, metastasis from a transplantable mouse mammary tumor and angiogenesis; however, it stimulates mammary tumorigenesis in transgenic mice overexpressing ErbB2 in the mammary epithelium (ErbB2 transgenic mice). Linoleic Acid 33-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 240-245 18339686-1 2008 The t10,c12 isomer of conjugated linoleic acid (CLA) inhibits rat mammary carcinogenesis, metastasis from a transplantable mouse mammary tumor and angiogenesis; however, it stimulates mammary tumorigenesis in transgenic mice overexpressing ErbB2 in the mammary epithelium (ErbB2 transgenic mice). Linoleic Acid 33-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 273-278 18339686-2 2008 In the current study, we report that a 4-week supplementation of the diet with 0.5% trans-10, cis-12 conjugated linoleic acid (t10,c12-CLA) stimulated the growth of established ErbB2-overexpressing mammary tumors by 30% and increased the number of new tumors from 11% to 82%. cis-12 94-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-182 18339686-1 2008 The t10,c12 isomer of conjugated linoleic acid (CLA) inhibits rat mammary carcinogenesis, metastasis from a transplantable mouse mammary tumor and angiogenesis; however, it stimulates mammary tumorigenesis in transgenic mice overexpressing ErbB2 in the mammary epithelium (ErbB2 transgenic mice). Linoleic Acids, Conjugated 48-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 240-245 18339686-2 2008 In the current study, we report that a 4-week supplementation of the diet with 0.5% trans-10, cis-12 conjugated linoleic acid (t10,c12-CLA) stimulated the growth of established ErbB2-overexpressing mammary tumors by 30% and increased the number of new tumors from 11% to 82%. Linoleic Acid 112-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-182 18339686-3 2008 Additionally, when t10,c12-CLA supplementation of ErbB2 transgenic mice was initiated at 21 weeks of age, a time just prior to tumor appearance, overall survival was decreased from 46.4 weeks in the control to 39.0 weeks in the CLA group, and survival after detection of a palpable tumor from 7.5 to 4.6 weeks. Linoleic Acids, Conjugated 27-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-55 18339686-1 2008 The t10,c12 isomer of conjugated linoleic acid (CLA) inhibits rat mammary carcinogenesis, metastasis from a transplantable mouse mammary tumor and angiogenesis; however, it stimulates mammary tumorigenesis in transgenic mice overexpressing ErbB2 in the mammary epithelium (ErbB2 transgenic mice). Linoleic Acids, Conjugated 48-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 273-278 18157531-7 2008 Some of the mice were pre-treated with non-labeled Z(HER2:342)-Cys. Cysteine 63-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 18076070-0 2008 Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Gefitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 17990290-3 2008 Using 3T3-L1 cells as model, we demonstrate that EGF (10 nM, 5 min) in addition to stimulate receptor tyrosine phosphorylation of both erbB2 and EGFR, is able to induce the heterodimer erbB2-EGFR. Tyrosine 102-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 135-140 17990290-8 2008 We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 17-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 17990290-8 2008 We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa. pyrazolanthrone 29-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 18413839-8 2008 ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers. Lapatinib 30-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 18413839-8 2008 ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers. Lapatinib 203-212 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 18076070-0 2008 Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Gefitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-83 18076070-1 2008 We tested the efficacy of gefitinib in the prevention of HER2/neu-mediated breast cancer development in BALB-NeuT transgenic mice. Gefitinib 26-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 18076070-1 2008 We tested the efficacy of gefitinib in the prevention of HER2/neu-mediated breast cancer development in BALB-NeuT transgenic mice. Gefitinib 26-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-65 18076070-6 2008 Gefitinib eliminated phosphorylation of HER2 and HER3 and signaling through MAPK and Akt in lobular hyperplasias and carcinomas. Gefitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-44 18245551-0 2008 Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Astatine 143-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 175-179 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 98-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 98-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 18245551-0 2008 Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Astatine 143-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 180-183 18061446-0 2008 A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. 5-substituted 4-anilinoquinazolines 24-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 18061446-1 2008 Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. glycolamide 83-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-158 18172276-2 2008 Ansamycins, such as 17-(allylamino)-17-demethoxygeldanmycin (17-AAG), inhibit Hsp90 function; induce the degradation of Hsp90 client proteins such as HER2, and have shown activity in early clinical trials. Lactams, Macrocyclic 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 18034452-2 2008 We investigated the properties of three structurally different conjugates of polyethylenglycol-modified polyethylenimine coupled to the HER2 specific antibody Trastuzumab. polyethylenglycol-modified polyethylenimine 77-120 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 18172276-2 2008 Ansamycins, such as 17-(allylamino)-17-demethoxygeldanmycin (17-AAG), inhibit Hsp90 function; induce the degradation of Hsp90 client proteins such as HER2, and have shown activity in early clinical trials. 17-(allylamino)-17-demethoxygeldanmycin 20-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 150-154 18172276-8 2008 A single dose of SNX-5542 causes HER2 degradation and inhibits its downstream signaling for up to 24 h, and daily dosing results in regression of HER2-dependent xenografts. snx-5542 17-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. Maleimide-DOTA 26-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. Maleimide-DOTA 26-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. Maleimide-DOTA 26-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. mma-dota 108-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. mma-dota 108-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 18163536-5 2008 In this study, the use of 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (MMA-DOTA) for 111 In-labeling of anti-HER2 Affibody molecules His 6-Z HER2:342-Cys and Z HER2:2395-Cys has been evaluated. mma-dota 108-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 18163536-9 2008 In vivo, the non-His-tagged variant 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys demonstrated appreciably lower liver uptake than its His-tag-containing counterpart. Histidine 17-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-66 18163536-9 2008 In vivo, the non-His-tagged variant 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys demonstrated appreciably lower liver uptake than its His-tag-containing counterpart. Cysteine 53-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-66 18163536-9 2008 In vivo, the non-His-tagged variant 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys demonstrated appreciably lower liver uptake than its His-tag-containing counterpart. Histidine 129-132 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-66 18163536-10 2008 In mice bearing HER2-expressing LS174T xenografts, 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys showed specific and rapid tumor localization, and rapid clearance from blood and nonspecific compartments, leading to a tumor-to-blood-ratio of 18 +/- 8 already 1 h p.i. mma-dota-cys61 59-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-20 18163536-10 2008 In mice bearing HER2-expressing LS174T xenografts, 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys showed specific and rapid tumor localization, and rapid clearance from blood and nonspecific compartments, leading to a tumor-to-blood-ratio of 18 +/- 8 already 1 h p.i. mma-dota-cys61 59-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-81 18163536-10 2008 In mice bearing HER2-expressing LS174T xenografts, 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys showed specific and rapid tumor localization, and rapid clearance from blood and nonspecific compartments, leading to a tumor-to-blood-ratio of 18 +/- 8 already 1 h p.i. Cysteine 68-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-20 18163536-10 2008 In mice bearing HER2-expressing LS174T xenografts, 111 In-[MMA-DOTA-Cys61]-Z HER2:2395-Cys showed specific and rapid tumor localization, and rapid clearance from blood and nonspecific compartments, leading to a tumor-to-blood-ratio of 18 +/- 8 already 1 h p.i. Cysteine 68-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-81 18172276-8 2008 A single dose of SNX-5542 causes HER2 degradation and inhibits its downstream signaling for up to 24 h, and daily dosing results in regression of HER2-dependent xenografts. snx-5542 17-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 17761519-2 2007 A simultaneous interrogation of 42 receptor tyrosine kinases (RTKs) in hESCs following stimulation with mouse embryonic fibroblast (MEF) conditioned medium (CM) revealed rapid and prominent tyrosine phosphorylation of insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R); less prominent tyrosine phosphorylation of epidermal growth factor receptor (EGFR) family members, including ERBB2 and ERBB3; and trace phosphorylation of fibroblast growth factor receptors. Tyrosine 190-198 erb-b2 receptor tyrosine kinase 2 Mus musculus 400-405 18056472-6 2007 Moreover, by reducing MDSC, amino-biphosphonates overcome the tumor-induced immune suppression and improved the generation and maintenance of antitumor immune response induced by immunization against the p185/HER-2. amino-biphosphonates 28-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 209-214 17916677-0 2007 Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. Bleomycin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 17916677-2 2007 Transgenic mice unable to signal through HER2/HER3 had significantly less bleomycin-induced pulmonary fibrosis and showed a survival benefit. Bleomycin 74-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-45 17916677-4 2007 We tested this hypothesis in a bleomycin lung injury model using 2C4, a monoclonal antibody directed against HER2 that blocks HER2/HER3 signaling. Bleomycin 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-113 17869514-0 2007 Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. 5-substituted 4-anilinoquinazolines 8-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-88 18171992-9 2007 Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner. Tetradecanoylphorbol Acetate 92-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 207-212 18171992-9 2007 Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner. Tetradecanoylphorbol Acetate 92-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 313-318 17565496-3 2007 Previously, Z(HER2:342) with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with (99m)Tc and demonstrated specific targeting of HER2-expressing xenografts. Technetium 131-133 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-18 17854941-5 2007 In summary, HER-PEG-ADV exhibited more enhanced level of GFP expression than PEG-ADV did for MDA-MB-435 and MDA-MB-468 cells (a HER2/neu positive cell line), but not for a HER2/neu deficient U251N cells. peg-adv 16-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 128-132 17982120-10 2007 Twenty-four hours after injection, A431 and NIH3T3/HER2+ tumors were detected distinctly by their peak on Cy5.5 and Cy7 spectral images, respectively; radionuclide imaging was unable to clearly distinguish tumors at this time point. cyanine dye 5 106-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-55 17982120-10 2007 Twenty-four hours after injection, A431 and NIH3T3/HER2+ tumors were detected distinctly by their peak on Cy5.5 and Cy7 spectral images, respectively; radionuclide imaging was unable to clearly distinguish tumors at this time point. cyanine dye 7 116-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-55 17565496-12 2007 The pharmacokinetics and uptake characteristics of technetium-labelled Z(HER2:342) were better than those of radioiodinated Z(HER2:342). Technetium 51-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-77 17565496-13 2007 CONCLUSION: The introduction of serine residues in the chelator results in better tumour imaging properties of the Affibody molecule Z(HER2:342) compared with glycyl-containing chelators and is favourable for imaging of tumours and metastases in the abdominal area. Serine 32-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 135-139 17947487-6 2007 In contrast, vaccination with FLneu induced CD8+ T cells specific for HER2/neu but a negligible anti-HER2/neu antibody response. flneu 30-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-78 17947487-6 2007 In contrast, vaccination with FLneu induced CD8+ T cells specific for HER2/neu but a negligible anti-HER2/neu antibody response. flneu 30-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 17942920-13 2007 of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects. cp-724 3-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-42 17909003-4 2007 Previously, we showed that the green tea polyphenol epigallocatechin-3 gallate (EGCG) inhibits growth and transformed phenotype of Her-2/neu-driven mouse mammary tumor cells. polyphenol epigallocatechin-3 gallate 41-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-140 17909003-4 2007 Previously, we showed that the green tea polyphenol epigallocatechin-3 gallate (EGCG) inhibits growth and transformed phenotype of Her-2/neu-driven mouse mammary tumor cells. epigallocatechin gallate 80-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-140 17869670-1 2007 PURPOSE: To investigate the potential use of astatine-211 (211At)-labeled trastuzumab for the treatment of HER-2-positive, radioresistant ovarian carcinoma. Astatine 45-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-112 17604617-7 2007 Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis. Dronabinol 31-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 17671747-3 2007 Previously, a benzyl-DTPA conjugate of Z(HER2:342) was labeled with 111In and demonstrated good targeting in murine xenografts. benzyl-DTPA 14-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-45 17671747-7 2007 Biodistribution of 111In-benzyl-DOTA-Z(HER2:342) was performed in nude mice bearing LS174T xenografts and compared directly with the biodistribution of 111In-benzyl-DTPA-Z(HER2:342). 111in-benzyl-dota 19-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-43 17699761-2 2007 Previously, we have shown that four ErbB-2/Neu tyrosine-autophosphorylation sites within the cytoplasmic tail of the receptor recruit distinct adaptor proteins and are sufficient to mediate transforming signals in vitro. Tyrosine 47-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-42 17699761-2 2007 Previously, we have shown that four ErbB-2/Neu tyrosine-autophosphorylation sites within the cytoplasmic tail of the receptor recruit distinct adaptor proteins and are sufficient to mediate transforming signals in vitro. Tyrosine 47-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-46 17604617-7 2007 Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis. Dronabinol 31-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-134 17699716-8 2007 In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression. Sirolimus 126-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 17699716-8 2007 In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression. Sirolimus 126-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 54-57 17699716-8 2007 In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression. Sirolimus 126-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 162-167 17699716-8 2007 In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression. Sirolimus 126-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-171 17372910-8 2007 Finally, peptidimer-c reduced the growth of a HER2(+) human breast cancer (BK111) xenograft in nude mice and potentiated the antitumor effect of docetaxel in a HER2+ hormone-independent human prostate adenocarcinoma (PAC120 HID28) xenograft. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Mus musculus 160-164 17575102-0 2007 Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. apricoxib 22-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-107 17638894-0 2007 Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Gefitinib 64-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-43 17638894-0 2007 Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Gefitinib 64-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-47 17638894-0 2007 Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Gefitinib 64-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-47 17638894-3 2007 We evaluated the effects of the epidermal growth factor receptor (EGFR)/HER2 inhibitor, gefitinib, on this breast tumor line in vitro and in vivo. Gefitinib 88-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-76 17638894-4 2007 We characterized the effects of gefitinib on EGFR, HER2, and ErbB-3 phosphorylation by Western blot and determined the effects on downstream signaling through growth, survival, and stress pathways and the effect on proliferation, cell cycle, and apoptosis. Gefitinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-55 17638894-5 2007 Gefitinib treatment diminished phosphorylation of the ErbB-3 > EGFR > HER2/neu and signal transducers and activators of transcriptions in a dose-dependent fashion. Gefitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-80 17638894-5 2007 Gefitinib treatment diminished phosphorylation of the ErbB-3 > EGFR > HER2/neu and signal transducers and activators of transcriptions in a dose-dependent fashion. Gefitinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-84 17638894-9 2007 Oral administration of gefitinib was able to prevent the outgrowth of Bam1a tumor cells from palpable lesions, shrink established tumors, eliminate HER2 and HER3 phosphorylation, and decrease MAPK and Akt signaling in vivo. Gefitinib 23-32 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-152 17638894-11 2007 IR-5 bears a novel point mutation in the HER2/neu that corresponds to a L726I in the ATP-binding pocket and correlates with a log decrease in sensitivity to gefitinib, increased heterodimerization with EGFR and HER3, and impaired down-regulation. Adenosine Triphosphate 85-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-45 17638894-11 2007 IR-5 bears a novel point mutation in the HER2/neu that corresponds to a L726I in the ATP-binding pocket and correlates with a log decrease in sensitivity to gefitinib, increased heterodimerization with EGFR and HER3, and impaired down-regulation. Adenosine Triphosphate 85-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-49 17638894-11 2007 IR-5 bears a novel point mutation in the HER2/neu that corresponds to a L726I in the ATP-binding pocket and correlates with a log decrease in sensitivity to gefitinib, increased heterodimerization with EGFR and HER3, and impaired down-regulation. Gefitinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-45 17638894-11 2007 IR-5 bears a novel point mutation in the HER2/neu that corresponds to a L726I in the ATP-binding pocket and correlates with a log decrease in sensitivity to gefitinib, increased heterodimerization with EGFR and HER3, and impaired down-regulation. Gefitinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-49 17259656-0 2007 The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium. Linoleic Acid 33-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-120 17489986-4 2007 We confirm that NEF-E6/E7 and NEF-E6/E7/ErbB-2, but not NEF-ErbB-2 cells, induce colony formation in soft agar and tumor formation in nude mice. Agar 106-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-46 17489986-7 2007 Nevertheless, D3(-/-)E6/E7/ErbB-2 cells resulted in up to a 60 and 50% decrease in colony and tumor formation in soft agar and nude mice, respectively, compared with NEF-E6/E7/ErbB-2 cells. Agar 118-122 erb-b2 receptor tyrosine kinase 2 Mus musculus 21-33 17606729-11 2007 Notably, mitigating immune tolerance by inhibiting regulatory T cell activity with cyclophosphamide revealed DC101-mediated augmentation of antitumor responses in vaccinated neu-N mice. Cyclophosphamide 83-99 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-177 17575102-10 2007 CS-706 treatment also down-regulated the activation of ErbB-2 and epidermal growth factor receptor, resulting in decreased levels of phosphorylated Akt and COX-2 in gallbladder cancers of BK5.ErbB-2 mice. apricoxib 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-61 17575102-10 2007 CS-706 treatment also down-regulated the activation of ErbB-2 and epidermal growth factor receptor, resulting in decreased levels of phosphorylated Akt and COX-2 in gallbladder cancers of BK5.ErbB-2 mice. apricoxib 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-198 17390057-0 2007 Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. 211at 19-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 17470737-14 2007 CONCLUSION: Combined treatment with gefitinib, trastuzumab, and pertuzumab to block signals from all HER homo- and heterodimers inhibited growth of HER2-overexpressing xenografts statistically significantly better than single agents and dual combinations. Gefitinib 36-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-152 17440093-6 2007 Rapamycin significantly reduced the incidence and severity of gallbladder carcinoma in BK5.erbB2 mice in a dose-dependent manner. Sirolimus 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-96 17409443-0 2007 A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. alpha-Tocopherol 23-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-86 17409443-2 2007 We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). alpha-Tocopherol 160-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 17409443-2 2007 We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). alpha-Tocopherol 160-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 17409443-2 2007 We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). alpha-Tocopherol 188-197 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 17409443-2 2007 We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). alpha-Tocopherol 188-197 erb-b2 receptor tyrosine kinase 2 Mus musculus 99-104 17409443-3 2007 Treating erbB2-low or erbB2-high cells with alpha-TOS induced similar levels of apoptosis, whereas alpha-TOS-LTVSPWY induced greater levels of apoptosis in erbB2-high cells. alpha-Tocopherol 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-14 17409443-3 2007 Treating erbB2-low or erbB2-high cells with alpha-TOS induced similar levels of apoptosis, whereas alpha-TOS-LTVSPWY induced greater levels of apoptosis in erbB2-high cells. alpha-Tocopherol 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-27 17409443-3 2007 Treating erbB2-low or erbB2-high cells with alpha-TOS induced similar levels of apoptosis, whereas alpha-TOS-LTVSPWY induced greater levels of apoptosis in erbB2-high cells. alpha-Tocopherol 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-27 17409443-4 2007 alpha-TOS rapidly accumulated in erbB2-high cells exposed to alpha-TOS-LTVSPWY. alpha-Tocopherol 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 17363599-0 2007 Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Lutetium-177 62-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-28 17363549-0 2007 Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. gemcitabine 38-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-65 17363599-0 2007 Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Lutetium-177 62-67 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-80 17211467-4 2007 Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-106 17332330-0 2007 Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. silybin-phosphatidylcholine 14-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-106 17332330-0 2007 Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. silybin-phosphatidylcholine 14-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-110 17203189-10 2007 A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-97 17203189-10 2007 A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines. GW2974 112-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-97 17322391-3 2007 In expressing Cre recombinase under the control of the MMTV promoter, the bigenic mice bearing Has2 and neu transgenes exhibited a deposition of hyaluronan matrix and aggressive growth of Neu-initiated mammary tumors. Hyaluronic Acid 145-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-107 17285134-7 2007 Cyclooxygenase-2 expression decreased following Celecoxib treatment (MCF7/HER2-18 median control 65.3% vs treated 22.5%, P=0.0001). Celecoxib 48-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-78 17283144-0 2007 The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. propeptide 51-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-106 17203234-7 2007 However, tyrosine-phosphorylated HER2/ neu, HER3, phospho-extracellular-regulated kinase-1/2 (ERK-1/2), and phospho-glycogen synthetase kinase 3alpha (GSK3alpha) and beta proteins were increased in MCF-7TAMLT tumors treated with fulvestrant compared to estradiol, control, or tamoxifen. Tyrosine 9-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 17203234-7 2007 However, tyrosine-phosphorylated HER2/ neu, HER3, phospho-extracellular-regulated kinase-1/2 (ERK-1/2), and phospho-glycogen synthetase kinase 3alpha (GSK3alpha) and beta proteins were increased in MCF-7TAMLT tumors treated with fulvestrant compared to estradiol, control, or tamoxifen. Tyrosine 9-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-42 17203234-13 2007 The results suggested that growth of MCF-7TAMLT tumors treated with fulvestrant in the presence of physiologic estradiol is in part mediated through enhanced signaling from the HER2/neu-HER3 pathway as pertuzumab partially inhibited growth and the interaction of HER2/neu with HER3 in vivo. Fulvestrant 68-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-181 17203234-13 2007 The results suggested that growth of MCF-7TAMLT tumors treated with fulvestrant in the presence of physiologic estradiol is in part mediated through enhanced signaling from the HER2/neu-HER3 pathway as pertuzumab partially inhibited growth and the interaction of HER2/neu with HER3 in vivo. Fulvestrant 68-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 182-185 17203234-13 2007 The results suggested that growth of MCF-7TAMLT tumors treated with fulvestrant in the presence of physiologic estradiol is in part mediated through enhanced signaling from the HER2/neu-HER3 pathway as pertuzumab partially inhibited growth and the interaction of HER2/neu with HER3 in vivo. Fulvestrant 68-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 263-267 17203234-13 2007 The results suggested that growth of MCF-7TAMLT tumors treated with fulvestrant in the presence of physiologic estradiol is in part mediated through enhanced signaling from the HER2/neu-HER3 pathway as pertuzumab partially inhibited growth and the interaction of HER2/neu with HER3 in vivo. Fulvestrant 68-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 268-271 17211467-4 2007 Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 204-208 17211467-4 2007 Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. Docetaxel 177-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-106 17211467-5 2007 This was followed by an increase of HER2 protein 3 days (two-fold) after docetaxel treatment and by a strong HER2 release in the serum of treated mice; expression of phospho-ERK, p27, BCL2 and HSP70 concomitantly increased. Docetaxel 73-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 17234795-10 2007 Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes. Azoxymethane 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 160-165 17257424-9 2007 In the second set of experiments using the activated Her-2/neu transgenic mouse model, short-term estradiol or estradiol plus progesterone treatment decreased mammary tumor incidence by 67% and 63%, and tumor multiplicity by 91% and 88%, respectively. Estradiol 98-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-62 17257424-9 2007 In the second set of experiments using the activated Her-2/neu transgenic mouse model, short-term estradiol or estradiol plus progesterone treatment decreased mammary tumor incidence by 67% and 63%, and tumor multiplicity by 91% and 88%, respectively. Estradiol 111-120 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-62 17257424-9 2007 In the second set of experiments using the activated Her-2/neu transgenic mouse model, short-term estradiol or estradiol plus progesterone treatment decreased mammary tumor incidence by 67% and 63%, and tumor multiplicity by 91% and 88%, respectively. Progesterone 126-138 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-62 16899478-10 2006 Dexamethasone modulated erbB receptor dimerisation patterns, such that erbB2 became the main dimerisation partner for erbB4. Dexamethasone 0-13 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-76 17210714-0 2007 [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Lutetium-177 1-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-48 17109639-8 2006 Because ErbB1 or ErbB2 receptors form heterodimers with the ErbB3 receptor, and ErbB3 heterodimers have been shown to be the most potent activators of PI3K, these findings strongly suggest that the antiproliferative effects of gamma-tocotrienol in neoplastic +SA mouse mammary epithelial cells are mediated by a suppression in ErbB3-receptor tyrosine phosphorylation and subsequent reduction in PI3K/PDK-1/Akt mitogenic signalling. plastochromanol 8 227-244 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-22 17109639-8 2006 Because ErbB1 or ErbB2 receptors form heterodimers with the ErbB3 receptor, and ErbB3 heterodimers have been shown to be the most potent activators of PI3K, these findings strongly suggest that the antiproliferative effects of gamma-tocotrienol in neoplastic +SA mouse mammary epithelial cells are mediated by a suppression in ErbB3-receptor tyrosine phosphorylation and subsequent reduction in PI3K/PDK-1/Akt mitogenic signalling. 2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine 260-262 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-22 17109639-8 2006 Because ErbB1 or ErbB2 receptors form heterodimers with the ErbB3 receptor, and ErbB3 heterodimers have been shown to be the most potent activators of PI3K, these findings strongly suggest that the antiproliferative effects of gamma-tocotrienol in neoplastic +SA mouse mammary epithelial cells are mediated by a suppression in ErbB3-receptor tyrosine phosphorylation and subsequent reduction in PI3K/PDK-1/Akt mitogenic signalling. Tyrosine 342-350 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-22 17113978-14 2006 EGFR/Her-2 inhibitors, gefitinib and AEE78S although not effective in the parental MCF-70a cells, restored the sensitivity of LTLT cells to letrozole. Letrozole 140-149 erb-b2 receptor tyrosine kinase 2 Mus musculus 5-10 17113978-15 2006 In xenografts, beginning treatment with letrozole and faslodex to down regulate the ER prevented increases in Her-2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment. Letrozole 40-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-115 17113978-15 2006 In xenografts, beginning treatment with letrozole and faslodex to down regulate the ER prevented increases in Her-2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment. Fulvestrant 54-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-115 16884304-4 2006 The iv administration of Gd-DOTAMA-C6-Gln allowed the MRI visualization of tumor masses in A/J mice grafted with the murine neuroblastoma cell line Neuro-2a and in Her-2/neu transgenic mice developing multiple mammary carcinoma, respectively. gd-dotama-c6-gln 25-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-127 17079459-6 2006 To resolve this apparent paradox, we examined the relationship between c-neu expression and estrogen/ERalpha-dependent cell proliferation in pubertal Tg (c-neu). Thioguanine 150-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-76 16912207-8 2006 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib, which can block EGFR/HER-2/neu signaling, significantly delayed the emergence of resistance to both estrogen deprivation and fulvestrant. Gefitinib 70-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-111 16912207-10 2006 Eventually, however, tumors progressed in mice treated with gefitinib combined with estrogen deprivation or fulvestrant accompanied again by loss of ER and IGF-IR, increased p-HER-2/neu, high p-MAPK, and now increased p-AKT. Gefitinib 60-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-185 16912207-11 2006 Thus, estrogen deprivation and fulvestrant can effectively inhibit HER-2/neu-overexpressing tumors but resistance develops quickly. Fulvestrant 31-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-72 16912207-1 2006 HER-2/neu in breast cancer is associated with tamoxifen resistance, but little data exist on its interaction with estrogen deprivation or fulvestrant. Tamoxifen 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-9 16470840-0 2006 Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Gefitinib 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-115 16912207-3 2006 MCF7/HER-2/neu-18 tumors were growth inhibited by estrogen deprivation and with fulvestrant, but resistance developed in 2 to 3 months. Fulvestrant 80-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 5-10 16912207-3 2006 MCF7/HER-2/neu-18 tumors were growth inhibited by estrogen deprivation and with fulvestrant, but resistance developed in 2 to 3 months. Fulvestrant 80-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-14 16912207-11 2006 Thus, estrogen deprivation and fulvestrant can effectively inhibit HER-2/neu-overexpressing tumors but resistance develops quickly. Fulvestrant 31-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-76 16470840-0 2006 Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. ammonium ferrous sulfate 39-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-115 16707480-11 2006 Collectively, our data indicate that COX-2 is the functional intermediate linking HER-2/neu and aromatase and suggest that inhibitors of PGE(2) synthesis will suppress estrogen biosynthesis in breast tissue. Dinoprostone 137-143 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-91 16482517-4 2006 Tyrosine-phosphorylated (activated) ErbB-2 and ErbB-3 receptors were detected in the majority of extracts from tumors that had formed spontaneously or as a result of oncogene expression. Tyrosine 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-42 16482517-10 2006 Treatment with HRG-1 siRNA oligonucleotides or infection with a retroviral construct to stably express HRG siRNA effectively reduced HRG protein levels, ErbB-2/ErbB-3 activation, and the rate of proliferation, which could be reversed by the addition of HRG. Oligonucleotides 27-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-159 16793894-2 2006 In the present study, the Tet-On system has been used in transgenic mice to enable inducible expression of a mutant, constitutively active neuregulin receptor (ErbB2) in SCs. tetramethylenedisulfotetramine 26-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 160-165 16707480-10 2006 Complementary in vitro studies showed that HER-2/neu-mediated induction of PGE(2) synthesis and aromatase activity were suppressed by inhibiting COX-2. Prostaglandins E 75-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-48 16538504-9 2006 CONCLUSION: The results indicate that the (Z(HER2:4))(2) affibody is an interesting candidate for applications in nuclear medicine, such as radionuclide-based tumour imaging and therapy. Radioisotopes 140-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-49 16496387-4 2006 Therefore, we used a mouse tumor model that allows downregulation of HER-2 in tumor tissue by administration of anhydrotetracycline (ATc). 4-epianhydrotetracycline 112-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-74 16707480-10 2006 Complementary in vitro studies showed that HER-2/neu-mediated induction of PGE(2) synthesis and aromatase activity were suppressed by inhibiting COX-2. Prostaglandins E 75-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-52 16678784-2 2006 It has been observed that in female CBA, SHR, SAM and transgenic HER-2/neu mice long-term administration of melatonin was followed by an increase in the mean life span. Melatonin 108-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-74 16644749-6 2006 CONCLUSION: HER2 PET is an earlier predictor of tumor response to 17AAG therapy than (18)F-FDG PET. tanespimycin 66-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-16 16644755-0 2006 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. benzyl-DTPA 5-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 16644755-6 2006 METHODS: Z(HER2:342) was labeled with (111)In via isothiocyanate-benzyl-DTPA (DTPA is diethylenetriaminepentaacetic acid) and the conjugate was characterized in vitro and in vivo. Pentetic Acid 72-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-15 16644755-6 2006 METHODS: Z(HER2:342) was labeled with (111)In via isothiocyanate-benzyl-DTPA (DTPA is diethylenetriaminepentaacetic acid) and the conjugate was characterized in vitro and in vivo. Pentetic Acid 86-120 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-15 16644755-7 2006 RESULTS: (111)In-Benzyl-DTPA-Z(HER2:342) preserved the capacity to bind living HER2-expressing cells specifically. benzyl-DTPA 17-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-35 16644755-7 2006 RESULTS: (111)In-Benzyl-DTPA-Z(HER2:342) preserved the capacity to bind living HER2-expressing cells specifically. benzyl-DTPA 17-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 16644755-8 2006 The affinity of In-benzyl-DTPA-Z(HER2:342) to HER2 was 21 pmol/L according to surface plasmon resonance measurements. in-benzyl-dtpa 16-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 16644755-8 2006 The affinity of In-benzyl-DTPA-Z(HER2:342) to HER2 was 21 pmol/L according to surface plasmon resonance measurements. in-benzyl-dtpa 16-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 46-50 16644755-12 2006 CONCLUSION: (111)In-Benzyl-DTPA-Z(HER2:342) is a promising candidate for visualization of HER2 expression in carcinomas, using the single-photon detection technique. benzyl-DTPA 20-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-38 16644755-12 2006 CONCLUSION: (111)In-Benzyl-DTPA-Z(HER2:342) is a promising candidate for visualization of HER2 expression in carcinomas, using the single-photon detection technique. benzyl-DTPA 20-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 90-94 16496387-4 2006 Therefore, we used a mouse tumor model that allows downregulation of HER-2 in tumor tissue by administration of anhydrotetracycline (ATc). 4-epianhydrotetracycline 133-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-74 16681883-0 2006 [Inhibitory effect of antisense oligodeoxynucleotides targeting HER-2 mRNA on growth of breast cancer: experiment in vivo with mice]. Oligodeoxyribonucleotides 32-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-69 16681883-4 2006 Antisense oligodeoxynucleotide HA6722 targeting HER-2 mRNA and its control sequence Scramble were synthesized. Oligodeoxyribonucleotides 10-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 16367926-8 2006 Systemic administration of SUCI02 in nude mice resulted in inhibition of erbB-2 tyrosine kinase phosphorylation of subcutaneous human breast cancer BT474 xenografts. N-(4-ethoyphenol)-2-hydroxy- acid amide 27-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-79 16441842-9 2006 Metformin extends the mean and maximum lifespans of female transgenic HER-2/neu mice by 8% and 13.1% in comparison with control mice. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-79 16278083-1 2006 We overexpressed a constitutively active form of the neuregulin receptor ErbB2 (CAErbB2) in skeletal muscle fibers in vivo and in vitro by tetracycline-inducible expression. Tetracycline 139-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-78 16278083-5 2006 Thus, a gain-of-function manipulation of ErbB2 signaling pathways renders an agrin-deficient-like phenotype that uncouples MuSK and AChR tyrosine phosphorylation. Tyrosine 137-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-46 16420067-5 2006 In an HER-2 degradation assay, the highest potency was achieved with the neopentylamine 42 (HER-2 IC(50) = 90 nM). neopentylamine 73-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-11 16420067-5 2006 In an HER-2 degradation assay, the highest potency was achieved with the neopentylamine 42 (HER-2 IC(50) = 90 nM). neopentylamine 73-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-97 16287254-0 2005 Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. SCHEMBL6809866 14-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-95 16287254-3 2005 An affibody molecule binding with high affinity to a tumor antigen HER2 was recently developed for radionuclide diagnostics and therapy in vivo. Radioisotopes 99-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-71 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. Cysteine 38-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. Cysteine 38-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. Cysteine 106-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. Cysteine 106-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. SCHEMBL6809866 119-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. SCHEMBL6809866 119-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 16287254-5 2005 A site-specific radiobromination of a cysteine-containing variant of the anti-HER2 affibody, (Z(HER2:4))(2)-Cys, using ((4-hydroxyphenyl)ethyl)maleimide (HPEM), was evaluated in this study. hpem 154-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-82 15833803-10 2005 However, levels of phosphorylated erbB2, Akt, and ERK-1/2 were significantly decreased in NRG-1(+/-)-Dox compared with WT-Dox mice. Doxorubicin 101-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 16055332-0 2005 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase. 5-substituted 4-anilinoquinazolines 0-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-94 16055332-1 2005 Starting from a 6,7-substituted quinazoline lead 4, optimisation of 5-substituted quinazolines containing an extended aniline motif led to potent and selective inhibitors of erbB2 receptor tyrosine kinase, and a representative compound 12a inhibited tumour growth in a mouse xenograft model. 5-substituted quinazolines 68-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-179 16055332-1 2005 Starting from a 6,7-substituted quinazoline lead 4, optimisation of 5-substituted quinazolines containing an extended aniline motif led to potent and selective inhibitors of erbB2 receptor tyrosine kinase, and a representative compound 12a inhibited tumour growth in a mouse xenograft model. aniline 118-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-179 16126344-2 2005 In this work, the possibility of inducing a Th1 type of immune response in vivo by mixing a HER-2/neu synthetic CTL (cytotoxic T lymphocyte) peptide [HER-2/neu (789-797)], with poly-lactide (PLA) microspheres was investigated. poly(lactide) 177-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-101 16126344-2 2005 In this work, the possibility of inducing a Th1 type of immune response in vivo by mixing a HER-2/neu synthetic CTL (cytotoxic T lymphocyte) peptide [HER-2/neu (789-797)], with poly-lactide (PLA) microspheres was investigated. poly(lactide) 177-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-101 16126344-2 2005 In this work, the possibility of inducing a Th1 type of immune response in vivo by mixing a HER-2/neu synthetic CTL (cytotoxic T lymphocyte) peptide [HER-2/neu (789-797)], with poly-lactide (PLA) microspheres was investigated. poly(lactide) 191-194 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-101 16126344-2 2005 In this work, the possibility of inducing a Th1 type of immune response in vivo by mixing a HER-2/neu synthetic CTL (cytotoxic T lymphocyte) peptide [HER-2/neu (789-797)], with poly-lactide (PLA) microspheres was investigated. poly(lactide) 191-194 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-101 16203963-4 2005 Consistent with our previous demonstration that Cdk5 phosphorylates ErbB2/3 to regulate its tyrosine phosphorylation, we report here that the phosphorylation of ErbB2 and ErbB3 and the ErbB2 kinase activity are reduced in Cdk5-deficient muscle. Tyrosine 92-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 16203963-4 2005 Consistent with our previous demonstration that Cdk5 phosphorylates ErbB2/3 to regulate its tyrosine phosphorylation, we report here that the phosphorylation of ErbB2 and ErbB3 and the ErbB2 kinase activity are reduced in Cdk5-deficient muscle. Tyrosine 92-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-166 16203963-4 2005 Consistent with our previous demonstration that Cdk5 phosphorylates ErbB2/3 to regulate its tyrosine phosphorylation, we report here that the phosphorylation of ErbB2 and ErbB3 and the ErbB2 kinase activity are reduced in Cdk5-deficient muscle. Tyrosine 92-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-166 16248771-0 2005 Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Lead-212 77-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 124-128 15883172-3 2005 However, treatment of neu-N mice with vaccine and cyclophosphamide-containing chemotherapy resulted in tumor protection in a proportion of mice. Cyclophosphamide 50-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-25 16125352-5 2005 The chronic treatment of female transgenic HER-2/neu mice with metformin (100 mg/kg in drinking water) slightly decreased the food consumption but failed in reducing the body weight or temperature, slowed down the age-related rise in blood glucose and triglycerides level, as well as the age-related switch-off of estrous function, prolonged the mean life span by 8% (p < 0.05), the mean life span of last 10% survivors by 13.1%, and the maximum life span by 1 month in comparison with control mice. Metformin 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-48 16125352-5 2005 The chronic treatment of female transgenic HER-2/neu mice with metformin (100 mg/kg in drinking water) slightly decreased the food consumption but failed in reducing the body weight or temperature, slowed down the age-related rise in blood glucose and triglycerides level, as well as the age-related switch-off of estrous function, prolonged the mean life span by 8% (p < 0.05), the mean life span of last 10% survivors by 13.1%, and the maximum life span by 1 month in comparison with control mice. Metformin 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-52 16224592-0 2005 Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-70 16224592-0 2005 Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Metformin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-74 16061875-6 2005 In the present study, we examined the effect of gefitinib, a selective epidermal growth factor receptor/tyrosine kinase inhibitor (EGFR/TKI), on the development of gallbladder carcinoma in BK5.erbB2 mice. Gefitinib 48-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 193-198 16061875-7 2005 In addition, we examined the effect of another quinazoline derivative, GW2974, which is able to block the activation of both the EGFR and erbB2, in this model. Quinazolines 47-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 16061875-7 2005 In addition, we examined the effect of another quinazoline derivative, GW2974, which is able to block the activation of both the EGFR and erbB2, in this model. GW2974 71-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 15922741-3 2005 Treatment of differentiating C2C12 myoblasts with geldanamycin blocked myogenin expression, inhibited myotubule formation, and led to the depletion of three Hsp90-dependent protein kinases, ErbB2, Fyn, and Akt, and induction of apoptosis. geldanamycin 50-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 190-195 15883172-7 2005 Cyclophosphamide seemed to inhibit regulatory T (T reg) cells by selectively depleting the cycling population of CD4(+)CD25(+) T cells in neu-N mice. Cyclophosphamide 0-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-141 15883172-8 2005 These findings demonstrate that neu-N mice possess latent pools of high-avidity neu-specific CD8(+) T cells that can be recruited to produce an effective antitumor response if T reg cells are blocked or removed by using approaches such as administration of cyclophosphamide before vaccination. Cyclophosphamide 257-273 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-35 15883172-8 2005 These findings demonstrate that neu-N mice possess latent pools of high-avidity neu-specific CD8(+) T cells that can be recruited to produce an effective antitumor response if T reg cells are blocked or removed by using approaches such as administration of cyclophosphamide before vaccination. Cyclophosphamide 257-273 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-83 15690356-0 2005 EGF-R and erbB-2 in murine tooth development after ethanol exposure. Ethanol 51-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-16 15743682-4 2005 Diabenol treatment slowed down age-related changes in estrous function in HER-2/neu mice, failed influence survival of these mice and slightly inhibited the incidence and decreased the size of mammary adenocarcinoma metastases into the lung. diabenol 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-83 15632176-6 2005 Furthermore, in HCT116 and TA3/St cells, inhibition of endogenous hyaluronan-CD44 interaction causes disassembly of a constitutive, lipid raft-associated, signaling complex containing phosphorylated ErbB2, CD44, ezrin, phosphoinositide 3-kinase, and the chaperone molecules, Hsp90 and cdc37. Hyaluronic Acid 66-76 erb-b2 receptor tyrosine kinase 2 Mus musculus 199-204 15735035-0 2005 Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Iodine-124 99-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 15735035-0 2005 Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Iodine-124 99-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-127 15735035-4 2005 We evaluated a small engineered antibody fragment specific for the HER2 receptor tyrosine kinase (C6.5 diabody) for its ability to function as a PET radiotracer when labeled with iodine-124. Iodine-124 179-189 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-71 15867269-0 2005 Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. Fatty Acids, Omega-3 8-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-55 15867269-0 2005 Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. Fatty Acids, Omega-3 8-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-59 15867269-5 2005 We hypothesized that a thiazolidinedione, rosiglitazone, may serve as a chemopreventive agent for HER-2/neu-associated mammary carcinogenesis, but that efficacy may be influenced by dietary fat content. 2,4-thiazolidinedione 23-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-103 15867269-5 2005 We hypothesized that a thiazolidinedione, rosiglitazone, may serve as a chemopreventive agent for HER-2/neu-associated mammary carcinogenesis, but that efficacy may be influenced by dietary fat content. Rosiglitazone 42-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-103 15867269-10 2005 Further studies focusing on the mechanisms by which (n-3) fatty acids suppress HER-2/neu signaling pathways involved in the pathogenesis of breast cancer are warranted. Fatty Acids, Omega-3 52-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-84 15704244-1 2005 A 35 kDa protein present in mammary tumors from Neu/ErbB2 transgenic mice was detected on the basis of its cross-reactivity with a phosphoserine-specific antibody against the transcription factor FKHR. Phosphoserine 131-144 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-51 15704244-1 2005 A 35 kDa protein present in mammary tumors from Neu/ErbB2 transgenic mice was detected on the basis of its cross-reactivity with a phosphoserine-specific antibody against the transcription factor FKHR. Phosphoserine 131-144 erb-b2 receptor tyrosine kinase 2 Mus musculus 52-57 15690356-9 2005 RESULTS: At days 16.5 and 18.5, fetuses from 15%, 20%, and 25% ethanol groups showed delayed differentiation, degenerative changes in dental epithelial tissues and reduced dental size; additionally, they displayed an enhanced immunoreactivity to EGF-R and erbB-2. Ethanol 63-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 256-262 15860267-5 2005 The results demonstrate that there are distinct phases of resistance to tamoxifen that correlate with time of treatment and expression of HER2/neu mRNA. Tamoxifen 72-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-146 15504738-3 2005 Treatment of breast cancer cells that overexpress HER2 with trastuzumab inhibited HER2-HER3 association, decreased PDK1 activity, reduced Thr-308 and Ser-473 phosphorylation of AKT, and reduced AKT enzymatic activity. Serine 150-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 15504738-3 2005 Treatment of breast cancer cells that overexpress HER2 with trastuzumab inhibited HER2-HER3 association, decreased PDK1 activity, reduced Thr-308 and Ser-473 phosphorylation of AKT, and reduced AKT enzymatic activity. Threonine 138-141 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 15504738-11 2005 In contrast, the antibody plus docetaxel markedly down-regulated two genes, HEC and DEEPEST, required for passage through G(2)-M. Thus, anti-HER2 antibody preferentially affects genes contributing to cell cycle progression and cell growth/maintenance, in part through the PI3K-AKT signaling. Docetaxel 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 141-145 15504738-12 2005 Transcriptional regulation by anti-HER2 antibody through PI3K-AKT pathway may potentiate the growth inhibitory activity of docetaxel by affecting cell cycle progression. Docetaxel 123-132 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Cerulenin 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 15691662-1 2005 The therapeutic efficacy of radioimmunotherapy (RIT) of 188Re-labeled herceptin, which is a humanized anti-p185-HER2/neu monoclonal antibody (mAb), was studied. Rhenium-188 56-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-120 15691662-2 2005 The nude mice bearing nasopharyngeal carcinoma (NPC) expressing HER2/neu protooncogene were injected with 188Re-herceptin intratumorally and intravenously. 188re-herceptin 106-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-72 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Agar 305-309 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 15381096-7 2004 4-ED and doxycycline were similarly efficient in switching on or -off HER2 expression. 4-ed 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 15381096-7 2004 4-ED and doxycycline were similarly efficient in switching on or -off HER2 expression. Doxycycline 9-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-74 15517891-5 2004 Two cohorts of Her2/NeuN female mice of different age (eleven-week-old and twenty-four-week-old) chronically treated with Sasa Health in drinking water showed both a delay in the development of tumors and reduced tumor multiplicity. Water 146-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 15-19 15501020-1 2004 The purpose of this study is to investigate possible influences of different stressors (saline injections, light deprivation and constant light regimen) and geroprotectors (Epitalon and melatonin) on survivals of female HER-2/neu transgenic mice. Melatonin 186-195 erb-b2 receptor tyrosine kinase 2 Mus musculus 220-225 15363300-0 2004 [Optimal effects of liposome on antisense oligodeoxynucleotides uptake by mouse breast cancer TM40D cells and the effects of antisense oligodeoxynucleotides targeting c-erbB-2 on cell proliferation and apoptosis]. Oligodeoxyribonucleotides 135-156 erb-b2 receptor tyrosine kinase 2 Mus musculus 167-175 15363300-1 2004 OBJECTIVE: To study the optimal effects of liposome on antisense oligodeoxynucleotides targeting c-erbB-2 uptake by mouse breast cancer TM40D cells and effects of AS-ODNs on cell proliferation and apoptosis. Oligodeoxyribonucleotides 65-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-105 15229656-6 2004 We report that NEF-wt cells transduced with E6/E7 alone and E6/E7/ErbB-2 together form small and large tumors in nude mice, respectively, as well as different sized colonies in soft agar; whereas ErbB-2 alone elicits neither tumor formation in vivo nor colony formation in soft agar. Agar 182-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-72 15122317-13 2004 Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[S]ODNs. Tyrosine 17-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 10-16 15229656-6 2004 We report that NEF-wt cells transduced with E6/E7 alone and E6/E7/ErbB-2 together form small and large tumors in nude mice, respectively, as well as different sized colonies in soft agar; whereas ErbB-2 alone elicits neither tumor formation in vivo nor colony formation in soft agar. Agar 278-282 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-72 15217493-0 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Doxorubicin 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-92 14973048-3 2004 Here we report that conjugating geldanamycin (GA) to the anti-HER2 mAb Herceptin improved the activity of Herceptin. geldanamycin 32-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-66 14973048-3 2004 Here we report that conjugating geldanamycin (GA) to the anti-HER2 mAb Herceptin improved the activity of Herceptin. geldanamycin 46-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-66 14973048-5 2004 The H-GA mode of action involved HER2 degradation, which was partially lactacystin sensitive and thus proteasome dependent. lactacystin 71-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-37 14647453-10 2004 Thus, signal transduction via EGFR and erbB2 could be related to the estrogen-induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF-like growth factors, leading to ERalpha activation that may result in cancerous lesions in vaginae from neonatally DES-exposed mice later in life. Diethylstilbestrol 286-289 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-44 15078985-0 2004 Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 58-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-147 15754958-8 2004 Dibenol treatment slowed down age-related changes in estrous function in HER-2/neu mice, failed influence survival of these mice and slightly inhibited the incidence and decreased the size of mammary adenocarcinoma metastases into the lung. dibenol 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-82 15217493-0 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Doxorubicin 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-96 15217493-0 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Paclitaxel 16-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-92 15217493-0 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Paclitaxel 16-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-96 15217493-9 2004 The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu. Doxorubicin 30-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 240-243 15217493-9 2004 The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu. Paclitaxel 46-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 240-243 14693742-0 2003 The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Celecoxib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-98 14729627-3 2004 To determine whether HER-2/neu influences the MHC class I antigen-processing pathway, the expression pattern of different APM components was examined in murine in vitro models of constitutive and tetracycline-controlled HER-2/neu expression. Tetracycline 196-208 erb-b2 receptor tyrosine kinase 2 Mus musculus 220-229 14729068-4 2003 In HC11 cells treated with only [D]-PDMP, p185(c-neu) levels remain similar to control cells, whereas levels of tyrosine-phosphorylated p185(c-neu) increase after treatment with [D]-PDMP in combination with EGF. Tyrosine 112-120 erb-b2 receptor tyrosine kinase 2 Mus musculus 141-146 14729068-5 2003 When exogenous GM(3) is added in combination with [D]-PDMP and EGF, the enhanced phosphorylated-p185(c-neu) returns to control levels. gm(3) 15-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-106 14729068-6 2003 Interestingly, EGFR levels also vary and, analogously to phosphorylated-p185(c-neu), the increase of EGFR content consequent to the [D]-PDMP and EGF addition is reversed by exogenous GM(3). gm(3) 183-188 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-82 14729068-8 2003 These findings indicate that changes in GM(3) content modulate the tyrosine-phosphorylated p185(c-neu) levels in a reversible manner, but this is not specific for p185(c-neu) because EGFR levels are also modified. gm(3) 40-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 14729068-8 2003 These findings indicate that changes in GM(3) content modulate the tyrosine-phosphorylated p185(c-neu) levels in a reversible manner, but this is not specific for p185(c-neu) because EGFR levels are also modified. Tyrosine 67-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 14729068-9 2003 Furthermore, these data suggest that GM(3) may play a functional role by affecting the internalisation pathway of p185(c-neu)/EGFR heterodimers, but not of p185(neu) homodimers. gm(3) 37-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-124 14707270-6 2003 In the presence of alliin, tumor-localized alliinase produced allicin, which effectively killed N87 and CB2, both ErbB2-expressing cells in vitro, whereas 32D cells (a murine hematopoietic progenitor cell line, devoid of the ErbB2 receptors) were not affected. allicin 62-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 114-119 14634087-3 2003 The expression of transmembrane ErbB-2 from the whey acidic protein-Her-2 cassette and its up-regulation by insulin and hydrocortisone was verified by in vitro transfection. Hydrocortisone 120-134 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-38 14634087-3 2003 The expression of transmembrane ErbB-2 from the whey acidic protein-Her-2 cassette and its up-regulation by insulin and hydrocortisone was verified by in vitro transfection. Hydrocortisone 120-134 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 14707270-6 2003 In the presence of alliin, tumor-localized alliinase produced allicin, which effectively killed N87 and CB2, both ErbB2-expressing cells in vitro, whereas 32D cells (a murine hematopoietic progenitor cell line, devoid of the ErbB2 receptors) were not affected. allicin 62-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 225-230 14612517-0 2003 Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Tetracycline 29-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-23 14612517-4 2003 Expression of HER-2 could be down-regulated below detection limit (>625-fold dilution) by exposure of NIH3T3-her2 cells to anhydrotetracycline (ATc). 4-epianhydrotetracycline 126-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 14612517-4 2003 Expression of HER-2 could be down-regulated below detection limit (>625-fold dilution) by exposure of NIH3T3-her2 cells to anhydrotetracycline (ATc). 4-epianhydrotetracycline 147-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 14523990-8 2003 EGF stimulation of serum-starved cells increased erbB2 tyrosine phosphorylation and retarded erbB2 migration in SDS-PAGE, suggesting receptor association and activation. Tyrosine 55-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-54 14523990-8 2003 EGF stimulation of serum-starved cells increased erbB2 tyrosine phosphorylation and retarded erbB2 migration in SDS-PAGE, suggesting receptor association and activation. Sodium Dodecyl Sulfate 112-115 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-98 14508823-0 2003 Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Paclitaxel 25-35 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-68 14508823-12 2003 In vitro, the ErbB-2-overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg/mL vs. 233.2 pg/mL, 261.3 pg/mL, and 286.4 pg/mL, respectively). Paclitaxel 81-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-20 14508823-12 2003 In vitro, the ErbB-2-overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg/mL vs. 233.2 pg/mL, 261.3 pg/mL, and 286.4 pg/mL, respectively). Paclitaxel 152-162 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-20 14508823-15 2003 CONCLUSIONS: Combined trastuzumab plus paclitaxel treatment more effectively inhibited ErbB-2-mediated angiogenesis than either treatment alone, which resulted in more pronounced tumoricidal effects. Paclitaxel 39-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-93 12684682-3 2003 Vaccination with HER2 protein and cholesteryl group-bearing pullulan (CHP-HER2 complex) induced HER2-specific CD8+ T cells, but their numbers continuously declined as tumors continued growing. cholesteryl 34-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-78 12824184-5 2003 Moreover, we demonstrated that Cdk5 phosphorylated Ser-1176 in the neuregulin receptor ErbB2 and phosphorylated Thr-871 and Ser-1120 in the ErbB3 receptor. Serine 51-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 87-92 12704673-0 2003 Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Tamoxifen 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 12704673-0 2003 Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Tamoxifen 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-23 12943694-6 2003 ErbB2(V-->E)/IGF-1R expressing cells exhibited ligand-independent, constitutive tyrosine phosphorylation of the receptor fusion protein. Tyrosine 83-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 12642595-5 2003 For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. Serine 23-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-10 12642595-5 2003 For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. Serine 23-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-97 12642595-5 2003 For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. Threonine 30-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-10 12642595-5 2003 For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. Threonine 30-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-97 12941838-21 2003 administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity. Actinium 27-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-66 12714603-5 2003 Furthermore, topical application of tyrphostin AG1478 or AG825, specific inhibitors of EGFR and ErbB2, respectively, completely inhibited new hair growth in wild type mice but not in transgenic mice. Tyrphostins 36-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 12714603-5 2003 Furthermore, topical application of tyrphostin AG1478 or AG825, specific inhibitors of EGFR and ErbB2, respectively, completely inhibited new hair growth in wild type mice but not in transgenic mice. RTKI cpd 47-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 12714603-5 2003 Furthermore, topical application of tyrphostin AG1478 or AG825, specific inhibitors of EGFR and ErbB2, respectively, completely inhibited new hair growth in wild type mice but not in transgenic mice. tyrphostin AG825 57-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 12790777-9 2003 Melatonin also reduces the incidence of spontaneous mammary tumors in different kinds of transgenic mice (c-neu and N-ras) and mice from strains with a high tumoral incidence. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-111 12920832-8 2003 MTT assay was used to confirm that 1H3 could inhibit the growth of cells that overexpressed p185erbB2 to different extent. monooxyethylene trimethylolpropane tristearate 0-3 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-101 12920832-8 2003 MTT assay was used to confirm that 1H3 could inhibit the growth of cells that overexpressed p185erbB2 to different extent. CHEMBL2335154 35-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-101 12619176-3 2003 Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide- producing vector system for biologic therapy against HER2- overexpressing cancers. Oligonucleotides 70-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-99 12621152-9 2003 HB-EGF induced tyrosine phosphorylation of ErbB2 and ErbB4, and to a lesser degree, of EGFR in cardiac myocytes. Tyrosine 15-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-48 12621152-10 2003 In addition, constitutive tyrosine phosphorylation of both ErbB2 and ErbB4 was significantly reduced in HB(del/del) hearts. Tyrosine 26-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-64 12209601-7 2002 HRGbeta1 treatment of LM3 cells induced tyrosine phosphorylation of ErbB-2, ErbB-3 and ErbB-4 as well as the formation of ErbB-2/ErbB-3 and ErbB-2/ErbB-4 heterodimers. Tyrosine 40-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-74 12498714-1 2002 To determine the impact of tumor progression on the reversibility of Neu-induced tumorigenesis, we have used the tetracycline regulatory system to conditionally express activated Neu in the mammary epithelium of transgenic mice. Tetracycline 113-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 179-182 21207860-3 2003 To explore possible mechanisms involved in fertilization, the relationship between c-erbB2 ASODNs and GABA, or dbcAMP, or verapamil during fertilization in vitro was also observed. gamma-Aminobutyric Acid 102-106 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-90 21207860-12 2003 Co-treated with c-erbB2 ASODN, verapamil showed synergic inhibiting effect on fertilization with c-erbB2 ASODN. Verapamil 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-23 21207860-12 2003 Co-treated with c-erbB2 ASODN, verapamil showed synergic inhibiting effect on fertilization with c-erbB2 ASODN. Verapamil 31-40 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-104 21207860-13 2003 Verapamil also inhibited the expression of c-erbB2 in sperms. Verapamil 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-50 12471612-0 2003 The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Melatonin 14-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-88 12471612-7 2003 Interrupted treatment with melatonin promote mammary carcinogenesis in HER-2/neu transgenic mice. Melatonin 27-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-80 12471612-8 2003 The data demonstrate the regimen-dependent inhibitory effect of melatonin on the development of spontaneous mammary tumors in HER-2/neu mice but not on overall survival with implication about the likely cause of the effect. Melatonin 64-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-131 12471612-8 2003 The data demonstrate the regimen-dependent inhibitory effect of melatonin on the development of spontaneous mammary tumors in HER-2/neu mice but not on overall survival with implication about the likely cause of the effect. Melatonin 64-73 erb-b2 receptor tyrosine kinase 2 Mus musculus 132-135 12208730-3 2002 We report that copper deficiency induced by tetrathiomolybdate (TM) significantly impairs tumor growth and angiogenesis in two animal models of breast cancer: an inflammatory breast cancer xenograft in nude mice and Her2/neu cancer-prone transgenic mice. tetrathiomolybdate 64-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 216-224 12459848-1 2002 Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death. alanyl-glutamyl-aspartyl-glycine 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-70 11884607-3 2002 Overexpression of ErbB2 or cyclin D1 in p27(+/-) primary murine mammary epithelial cells resulted in increased proliferation, cyclin D1 nuclear localization, and colony formation in soft agar compared to those in p27(+/+) cells. Agar 187-191 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-23 11986228-7 2002 We report here that HLA-A2402(+) DCs could incorporate hydrophobized polysaccharide-truncated HER2 protein complexes and process the protein to present major histocompatibility complex class 1-binding HER2p63 peptide. Polysaccharides 69-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-98 12006510-0 2002 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. tanespimycin 0-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-97 11786271-5 2002 In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, (188)Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. perrhenate 116-126 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-84 11850835-0 2002 Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Rifabutin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-113 11850835-5 2002 Moreover, in HER2 overexpressing breast cancer cells, 17-AAG caused rapid inhibition of Akt activity prior to any change in Akt protein. tanespimycin 54-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 11850835-6 2002 Ansamycins caused rapid degradation of HER2 and a concomitant loss in HER3 associated PI3 kinase activity. Lactams, Macrocyclic 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-43 11850835-10 2002 In murine xenograft models, non-toxic doses of 17-AAG markedly reduced the expression of HER2 and phosphorylation of Akt and inhibited tumor growth. tanespimycin 47-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 11881999-6 2002 Further examination of compound 2 (ZD6474) in recombinant enzyme assays revealed excellent selectivity for the inhibition of KDR tyrosine kinase (IC(50) 0.04 microM) vs the kinase activity of erbB2, MEK, CDK-2, Tie-2, IGFR-1R, PDK, PDGFRbeta, and AKT (IC(50) range: 1.1 to >100 microM). vandetanib 35-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-197 11830514-5 2002 EGCG similarly inhibited basal receptor phosphorylation in SMF and Ba/F3 2 + 4 cells, which suggests the potential beneficial use of EGCG in adjuvant therapy of tumors with Her-2/neu overexpression. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Mus musculus 173-182 11800023-14 2001 Although the plasma concentrations of these compounds were equivalent, KF58333, but not KF58332, depleted hsp90 client proteins such as erbB2, raf-1 and Akt in the tumor specimen recovered from nude mice. KF58333 71-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-141 10744756-0 2000 Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. Phosphatidylinositols 98-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-65 11916237-9 2001 Treatment with both tamoxifen and the small molecule HER1/2 kinase inhibitor AG1478 reduced mitogen-activated protein kinase activity and markedly reduced growth of established MCF-7/HER2 xenografts in athymic nude mice. Tamoxifen 20-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-187 11916237-9 2001 Treatment with both tamoxifen and the small molecule HER1/2 kinase inhibitor AG1478 reduced mitogen-activated protein kinase activity and markedly reduced growth of established MCF-7/HER2 xenografts in athymic nude mice. RTKI cpd 77-83 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-187 11781542-10 2001 CONCLUSION: The data demonstrate the influence of the LD light regiment and melatonin treatment in the development of spontaneous mammary tumors in HER-2/neu mice suggesting a melatonin-dependent modulation of HER-2/neu gene expression in mammary adenocarcinoma. Melatonin 176-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-157 11781542-10 2001 CONCLUSION: The data demonstrate the influence of the LD light regiment and melatonin treatment in the development of spontaneous mammary tumors in HER-2/neu mice suggesting a melatonin-dependent modulation of HER-2/neu gene expression in mammary adenocarcinoma. Melatonin 176-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 210-219 11593408-0 2001 MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Methylnitrosourea 59-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-79 11378364-0 2001 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. indazolylamino quinazolines 0-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-88 11378364-0 2001 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. pyridopyrimidines 32-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-88 11260258-5 2001 RESULTS: We show that Tob is phosphorylated on serines and threonines, but not tyrosines, by a kinase(s) that associates with Tob in the lysates of various cells, including ErbB2-over-expressed cells. Serine 47-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 173-178 11260258-5 2001 RESULTS: We show that Tob is phosphorylated on serines and threonines, but not tyrosines, by a kinase(s) that associates with Tob in the lysates of various cells, including ErbB2-over-expressed cells. Threonine 59-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 173-178 11059787-5 2000 Treatment with a combination of tamoxifen and a HER2 kinase inhibitor reduced tumor MAPK activity and markedly prevented growth of HER2-overexpressing MCF-7 xenografts in athymic mice. Tamoxifen 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-135 10980598-8 2000 Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. Phosphotyrosine 0-15 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-41 10955821-0 2000 Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Radioisotopes 78-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-181 11751524-5 2001 Consistent with the proposed mechanism of action of this inhibitor, SU11925 inhibited the s.c. growth of EGFR- and HER-2-dependent tumors in athymic mice at doses that produced substantial inhibition of target receptor phosphorylation in vivo. SU11925 68-75 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-120 11781542-0 2001 The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Melatonin 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-103 11781542-0 2001 The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Melatonin 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-163 11781542-9 2001 Melatonin treatment resulted in a 2.5-fold reduction in the expression of HER-2/neu mRNA in mammary tumors from HER-2 /neu transgenic mice. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-83 11781542-9 2001 Melatonin treatment resulted in a 2.5-fold reduction in the expression of HER-2/neu mRNA in mammary tumors from HER-2 /neu transgenic mice. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-79 11781542-9 2001 Melatonin treatment resulted in a 2.5-fold reduction in the expression of HER-2/neu mRNA in mammary tumors from HER-2 /neu transgenic mice. Melatonin 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-83 11781542-10 2001 CONCLUSION: The data demonstrate the influence of the LD light regiment and melatonin treatment in the development of spontaneous mammary tumors in HER-2/neu mice suggesting a melatonin-dependent modulation of HER-2/neu gene expression in mammary adenocarcinoma. Melatonin 76-85 erb-b2 receptor tyrosine kinase 2 Mus musculus 148-157 11781542-10 2001 CONCLUSION: The data demonstrate the influence of the LD light regiment and melatonin treatment in the development of spontaneous mammary tumors in HER-2/neu mice suggesting a melatonin-dependent modulation of HER-2/neu gene expression in mammary adenocarcinoma. Melatonin 76-85 erb-b2 receptor tyrosine kinase 2 Mus musculus 210-219 11325840-0 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cyclophosphamide 0-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-178 11325840-0 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Doxorubicin 18-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-178 11325840-0 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Paclitaxel 35-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 169-178 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Cyclophosphamide 14-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-122 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Cyclophosphamide 14-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 212-215 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-122 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 212-215 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Doxorubicin 48-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-122 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Doxorubicin 48-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 212-215 11325840-8 2001 Furthermore, paclitaxel and cyclophosphamide appear to amplify the T helper 1 neu-specific T-cell response. Paclitaxel 13-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 11325840-8 2001 Furthermore, paclitaxel and cyclophosphamide appear to amplify the T helper 1 neu-specific T-cell response. Cyclophosphamide 28-44 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 10932223-4 2000 In addition to characterizing the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy that mammary adenocarcinomas in transgenic mice bearing Ras or Neu oncogenes actively accumulate iodide by this symporter in vivo. Sodium 75-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 194-197 10932223-4 2000 In addition to characterizing the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy that mammary adenocarcinomas in transgenic mice bearing Ras or Neu oncogenes actively accumulate iodide by this symporter in vivo. Iodides 82-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 194-197 10932223-4 2000 In addition to characterizing the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy that mammary adenocarcinomas in transgenic mice bearing Ras or Neu oncogenes actively accumulate iodide by this symporter in vivo. Iodides 228-234 erb-b2 receptor tyrosine kinase 2 Mus musculus 194-197 10861472-5 2000 In vitro, analysis of anchorage-independent growth in soft agar revealed colony formation from p185(neu)-positive but not p185(neu)-negative cells. Agar 59-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-103 10861472-6 2000 The direct involvement of p185(neu) in clonogenicity was demonstrated by the inhibition of p185(neu)-positive colony growth in soft agar in the presence of an anti-p185(neu) monoclonal antibody. Agar 132-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-34 10861472-6 2000 The direct involvement of p185(neu) in clonogenicity was demonstrated by the inhibition of p185(neu)-positive colony growth in soft agar in the presence of an anti-p185(neu) monoclonal antibody. Agar 132-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-99 10861472-6 2000 The direct involvement of p185(neu) in clonogenicity was demonstrated by the inhibition of p185(neu)-positive colony growth in soft agar in the presence of an anti-p185(neu) monoclonal antibody. Agar 132-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-35 10941905-0 2000 Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Polyethylene Glycols 30-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-77 10851070-6 2000 Furthermore, when T/t-common was transiently cotransfected with the activated genomic neu into NIH3T3 cells, the transforming activity of the latter was suppressed by T/t-common in soft-agarose microcolony formation assays. Sepharose 186-193 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-89 10655441-9 2000 All three coumarins markedly reduced cellular levels of p185(erbB2), p60(v-src), Raf-1, and mutated p53. Coumarins 10-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-66 10786665-5 2000 GMD-4c is a potent inducer of G1 block and apoptosis of breast cancer cell lines that overexpress HER2, but does not appreciably inhibit the growth of 32D cells that lack HER-kinases. gmd-4c 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 10718486-0 1999 Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Retinoids 51-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-102 10667575-0 2000 Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Tamoxifen 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 70-73 10585492-3 1999 Although EGF enhanced ErbB-2 tyrosine phosphorylation, GH, while causing retardation of its migration on SDS-polyacrylamide gel electrophoresis, decreased ErbB-2"s tyrosine phosphorylation. Tyrosine 29-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-28 10585492-3 1999 Although EGF enhanced ErbB-2 tyrosine phosphorylation, GH, while causing retardation of its migration on SDS-polyacrylamide gel electrophoresis, decreased ErbB-2"s tyrosine phosphorylation. Tyrosine 164-172 erb-b2 receptor tyrosine kinase 2 Mus musculus 155-161 10585492-4 1999 GH-induced retardation was reversed by treatment of anti-ErbB-2 precipitates with both alkaline phosphatase and protein phosphatase 2A, suggesting that GH induced serine/threonine phosphorylation of ErbB-2. Serine 163-169 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-63 10585492-4 1999 GH-induced retardation was reversed by treatment of anti-ErbB-2 precipitates with both alkaline phosphatase and protein phosphatase 2A, suggesting that GH induced serine/threonine phosphorylation of ErbB-2. Threonine 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-63 10585492-5 1999 Both GH-induced shift in ErbB-2 migration and GH-induced MAP kinase activation were unaffected by a protein kinase C inhibitor but were blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 (MEK1) inhibitor, PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 249-256 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-31 10585492-7 1999 Cotreatment with EGF and GH versus EGF alone resulted in a 35% decline in acute ErbB-2 tyrosine 1248 autophosphorylation, a marked decline (approximately 50%) in DNA synthesis, and substantially decreased cyclin D1 expression. Tyrosine 87-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-86 10585492-8 1999 We conclude that in 3T3-F442A cells, 1) the GH-induced decrease in ErbB-2 tyrosine phosphorylation correlates with MEK1/mitogen-activated protein kinase activity and 2) GH antagonizes EGF-induced DNA synthesis and cyclin D1 expression in a pattern consistent with its alteration in ErbB-2 phosphorylation status. Tyrosine 74-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-73 10950153-10 2000 We have developed a novel formula of hydrophobized polysaccharide nanoparticles which can deliver a HER2 oncoprotein containing an epitope peptide to the MHC class I pathway. Polysaccharides 51-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-104 10950153-11 2000 We designed a simple protein delivery system: cholesteryl group-bearing polysaccharides, mannan or pullulan (CHM or CHP, respectively), complexed with the truncated HER2 protein containing the 147 N-terminal amino acids. cholesteryl 46-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 10950153-11 2000 We designed a simple protein delivery system: cholesteryl group-bearing polysaccharides, mannan or pullulan (CHM or CHP, respectively), complexed with the truncated HER2 protein containing the 147 N-terminal amino acids. Polysaccharides 72-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 10950153-11 2000 We designed a simple protein delivery system: cholesteryl group-bearing polysaccharides, mannan or pullulan (CHM or CHP, respectively), complexed with the truncated HER2 protein containing the 147 N-terminal amino acids. pullulan 99-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-169 10975281-0 2000 Phospholipid distribution in murine mammary adenocarcinomas induced by activated neu oncogene. Phospholipids 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-84 10975281-1 2000 The aim of this study was to analyze possible changes in the total phospholipid distribution in murine mammary adenocarcinomas induced in transgenic mice by the tissue-specific expression of the neu oncogene, as compared with normal tissues. Phospholipids 67-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-207 10975281-5 2000 We conclude that neu transgenic mice provide a good model to clarify the involvement of phospholipids in neu-induced neoplastic transformation and to study in vivo the metabolic pathways related to the intracellular signaling. Phospholipids 88-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-20 10975281-5 2000 We conclude that neu transgenic mice provide a good model to clarify the involvement of phospholipids in neu-induced neoplastic transformation and to study in vivo the metabolic pathways related to the intracellular signaling. Phospholipids 88-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 105-108 10718486-12 1999 The oncogene erbB2 (c-neu) and the growth factor EGF expression were more prominent in the small tumors of the mice treated with arotinoid than in the larger tumors of the control group. mofarotene 129-138 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-18 10718486-12 1999 The oncogene erbB2 (c-neu) and the growth factor EGF expression were more prominent in the small tumors of the mice treated with arotinoid than in the larger tumors of the control group. mofarotene 129-138 erb-b2 receptor tyrosine kinase 2 Mus musculus 20-25 9855018-0 1998 The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling. phorbol 16-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 10463601-0 1999 Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Disulfides 54-63 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-128 10213223-1 1999 TAB-250 and BACH-250 are murine and human chimeric antibodies directed at the extracellular domain of the gp185c-erb-2 (HER2/neu) growth factor receptor overexpressed in a variety of tumor types, including ovarian and breast carcinoma. tab-250 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-152 10087316-3 1999 The aim of this study was to see whether DCs are able to elicit antigen specific host immune responses by stimulating the proliferation of T cells after exposure to cholesteryl group bearing pullulan (CHP) and HER2 protein complex. cholesteryl 165-176 erb-b2 receptor tyrosine kinase 2 Mus musculus 210-214 10037184-5 1999 Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Emodin 32-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-136 10037184-5 1999 Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Emodin 32-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-140 10037184-5 1999 Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Paclitaxel 43-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-136 10037184-5 1999 Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Paclitaxel 43-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-140 10037184-6 1999 Both immunohistochemical staining and Western blot analysis showed that emodin decreases tyrosine phosphorylation of HER-2/neu in tumor tissue. Tyrosine 89-97 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-126 10037184-7 1999 Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. Paclitaxel 284-294 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-82 10037184-7 1999 Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. Paclitaxel 284-294 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-78 10037184-7 1999 Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. Paclitaxel 284-294 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-82 10592097-0 1999 Activation of neu by missense point mutation in the transmembrane domain in schwannomas induced in C3H/HeNCr mice by transplacental exposure to N-nitrosoethylurea. Ethylnitrosourea 144-162 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-17 10597237-10 1999 Treatment of these cells with either MPA or HRG resulted in tyrosine phosphorylation of both ErbB-2 and ErbB-3. Tyrosine 60-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 93-99 10404066-10 1999 The 2 non-conformational epitopes PB3 and NB3 were localized to regions corresponding to amino acides 78-242 of the p185(HER-2) protein. amino acides 89-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 121-126 10380881-5 1999 These mice were normal until the ErbB2 transgene was induced by exposure to doxycycline (Dox). Doxycycline 76-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 10380881-5 1999 These mice were normal until the ErbB2 transgene was induced by exposure to doxycycline (Dox). Doxycycline 89-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 10380881-7 1999 Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. Doxycycline 84-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-18 10380881-7 1999 Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. Doxycycline 201-204 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-18 10380881-11 1999 We conclude that ErbB2 plays important roles in both development and maintenance of hair follicles and diverse squamous epithelia and that this ligand-inducible and tissue-specific "Tet-On" transgenic mouse system provides a means to study transgenes with perinatal toxicity. tetramethylenedisulfotetramine 182-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 17-22 10668481-9 1999 Taken together, these observations suggest that this cysteine-rich region plays an important role in regulating the catalytic activity of Neu. Cysteine 53-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-141 9845446-5 1998 Expression of Ki67, p53, Her-2/ neu (c-erbB2), and 17-1A could be detected on A45-B/B3-stained cells by immunofluorescence using a fluorescein-labeled anti-mouse immunoglobulin specific for the Fc part of mouse immunoglobulins. Fluorescein 131-142 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-44 9855018-0 1998 The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling. Tyrosine 40-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 34-39 9751121-3 1998 Tyrosine phosphorylation of both EGFR and erbB-2 was detected in normal female BALB/c mice at 5-6 weeks of age, but not during the prepubertal stage, e.g., 24 days of age. Tyrosine 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-48 9786961-8 1998 An activated hybrid receptor that contained the intracellular domain of c-erbB2 receptor suffices to induce alveolar morphogenesis, and was observed in the presence of tyrosine residues Y1028, Y1144, Y1201, and Y1226/27 in the substrate-binding domain of c-erbB2. Tyrosine 168-176 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-79 9786961-8 1998 An activated hybrid receptor that contained the intracellular domain of c-erbB2 receptor suffices to induce alveolar morphogenesis, and was observed in the presence of tyrosine residues Y1028, Y1144, Y1201, and Y1226/27 in the substrate-binding domain of c-erbB2. Tyrosine 168-176 erb-b2 receptor tyrosine kinase 2 Mus musculus 255-262 9751121-4 1998 Treatment of mice with estradiol or epidermal growth factor also stimulated the formation of mammary EGFR/erbB-2 phosphotyrosine. Phosphotyrosine 113-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-112 9893641-0 1998 Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours. oncotoxin 41-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-69 9893641-5 1998 One such oncotoxin, AR209 (formerly OLX-209 [e23(Fv)PE38KDEL]), has the specificity of an anti-ErbB-2 antibody contained within a single-chain antibody domain (e23v) coupled to a portion of the Pseudomonas exotoxin A (PE38KDEL). oncotoxin 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 95-101 9488037-4 1998 For example, mammary tumors initiated by neu, v-Ha-ras and c-myc have high levels of active Erk/MAP kinase and their anchorage independent growth is strongly inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 171-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 41-44 9710588-8 1998 ErbB-2 binding to peptides containing the Src homology 2 domain of Grb2 or p85 and the phosphotyrosine binding domain of Shc varied according to the mode of receptor activation. Phosphotyrosine 87-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-6 9699670-2 1998 We report here a novel formula of hydrophobized polysaccharide nanoparticles, which can deliver a HER2 oncoprotein containing an epitope peptide to the MHC class I pathway. Polysaccharides 48-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). Polysaccharides 140-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-77 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). Polysaccharides 140-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). Polysaccharides 140-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). Polysaccharides 140-155 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 157-168 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-77 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 157-168 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 157-168 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 157-168 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 200-211 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-77 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 200-211 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 200-211 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 9699670-3 1998 A protein consisting of the 147 amino-terminal amino acids of oncogene erbB-2/neu/HER2 (HER2) was complexed with two kinds of hydrophobized polysaccharides, cholesteryl group-bearing mannan (CHM) and cholesteryl group-bearing pullulan (CHP), to form nanoparticles (CHM-HER2 and CHP-HER2). cholesteryl 200-211 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-92 10837613-9 1998 Based on these data, a phase I clinical trial of DC-Chol-mediated E1A gene therapy for ovarian and breast cancers that overexpress HER-2/neu has been initiated in our institute. 3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol 49-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-140 9484775-5 1998 Only PR/neu* and not PR/neu displayed significantly increased levels of phosphotyrosine compared to the wild type PDGF receptor in C127 and Ba/F3 cells. Phosphotyrosine 72-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 8-11 9484775-7 1998 Furthermore, novel tyrosine phosphorylated proteins of approximately 60 kDa appeared to specifically complex with PR/neu*, suggesting that PR/neu* may activate distinct signaling pathways. Tyrosine 19-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-120 9484775-7 1998 Furthermore, novel tyrosine phosphorylated proteins of approximately 60 kDa appeared to specifically complex with PR/neu*, suggesting that PR/neu* may activate distinct signaling pathways. Tyrosine 19-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-145 9598873-0 1998 Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Retinoids 10-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-76 9412494-8 1998 These genes-Rara, Thra, and Erbb2- encode receptors for retinoic acid, thyroxine, and neuregulin, respectively. Tretinoin 56-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-33 9513719-7 1998 These observations suggest that this cysteine-rich region plays an important role in regulating the catalytic activity of Neu. Cysteine 37-45 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-125 9412494-8 1998 These genes-Rara, Thra, and Erbb2- encode receptors for retinoic acid, thyroxine, and neuregulin, respectively. Thyroxine 71-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-33 9394675-8 1997 CONCLUSION: Broadened 1H spectra observed after c-erbB-2 or c-Ha-ras transfection suggest changes of plasma membrane viscosity, which may be related to the oncogene expression. Hydrogen 22-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-56 9048643-4 1997 Thus, we examined the expression of the erbB2 gene in the mouse uterus during the periimplantation period (days 1-8 of pregnancy) and after 17 beta-estradiol and/or progesterone stimulation. Estradiol 143-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 9199335-5 1997 We have isolated four splice variants, two each from human and mouse, and have shown that they are capable of inducing tyrosine phosphorylation of erbB3, erbB4, and erbB2. Tyrosine 119-127 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-170 9309155-1 1997 Azatyrosine is known to convert ras, raf or c-erbB-2-transformed NIH3T3 cells to a normal phenotype. beta-(5-hydroxy-2-pyridyl)alanine 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-52 9309155-2 1997 We attempted to identify the signal-transduction process triggered by oncogenic c-ErbB-2 that was inhibited by azatyrosine. beta-(5-hydroxy-2-pyridyl)alanine 111-122 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-88 9309155-5 1997 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. beta-(5-hydroxy-2-pyridyl)alanine 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 9309155-5 1997 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. Tetradecanoylphorbol Acetate 53-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 9309155-5 1997 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. Tetradecanoylphorbol Acetate 91-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 9285690-3 1997 Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-76 9285690-3 1997 Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-80 9285690-3 1997 Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-171 9285690-3 1997 Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. Paclitaxel 32-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-80 9113511-5 1997 Twenty-four hours after exposing NIH3T3.HER2 cells to the PL-rhuMAbHER2-pRSVLuc complexes and 100 microM chloroquine, luciferase expression was 180-fold higher than that obtained from a conjugate made with an isotype-matched antibody against an irrelevant target. Chloroquine 105-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-44 9136987-0 1997 Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Phorbol Esters 33-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 9136987-4 1997 In cultured mouse keratinocytes, EGF stimulated rapid tyrosine phosphorylation of erbB2 followed by a time-dependent degradation of erbB2 protein. Tyrosine 54-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-87 9136987-8 1997 In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Tetradecanoylphorbol Acetate 54-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-134 9136987-8 1997 In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Tetradecanoylphorbol Acetate 92-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-134 9136987-8 1997 In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Phosphotyrosine 102-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-134 9136987-9 1997 Concomittantly, erbB2:EGFr heterodimer formation and c-src kinase activity were also elevated in TPA-treated epidermis. Tetradecanoylphorbol Acetate 97-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-21 9136987-10 1997 Structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting ability. Phorbol Esters 46-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-117 9136987-12 1997 Collectively, the current data suggest that the activation of erbB2 in phorbol ester treated skin can be explained solely by a mechanism involving elevation of EGFr ligands and activation of the EGFr. Phorbol Esters 71-84 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-67 9048643-4 1997 Thus, we examined the expression of the erbB2 gene in the mouse uterus during the periimplantation period (days 1-8 of pregnancy) and after 17 beta-estradiol and/or progesterone stimulation. Progesterone 165-177 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-45 9048643-14 1997 Treatment of adult ovariectomized mice with 17 beta-estradiol, but not progesterone, up-regulated the expression of the erbB2 mRNA by more than 3.5-fold, as determined by quantitative reverse transcription-PCR, and this increase was limited to the epithelium, as revealed by in situ hybridization. Estradiol 44-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-125 8816486-5 1996 The development of these mammary tumors was correlated with the tyrosine phosphorylation of Neu and the recruitment of c-Src to the Neu complex. Tyrosine 64-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-95 8875978-4 1996 Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines. Sepharose 57-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 117-122 8875978-4 1996 Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines. Sepharose 57-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-126 8806679-2 1996 Cell lines expressing HER2 under control of a tetracycline-responsive promoter were isolated. Tetracycline 46-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-26 8808711-5 1996 The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined. Paclitaxel 14-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 107-115 8808711-5 1996 The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined. Paclitaxel 14-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 116-119 8702975-9 1996 Phosphorylation-specific antibodies to the juxtamembrane PKC site Thr686 recognize tyrosine-dephosphorylated wild-type c-erbB-2 following G8/DHFR 3T3 cell treatment with PKC agonists. Tyrosine 83-91 erb-b2 receptor tyrosine kinase 2 Mus musculus 119-127 8806679-4 1996 Subsequent treatment of these cells with the effector anhydrotetracyline switched-off HER2 expression and induced morphological and functional changes characteristic for non-transformed cells. anhydrotetracyline 54-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 86-90 8649770-0 1996 Overexpression of CD44 in pl85(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion. Hyaluronic Acid 90-105 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-34 8799121-0 1996 Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Cysteine 30-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 83-86 8799121-4 1996 Here we demonstrate that these mutations promote dimerization of the Neu receptor through the formation of disulfide bonds, resulting in its constitutive activation. Disulfides 107-116 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-72 8799121-6 1996 These analyses indicated that mutation of certain cysteine residues resulted in the oncogenic activation of Neu. Cysteine 50-58 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-111 8799121-8 1996 We further demonstrate that addition of 2-mercaptoethanol to the culture medium interfered with the specific transforming activity of the mutant Neu receptors. Mercaptoethanol 40-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-148 8799121-9 1996 These observations suggest that oncogenic activation of Neu results from constitutive disulfide bond-dependent dimerization. Disulfides 86-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-59 21594424-1 1996 We reported recently that azatyrosine inhibits the growth of c-Ha-ras, c-raf or c-erbB-2-transformed NIH3T3 cells and converts the transformed cells to cells with a normal phenotype. beta-(5-hydroxy-2-pyridyl)alanine 26-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-88 8825119-2 1996 OLX-209 is a recombinant toxin targeting the erbB-2 oncoprotein. OLX 209 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-51 21594311-7 1996 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. Tetradecanoylphorbol Acetate 91-94 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 21594311-2 1996 We report herein that azatyrosine also inhibits the growth of c-erbB-2-transformed cells and induces normal morphology. beta-(5-hydroxy-2-pyridyl)alanine 22-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 62-70 21594311-3 1996 We attempted to identify the signal-transduction process triggered by oncogenic c-ErbB-2 that was inhibited by azatyrosine. beta-(5-hydroxy-2-pyridyl)alanine 111-122 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-88 21594311-8 1996 These results suggest that azatyrosine acts downstream of Ras in signal transduction from oncogenic c-ErbB-2 to nuclear factors. beta-(5-hydroxy-2-pyridyl)alanine 27-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-108 21594311-6 1996 However, azatyrosine inhibited increases in phosphorylation of c-Raf-1 and c-Jun induced by oncogenic c-ErbB-2. beta-(5-hydroxy-2-pyridyl)alanine 9-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-110 21594311-7 1996 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. beta-(5-hydroxy-2-pyridyl)alanine 13-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 21594314-0 1996 Stimulation of the expression of rhoB contributes to the ability of azatyrosine to convert c-erbB-2-transformed cells to a normal morphology. beta-(5-hydroxy-2-pyridyl)alanine 68-79 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-99 21594311-7 1996 Furthermore, azatyrosine inhibited activation of the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element in response to stimulation by oncogenic c-ErbB-2. Tetradecanoylphorbol Acetate 53-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-161 21594314-1 1996 We have reported recently that azatyrosine inhibits the growth of ras-, raf-, or c-erbB-2 transformed NIH3T3 cells and converts the transformed cells to cells with normal morphology. beta-(5-hydroxy-2-pyridyl)alanine 31-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-89 21594314-7 1996 These results suggest that expression of rhoB is involved in the conversion of c-erbB-2-transformed cells to a normal phenotype that is induced by azatyrosine, but such expression is insufficient by itself for complete reversion. beta-(5-hydroxy-2-pyridyl)alanine 147-158 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-87 8523119-0 1995 Enhanced tumor specificity of 741F8-1 (sFv")2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. Iodine-131 106-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-63 7478576-1 1995 In murine fibroblasts activation of the Shc/Grb-2 pathway by the ErbB-2 kinase involves tyrosine phosphorylation of Shc products and the formation of Shc/ErbB-2, Shc/Grb-2 and Grb-2/ErbB-2 complexes. Tyrosine 88-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-71 7592814-4 1995 By focusing on the tyrosine phosphorylation pathway, we have found that the transmembranal protein-tyrosine phosphatase epsilon (PTP epsilon) is highly expressed in murine mammary tumors initiated by c-neu and v-Haras, but not in mammary tumors initiated by c-myc or int-2. Tyrosine 19-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 200-205 7478576-3 1995 Tyr 1221 and 1248 are binding sites of gp185ErbB-2 for Shc SH2 domain in vitro whereas Tyr 1196 and 1248 are major binding sites of ErbB-2 for Shc PTB domain. Tyrosine 0-3 erb-b2 receptor tyrosine kinase 2 Mus musculus 44-50 7478576-2 1995 Tyr 1139 of ErbB-2 bound to the Grb-2 SH2 domain in vitro as well as in intact cells. Tyrosine 0-3 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-18 7478576-5 1995 Shc/ErbB-2 complexes are formed upon activation of the ErbB-2 kinase and tyrosine phosphorylation of Shc proteins; they are located in both cytosol and cellular membranes. Tyrosine 73-81 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-10 7584128-0 1995 Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Ganciclovir 57-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 121-124 7562056-0 1995 Autoradiography and radioscintigraphy of technetium-99m-sestamibi in c-neu transgenic mice. Technetium Tc 99m Sestamibi 41-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-74 7642554-2 1995 Within minutes of phorbol 12-myristate 13-acetate treatment, epidermal growth factor receptor and HER2 tyrosine phosphorylation was decreased, while platelet-derived growth factor receptor and insulin receptor autophosphorylation was upregulated. Tetradecanoylphorbol Acetate 18-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 7642554-2 1995 Within minutes of phorbol 12-myristate 13-acetate treatment, epidermal growth factor receptor and HER2 tyrosine phosphorylation was decreased, while platelet-derived growth factor receptor and insulin receptor autophosphorylation was upregulated. Tyrosine 103-111 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-102 7784091-5 1995 The truncated neu product, however, fully retained its ability to transform NIH3T3 cells, induce Shc tyrosine phosphorylation and Shc/Grb2 complex formation. Tyrosine 101-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-17 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 41-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-68 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 41-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-106 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 41-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-106 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 213-221 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-68 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 213-221 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-106 7542762-4 1995 Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. Tyrosine 213-221 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-106 7542762-6 1995 Moreover, in established cell lines expressing elevated levels of EGFR, EGF stimulation results in transphosphorylation of Neu and formation of complexes between c-Src and tyrosine phosphorylated Neu. Tyrosine 172-180 erb-b2 receptor tyrosine kinase 2 Mus musculus 196-199 7542762-7 1995 Taken together, these observations suggest that activation of c-Src by these two closely related EGFR family members results from a direct and specific interaction of c-Src with tyrosine phosphorylated Neu. Tyrosine 178-186 erb-b2 receptor tyrosine kinase 2 Mus musculus 202-205 7784091-0 1995 Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Tyrosine 0-8 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-167 7784091-6 1995 Our results suggest that tyrosine phosphorylation of Shc which allows formation of Shc/Grb2 complex may play an important role for cell transformation induced by the point mutation-activated neu, and that stable binding to mutant p185neu may not be necessary for Shc to mediate this signaling pathway. Tyrosine 25-33 erb-b2 receptor tyrosine kinase 2 Mus musculus 191-194 7913407-8 1994 In addition, transforming growth factor-alpha increased cisplatin-induced cytotoxicity against NIH 3T3 cells overexpressing an epidermal growth factor receptor/c-erbB-2 chimera. Cisplatin 56-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 160-168 7816098-8 1995 We show that C2 muscle cells contain erbB2 and erbB3 messenger RNA but little or no erbB4 mRNA, and that neuregulin stimulates tyrosine phosphorylation of erbB2 and erbB3, indicating that neuregulin signalling in skeletal muscle may be mediated by a complex of erbB2 and erbB3. Tyrosine 127-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 155-160 7816098-8 1995 We show that C2 muscle cells contain erbB2 and erbB3 messenger RNA but little or no erbB4 mRNA, and that neuregulin stimulates tyrosine phosphorylation of erbB2 and erbB3, indicating that neuregulin signalling in skeletal muscle may be mediated by a complex of erbB2 and erbB3. Tyrosine 127-135 erb-b2 receptor tyrosine kinase 2 Mus musculus 155-160 7760847-4 1995 In these cells, NDF induces tyrosine phosphorylation of erbB-2 and erbB-3. Tyrosine 28-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-62 7535767-3 1995 While HRG appears to be capable of stimulating the autophosphorylation activity of p180erbB4, the co-expression of p185erbB2/neu with p180erbB3 is necessary for the HRG-stimulated tyrosine phosphorylation of both of these receptors. Tyrosine 180-188 erb-b2 receptor tyrosine kinase 2 Mus musculus 115-124 7887448-4 1995 Diffuse and membrane staining of c-ErbB2 was well correlated with high urinary catecholamine secretion. Catecholamines 79-92 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-40 21559693-3 1994 Expression of the ras, raf, erbB-2 and fgf-3 (former int-2) oncogenes in HC11 cells leads to their growth in soft-agar, a parameter of cell transformation. Agar 114-118 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-34 7909754-0 1994 Enhancement of CDP-DG:inositol transferase activity in src- and erbB2-transformed cells. cdp-dg 15-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-69 7909754-1 1994 Phosphatidylinositol (PI) synthesis was activated in Rous sarcoma virus-infected NIH3T3 or activated erbB2-transformed NIH3T3 cells. Phosphatidylinositols 0-20 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-106 7909754-3 1994 A tyrosine kinase inhibitor, erbstatin, inhibited the PI synthesis in cultured cells, suggesting that Src and ErbB2-associated tyrosine kinases are involved in activation of CDP-DG:inositol transferase in these cell lines. erbstatin 29-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-115 1359541-5 1992 Overexpression of neu in the mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity and the de novo tyrosine phosphorylation of several cellular proteins. Tyrosine 92-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-21 7736532-4 1994 The tumor binding properties of 125I-labeled anti-c-erbB-2 741F8 sFv, sFv", and (sFv)2 were compared with radiolabeled antidigoxin 26-10 sFv" and (sFv")2 controls. Iodine-125 32-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-58 7902571-0 1993 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Estradiol 0-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-55 7902571-2 1993 The ErbB2 protein immunoprecipitated from estrogen-treated [10(-8) to 10(-6) M 17 beta-estradiol (E2)] RC cells showed higher autophosphorylation activity than that from untreated cells. Estradiol 82-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-9 7908285-6 1994 A chimeric monoclonal antibody CH401 retained full binding reactivity to erbB-2 product, compared with murine E401 parental antibody. ch401 31-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 73-79 7688739-2 1993 To study neu-induced cellular transformation, we developed revertant cells from the neu-transformed NIH 3T3 cell line, B104-1-1, by treating the cells with the chemical mutagen ethyl methanesulfonate. Ethyl Methanesulfonate 177-199 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-12 7688739-2 1993 To study neu-induced cellular transformation, we developed revertant cells from the neu-transformed NIH 3T3 cell line, B104-1-1, by treating the cells with the chemical mutagen ethyl methanesulfonate. Ethyl Methanesulfonate 177-199 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-87 7688739-7 1993 These results indicated that we had successfully developed, from neu-transformed cells, revertants exhibiting defective tyrosine phosphorylation of the neu oncoprotein. Tyrosine 120-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-68 7688739-7 1993 These results indicated that we had successfully developed, from neu-transformed cells, revertants exhibiting defective tyrosine phosphorylation of the neu oncoprotein. Tyrosine 120-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 152-155 8098709-0 1993 Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. Tyrphostins 78-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 56-60 8098709-0 1993 Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. Tyrphostins 78-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-64 8098709-2 1993 The high incidence of HER2 overexpression in breast and ovary carcinomas prompted us to synthesize protein tyrosine kinase inhibitors (tyrphostins) which selectively inhibit the HER2 kinase activity. Tyrphostins 135-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-26 8098709-2 1993 The high incidence of HER2 overexpression in breast and ovary carcinomas prompted us to synthesize protein tyrosine kinase inhibitors (tyrphostins) which selectively inhibit the HER2 kinase activity. Tyrphostins 135-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 178-182 8098709-3 1993 Two groups of tyrphostins were developed: one highly selective in inhibiting HER1 as opposed to HER2, the other highly selective in inhibiting HER2. Tyrphostins 14-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 8098709-3 1993 Two groups of tyrphostins were developed: one highly selective in inhibiting HER1 as opposed to HER2, the other highly selective in inhibiting HER2. Tyrphostins 14-25 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 8098709-4 1993 Both the HER1 and the HER2 selective blockers were competitive with ATP binding. Adenosine Triphosphate 68-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-26 1359541-5 1992 Overexpression of neu in the mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity and the de novo tyrosine phosphorylation of several cellular proteins. Tyrosine 92-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-81 1328988-1 1992 An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. beta-(5-hydroxy-2-pyridyl)alanine 15-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-110 1328988-1 1992 An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. beta-(5-hydroxy-2-pyridyl)alanine 15-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-115 1328988-1 1992 An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. l-beta-(5-hydroxy-2-pyridyl) alanine 28-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-110 1328988-1 1992 An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. l-beta-(5-hydroxy-2-pyridyl) alanine 28-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 112-115 1685444-5 1991 The activated neu gene was detected in tumors of the nervous system that arose in mice following transplacental exposure to N-ethyl-N-nitrosourea. Ethylnitrosourea 124-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-17 1677566-0 1991 Transactivation of the TPA-responsive element by the oncogenic C-erbB-2 protein is partly mediated by protein kinase C. The mutant c-erbB-2 gene encoding a protein with Glu instead of Val-659 in the transmembrane domain is able to transform NIH3T3 cells, while the wild type c-erbB-2 unless overexpressed does not. Tetradecanoylphorbol Acetate 23-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-71 1677566-0 1991 Transactivation of the TPA-responsive element by the oncogenic C-erbB-2 protein is partly mediated by protein kinase C. The mutant c-erbB-2 gene encoding a protein with Glu instead of Val-659 in the transmembrane domain is able to transform NIH3T3 cells, while the wild type c-erbB-2 unless overexpressed does not. Tetradecanoylphorbol Acetate 23-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 131-139 1677566-0 1991 Transactivation of the TPA-responsive element by the oncogenic C-erbB-2 protein is partly mediated by protein kinase C. The mutant c-erbB-2 gene encoding a protein with Glu instead of Val-659 in the transmembrane domain is able to transform NIH3T3 cells, while the wild type c-erbB-2 unless overexpressed does not. Tetradecanoylphorbol Acetate 23-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 275-283 1677566-2 1991 Transient expression of this active c-erbB-2 stimulated the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element, serum response element, and cyclic AMP response element. Tetradecanoylphorbol Acetate 60-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-44 1677566-2 1991 Transient expression of this active c-erbB-2 stimulated the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element, serum response element, and cyclic AMP response element. Tetradecanoylphorbol Acetate 98-101 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-44 1677566-2 1991 Transient expression of this active c-erbB-2 stimulated the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element, serum response element, and cyclic AMP response element. Cyclic AMP 149-159 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-44 1351885-3 1992 Recombinantly derived ricin A chain (RTA) was conjugated with murine monoclonal antibodies (MAbs) 317G5, 260F9, 454A12 and 741F8 that bound to cell-surface determinants of 42, 55, 180 (transferrin receptor) and 185 kDa (HER-2/neu) expressed by the SKBr3 human breast-cancer cell line. ricin a 22-29 erb-b2 receptor tyrosine kinase 2 Mus musculus 220-229 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 22-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-70 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 22-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-77 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 22-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-167 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 22-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-174 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 22-30 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-167 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 123-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-167 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 123-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-174 1350785-3 1992 NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). Tyrosine 123-131 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-167 1348016-4 1992 After binding to NIH3T3 HER-2/neu cells, which show high surface expression of p185, the muMABs were endocytosed via coated pits, routed to lysosomes, and degraded. mumabs 89-95 erb-b2 receptor tyrosine kinase 2 Mus musculus 24-33 8095168-12 1992 This pattern of hormone-dependent, TAM-resistant growth exhibited by the MCF/HER2-18 tumors in nude mice supports the possibility that p185HER2 overexpression in human breast cancers may be linked to therapeutic resistance. Tamoxifen 35-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 77-81 1684897-4 1991 The c-erbB-2 protein in these cells was under-phosphorylated on tyrosine residues in vivo. Tyrosine 64-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-12 1684897-5 1991 On the contrary, the active c-erbB-2 protein, in which Val-659 was replaced by Glu in the transmembrane domain, and EGF-stimulated EGFR showed significant levels of tyrosine phosphorylation in vivo. Tyrosine 165-173 erb-b2 receptor tyrosine kinase 2 Mus musculus 28-36 1677566-3 1991 Particularly, stimulation of the TPA response element by active c-erbB-2 was prominent. Tetradecanoylphorbol Acetate 33-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 64-72 1677566-5 1991 Transactivation of the TPA response element was also observed in a cell line that stably expresses active c-erbB-2. Tetradecanoylphorbol Acetate 23-26 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-114 1677566-6 1991 The active c-erbB-2-induced transactivation of the TPA response element was partially prevented either by down-regulation of protein kinase C or by the protein kinase C inhibitor H7. Tetradecanoylphorbol Acetate 51-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 11-19 1672440-0 1991 The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Tyrosine 40-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-10 1672440-5 1991 However, under conditions in which activation of the erbB-2 kinase induced DNA synthesis at least fivefold more efficiently than the EGFR, the levels of erbB-2- or EGFR-induced tyrosine phosphorylation of PLC-gamma and GAP were comparable. Tyrosine 177-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-59 1672440-5 1991 However, under conditions in which activation of the erbB-2 kinase induced DNA synthesis at least fivefold more efficiently than the EGFR, the levels of erbB-2- or EGFR-induced tyrosine phosphorylation of PLC-gamma and GAP were comparable. Tyrosine 177-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-159 1672440-6 1991 In addition, the stoichiometry of tyrosine phosphorylation of these putative substrates by erbB-2 appeared to be at least an order of magnitude lower than that induced by platelet-derived growth factor receptors at comparable levels of mitogenic potency. Tyrosine 34-42 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-97 1706346-2 1991 We analyzed the neu tyrosine kinase and its substrates in transfected NIH 3T3 fibroblasts by phosphotyrosine immunoblotting. Phosphotyrosine 93-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-19 1685656-0 1991 Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene. Tyrosine 19-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 1671296-3 1991 Enhanced tyrosine phosphorylation of several cellular proteins was detected in cells expressing the Glu-659 c-erbB-2 protein. Tyrosine 9-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-116 1671296-3 1991 Enhanced tyrosine phosphorylation of several cellular proteins was detected in cells expressing the Glu-659 c-erbB-2 protein. Glutamic Acid 100-103 erb-b2 receptor tyrosine kinase 2 Mus musculus 108-116 1671296-6 1991 To investigate the role of autophosphorylation in cell transformation, we introduced an additional mutation at the autophosphorylation site of the Glu-659 c-erbB-2 protein (Tyr-1248 to Phe). Glutamic Acid 147-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 155-163 1706346-4 1991 The neu oncoprotein in the latter cells was phosphorylated in tyrosine in a ligand-independent manner and had a shortened half-life in comparison with the normal neu protein. Tyrosine 62-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-7 1706346-5 1991 Tumor promoter pretreatment inhibited ligand-induced receptor tyrosine phosphorylation and decreased tyrosine phosphorylated neu oncoprotein. Tyrosine 101-109 erb-b2 receptor tyrosine kinase 2 Mus musculus 125-128 1968737-5 1990 The C-erbB-2 gene acquires the ability to transform NIH 3 T 3 cells by, 1) mutation which alters valine 659 in transmembrane region to glutamic acid as was found in neu gene activation, 2) deletion of c-terminal regulatory domain or 3) gene-amplification or overexpression. Valine 97-103 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-12 1706346-6 1991 Prolonged pretreatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) also prevented the induction of immediate early growth factor-regulated genes in response to neu activation. Tetradecanoylphorbol Acetate 28-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-168 1706346-6 1991 Prolonged pretreatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) also prevented the induction of immediate early growth factor-regulated genes in response to neu activation. Tetradecanoylphorbol Acetate 67-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 165-168 1968737-5 1990 The C-erbB-2 gene acquires the ability to transform NIH 3 T 3 cells by, 1) mutation which alters valine 659 in transmembrane region to glutamic acid as was found in neu gene activation, 2) deletion of c-terminal regulatory domain or 3) gene-amplification or overexpression. Glutamic Acid 135-148 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-12 1968062-1 1990 In nontransformed DHFR/G-8 cells (NIH 3T3 cells transfected with normal rat neu gene), the normal neu gene product was initially synthesized as a 170-kDa protein bearing endoglycosidase H-sensitive oligosaccharide chains and was then processed to a 175-kDa mature form with endoglycosidase H-resistant, endoglycosidase F-sensitive oligosaccharide chains. Oligosaccharides 198-213 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-101 1968062-1 1990 In nontransformed DHFR/G-8 cells (NIH 3T3 cells transfected with normal rat neu gene), the normal neu gene product was initially synthesized as a 170-kDa protein bearing endoglycosidase H-sensitive oligosaccharide chains and was then processed to a 175-kDa mature form with endoglycosidase H-resistant, endoglycosidase F-sensitive oligosaccharide chains. Oligosaccharides 331-346 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-101 1968062-3 1990 In B104-1-1 cells (NIH 3T3 cells transfected with neu gene activated oncogenically by a point mutation that changes a valine residue to a glutamic acid residue in the putative transmembrane region), the oncogenically activated neu gene product was also synthesized as a 170-kDa precursor with endoglycosidase H-sensitive oligosaccharide chains. Valine 118-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-53 1968062-3 1990 In B104-1-1 cells (NIH 3T3 cells transfected with neu gene activated oncogenically by a point mutation that changes a valine residue to a glutamic acid residue in the putative transmembrane region), the oncogenically activated neu gene product was also synthesized as a 170-kDa precursor with endoglycosidase H-sensitive oligosaccharide chains. Glutamic Acid 138-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-53 1968062-3 1990 In B104-1-1 cells (NIH 3T3 cells transfected with neu gene activated oncogenically by a point mutation that changes a valine residue to a glutamic acid residue in the putative transmembrane region), the oncogenically activated neu gene product was also synthesized as a 170-kDa precursor with endoglycosidase H-sensitive oligosaccharide chains. h-sensitive oligosaccharide 309-336 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-53 1968062-5 1990 The 185-kDa activated neu gene product possessed an unidentified post-translational modification in addition to N-linked oligosaccharide chains. n-linked oligosaccharide 112-136 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-25 1968062-6 1990 Both the precursor and mature forms of the mutationally activated neu gene product showed increased tyrosine-specific phosphorylation as compared with those of their normal counterparts in DHFR/G-8 cells. Tyrosine 100-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 66-69 33941612-10 2021 JIB04 treatment of patient-derived xenograft mouse models in vivo reduced HER2+ LC tumor growth and prolonged animal survival. JIB-04 0-5 erb-b2 receptor tyrosine kinase 2 Mus musculus 74-78 1982072-4 1990 Abolition of erbB-2 gp185 tyrosine kinase function resulted in complete loss of its transforming activity and the absence of in vivo tyrosine phosphorylation. Tyrosine 26-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-19 1982072-5 1990 The steady-state content of phosphotyrosine in erbB-2 gp185 was found to be solely dependent on receptor autophosphorylation and to be dependent on the specific enzymatic activity of the erbB-2 protein. Phosphotyrosine 28-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-53 1982072-5 1990 The steady-state content of phosphotyrosine in erbB-2 gp185 was found to be solely dependent on receptor autophosphorylation and to be dependent on the specific enzymatic activity of the erbB-2 protein. Phosphotyrosine 28-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 187-193 1982072-7 1990 Biological analysis of erbB-2 mutants containing either individual or multiple Tyr----Phe substitutions at the potential sites of autophosphorylation revealed that autophosphorylation upregulates erbB-2 gp185 transforming activity. Tyrosine 79-82 erb-b2 receptor tyrosine kinase 2 Mus musculus 23-29 1982072-7 1990 Biological analysis of erbB-2 mutants containing either individual or multiple Tyr----Phe substitutions at the potential sites of autophosphorylation revealed that autophosphorylation upregulates erbB-2 gp185 transforming activity. Phenylalanine 86-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 23-29 1982072-9 1990 A Tyr----Phe substitution of erbB-2 Tyr-877 homologous to pp60c-src Tyr-416 did not alter erbB-2 biological and biochemical properties, thus excluding the possibility that phosphorylation of this residue, located in the kinase domain, modulates erbB-2 gp185 catalytic function. Phenylalanine 9-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-35 1982072-9 1990 A Tyr----Phe substitution of erbB-2 Tyr-877 homologous to pp60c-src Tyr-416 did not alter erbB-2 biological and biochemical properties, thus excluding the possibility that phosphorylation of this residue, located in the kinase domain, modulates erbB-2 gp185 catalytic function. Tyrosine 36-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-35 1982072-9 1990 A Tyr----Phe substitution of erbB-2 Tyr-877 homologous to pp60c-src Tyr-416 did not alter erbB-2 biological and biochemical properties, thus excluding the possibility that phosphorylation of this residue, located in the kinase domain, modulates erbB-2 gp185 catalytic function. Tyrosine 36-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-35 1982072-10 1990 Hence, autophosphorylation of tyrosine residues localized in its COOH terminus appears to be required for optimal coupling of erbB-2 gp185 with its mitogenic pathway. Tyrosine 30-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-132 1982072-10 1990 Hence, autophosphorylation of tyrosine residues localized in its COOH terminus appears to be required for optimal coupling of erbB-2 gp185 with its mitogenic pathway. Carbonic Acid 65-69 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-132 33800754-9 2021 A statistically significant increase of senescence-associated p16 expression was observed in tumors from NAX014-treated mice, and the induction of cell senescence was observed in HER-2 overexpressing BC cells after in vitro treatment with NAX014. 13-(4-chlorophenylethyl)berberine 239-245 erb-b2 receptor tyrosine kinase 2 Mus musculus 179-184 33776765-5 2021 The adenosine A2b receptor agonist, BAY 60-6583, was found to significantly increase cytokine secretion of CD133-or HER2-specific CAR T cells when co-cultured with the respective target tumor cells. BAY 60-6583 36-47 erb-b2 receptor tyrosine kinase 2 Mus musculus 116-120 33800723-0 2021 Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy. Doxorubicin 99-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-51 33803327-1 2021 We herein report the development and evaluation of a novel HER2-targeting antibody-drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). polysarcosine 196-209 erb-b2 receptor tyrosine kinase 2 Mus musculus 59-63 33800852-10 2021 Next-generation, clinical-grade FASN inhibitors may be therapeutically relevant to countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas. Tamoxifen 108-117 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-149 33800754-11 2021 The overall results address the NAX014 compound as potential tool for therapeutic strategies against HER-2 overexpressing breast cancer. 13-(4-chlorophenylethyl)berberine 32-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-106 33800723-10 2021 In conclusion, this study demonstrated that the SA-5-Dox-LP liposome has the potential to increase therapeutic efficiency and targeted delivery of Dox in HER2 overexpressing cancer. sa-5-dox-lp 48-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 34704434-3 2021 A trastuzumab (Tz)-based HER2 pretargeting component (Tz-TCO-(89Zr-DFO)) was developed by conjugating with trans-cyclooctene (TCO) bioorthogonal click chemistry functional groups and deferoxamine (DFO) to enable radiolabeling with a 89Zr PET tracer. tz-tco-(89zr-dfo 54-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-29 33800723-10 2021 In conclusion, this study demonstrated that the SA-5-Dox-LP liposome has the potential to increase therapeutic efficiency and targeted delivery of Dox in HER2 overexpressing cancer. Doxorubicin 53-56 erb-b2 receptor tyrosine kinase 2 Mus musculus 154-158 33800754-3 2021 We previously showed that intraperitoneal (IP) administration of the BBR-derived NAX014 compound was able to counteract HER-2 overexpressing mammary tumors onset and progression in transgenic mice. Berberine 69-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-125 33800754-3 2021 We previously showed that intraperitoneal (IP) administration of the BBR-derived NAX014 compound was able to counteract HER-2 overexpressing mammary tumors onset and progression in transgenic mice. 13-(4-chlorophenylethyl)berberine 81-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-125 33800754-5 2021 In this study, we evaluated the effect of intragastric (IG) administration of 20 mg/kg of NAX014 on both safety and anticancer efficacy in HER-2/neu transgenic mice. 13-(4-chlorophenylethyl)berberine 90-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-144 33800754-5 2021 In this study, we evaluated the effect of intragastric (IG) administration of 20 mg/kg of NAX014 on both safety and anticancer efficacy in HER-2/neu transgenic mice. 13-(4-chlorophenylethyl)berberine 90-96 erb-b2 receptor tyrosine kinase 2 Mus musculus 145-148 33800754-8 2021 NAX014 reduced HER-2 overexpressing BC cells migration in vitro and the frequency of lung metastasis in HER-2/neu transgenic mice. 13-(4-chlorophenylethyl)berberine 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 15-20 33800754-8 2021 NAX014 reduced HER-2 overexpressing BC cells migration in vitro and the frequency of lung metastasis in HER-2/neu transgenic mice. 13-(4-chlorophenylethyl)berberine 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-109 33800754-8 2021 NAX014 reduced HER-2 overexpressing BC cells migration in vitro and the frequency of lung metastasis in HER-2/neu transgenic mice. 13-(4-chlorophenylethyl)berberine 0-6 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-113 32795383-3 2020 METHODS: To investigate a potential protective effect of adipocyte-conditioned medium on HER2 positive breast cancer cells exposed to tyrosine kinase inhibitors (TKI) such as lapatinib, we analyzed the sensitivity of HER2 positive breast cancer models in vitro and in vivo on SCID mice in the presence or absence of adipocytes or adipocyte-conditioned medium. Lapatinib 175-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 34973460-8 2022 The HER2-targeting AMDC was also effective in vivo against a mouse KPL-4 xenograft model. amdc 19-23 erb-b2 receptor tyrosine kinase 2 Mus musculus 4-8 34101105-8 2021 Mouse HER2+ breast cancer models treated with lapatinib were imaged with a peptide-based HER3-specific PET imaging agent (68Ga)HER3P1 to assess for dynamic changes in tumoral HER3 expression and uptake confirmed by biodistribution. Lapatinib 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-10 34101105-9 2021 Subsequently, HER2+ cell lines were treated with the HER2 inhibitor lapatinib as well HER3-specific siRNA to assess for changes in viability and correlate with HER3 expression upregulation. Lapatinib 68-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 34101105-12 2021 Evaluation of (68Ga)HER3P1 uptake in mice implanted with the HER2+ breast cancer cell lines MDA-MB453 or HCC-1569 prior to and after treatment with lapatinib demonstrated a significant increase in MDA-MB453 tumors only, consistent with in vitro findings. Lapatinib 148-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-65 34704434-3 2021 A trastuzumab (Tz)-based HER2 pretargeting component (Tz-TCO-(89Zr-DFO)) was developed by conjugating with trans-cyclooctene (TCO) bioorthogonal click chemistry functional groups and deferoxamine (DFO) to enable radiolabeling with a 89Zr PET tracer. Cyclooctanes 107-124 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-29 34704434-3 2021 A trastuzumab (Tz)-based HER2 pretargeting component (Tz-TCO-(89Zr-DFO)) was developed by conjugating with trans-cyclooctene (TCO) bioorthogonal click chemistry functional groups and deferoxamine (DFO) to enable radiolabeling with a 89Zr PET tracer. Cyclooctanes 126-129 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-29 34704434-3 2021 A trastuzumab (Tz)-based HER2 pretargeting component (Tz-TCO-(89Zr-DFO)) was developed by conjugating with trans-cyclooctene (TCO) bioorthogonal click chemistry functional groups and deferoxamine (DFO) to enable radiolabeling with a 89Zr PET tracer. Deferoxamine 183-195 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-29 34704434-3 2021 A trastuzumab (Tz)-based HER2 pretargeting component (Tz-TCO-(89Zr-DFO)) was developed by conjugating with trans-cyclooctene (TCO) bioorthogonal click chemistry functional groups and deferoxamine (DFO) to enable radiolabeling with a 89Zr PET tracer. Deferoxamine 197-200 erb-b2 receptor tyrosine kinase 2 Mus musculus 25-29 34638488-0 2021 The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. msu42011 16-24 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 34507952-3 2021 P75 regulates Schwann cell cholesterol biosynthesis in response to BDNF, forming a co-receptor complex with ErbB2 and activating ErbB2-mediated stimulation of SREBP2, a master regulator of cholesterol synthesis. Cholesterol 27-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-134 34507952-3 2021 P75 regulates Schwann cell cholesterol biosynthesis in response to BDNF, forming a co-receptor complex with ErbB2 and activating ErbB2-mediated stimulation of SREBP2, a master regulator of cholesterol synthesis. Cholesterol 189-200 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-134 34380634-8 2021 In genetically engineered mouse models, HER2 exon 20G776>VC lung tumors exhibited a sustained complete response to mobocertinib, while HER2 exon 20YVMA tumors showed only partial and transient response. Mobocertinib 115-127 erb-b2 receptor tyrosine kinase 2 Mus musculus 40-44 34380634-9 2021 Combined treatment with a second antibody-drug conjugate (ADC) against HER2, ado-trastuzumab emtansine (T-DM1) synergized with mobocertinib in HER2 exon 20YVMA tumors. Mobocertinib 127-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 71-75 34380634-9 2021 Combined treatment with a second antibody-drug conjugate (ADC) against HER2, ado-trastuzumab emtansine (T-DM1) synergized with mobocertinib in HER2 exon 20YVMA tumors. Mobocertinib 127-139 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 34584864-5 2021 Resistant clones were established from N-ethyl-N-nitrosourea (ENU)-treated HER2-mutant Ba/F3 cells and H1781 cells by chronic exposure to tarloxotinib-E. Ethylnitrosourea 39-60 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 34131071-8 2021 d16HER2 incited homogenous and proliferative luminal-like lesions which infrequently progressed to invasive phenotypes whereas p95HER2 lesions were heterogenous and invasive at the smallest detectable stage. Phenobarbital 45-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 3-7 34146837-10 2021 Both sdAbs, labeled using (18F)RL-III, retained affinity and immunoreactivity to HER2. sdabs 5-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 81-85 34578328-1 2021 We report on the efficacy of the non-attenuated HER2-retargeted oHSV named R-337 against the immunologically hot CT26-HER2 tumor, and an insight into the basis of the immune protection. ohsv 64-68 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-52 34389732-10 2021 These studies uncover the mechanistic insights how obese/hyperleptinemic state may contribute to poor response to tamoxifen implicating leptin-miR205-Med1 and leptin-Her2-EGFR-Med1 axes, and present bioactive compound honokiol and adipocytokine adiponectin as agents that can block leptin"s negative effect on tamoxifen. Tamoxifen 114-123 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-170 34156519-9 2021 RESULTS: Infigratinib-resistant tumours exhibited higher levels of p-ErbB2 and p-ErbB3, concomitant with an increase in EZH2 expression. infigratinib 9-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-74 34156519-10 2021 Gene overexpression and knockdown studies revealed that EZH2 directly regulates the levels of p-ErbB2 and p-ErbB3 in acquired resistance to infigratinib. infigratinib 140-152 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 34376577-0 2021 Itraconazole Exerts its Anti-Tumor Effect in Esophageal Cancer by Suppressing the HER2/AKT Signaling Pathway. Itraconazole 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 34376577-8 2021 HER2 total protein and phosphorylation of AKT and S6 proteins were decreased in xenografts from itraconazole-treated mice compared to xenografts from placebo-treated mice. Itraconazole 96-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 34284047-0 2021 Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI. Gadolinium 0-10 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 34578328-1 2021 We report on the efficacy of the non-attenuated HER2-retargeted oHSV named R-337 against the immunologically hot CT26-HER2 tumor, and an insight into the basis of the immune protection. r-337 75-80 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-52 34445092-6 2021 Here we test the efficacy of DCs pulsed with TMVs incorporated with glycolipid-anchored immunostimulatory molecules (GPI-ISMs) in HER2-positive and triple negative breast cancer murine models. Glycolipids 68-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-134 34361080-4 2021 PIT was conducted with an indocyanine green-labeled anti-HER2 antibody and an 808 nm laser irradiation. Indocyanine Green 26-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 34584864-5 2021 Resistant clones were established from N-ethyl-N-nitrosourea (ENU)-treated HER2-mutant Ba/F3 cells and H1781 cells by chronic exposure to tarloxotinib-E. Ethylnitrosourea 62-65 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 34584864-5 2021 Resistant clones were established from N-ethyl-N-nitrosourea (ENU)-treated HER2-mutant Ba/F3 cells and H1781 cells by chronic exposure to tarloxotinib-E. Tarloxotinib 138-150 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-79 34584864-6 2021 Results: Tarloxotinib-E showed potent activity against HER2-mutant Ba/F3 cells and H1781 cells. Tarloxotinib 9-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-59 34148497-3 2021 In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), atype of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). ferric oxide 40-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 161-165 34148497-3 2021 In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), atype of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). ferric oxide 40-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 208-212 34208799-5 2021 Molecular docking predicted that Rg3 epimers had a better binding score with IGF-1R than with EGFR, HER-2 or PDGFR, and predicted an mTOR inhibitory function of Rg3. ginsenoside Rg3 33-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-105 34200197-1 2021 Radiolabeled Affibody-based targeting agent 177Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumin prevents glomerular filtration and significantly reduces renal uptake. Lutetium-177 44-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 34145369-0 2021 Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model. lanatoside C 36-48 erb-b2 receptor tyrosine kinase 2 Mus musculus 82-86 34145369-4 2021 Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. lanatoside C 86-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 147-151 34145369-8 2021 Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor. lanatoside C 74-86 erb-b2 receptor tyrosine kinase 2 Mus musculus 168-172 34144976-3 2021 Paradoxically, DMBA-treated PyMT and Her2 animals were protected from metastasis. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 15-19 erb-b2 receptor tyrosine kinase 2 Mus musculus 37-41 34200197-1 2021 Radiolabeled Affibody-based targeting agent 177Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumin prevents glomerular filtration and significantly reduces renal uptake. aby-027 50-57 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 34234980-8 2021 Results: Trastuzumab-IRDye800CW exhibited high affinity for HER2 (KD=2.093(3) pM). IRDye 800CW 21-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 34194942-4 2021 muGCVax is effective in inhibiting lung metastatic melanoma, primary breast cancer, and subcutaneous colorectal cancer in their respective murine models, including functional cure of HER2-positive breast cancer. mugcvax 0-7 erb-b2 receptor tyrosine kinase 2 Mus musculus 183-187 35212924-11 2022 To enhance the effect of anti-HER2-targeted therapies and minimize chemotherapy-related side effects, modulation of TAM should be considered in novel therapeutic combinations. tam 116-119 erb-b2 receptor tyrosine kinase 2 Mus musculus 30-34 35212924-3 2022 The aim of this study is to evaluate the role of TAM in tumor response to anti-HER2-targeted therapies and chemotherapy in an experimental model of HER2-amplified breast cancer. tam 49-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 79-83 35529851-4 2022 In methionine-choline-deficient and high-fat (MCDHF) diet induced liver inflammation in mice, tail vein injection of activated neutrophils (A-Neu, stimulated by sphingosine 1-phosphate) inhibited the expressions of pro-inflammatory cytokines in the liver, including C-C chemokine motif ligand 4, tumor necrosis factor and nitric oxide synthase 2, and attenuated liver injury. sphingosine 1-phosphate 161-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 142-145 35506286-11 2022 This radio-immunoconjugate will likely be an effective agent for HER2-targeting by AE-RIT. ae-rit 83-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 35633393-14 2022 In summary, normal SC and the novel luminal progenitor cell population likely give rise to basal-like and HER2-overexpressing BrCs, respectively. Phenobarbital 36-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-110 35611948-10 2022 In vivo optical imaging with M1-Cy5 in an immune-competent mouse model of lymphoma revealed significant tumor uptake relative to a Cy5-conjugated Her2 affibody. cyanine dye 5 131-134 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-150 35502723-6 2022 Additionally, we found that only cells with luminal features were able to acquire transformed characteristics after an oncogenic HER2 mutant was introduced in their genomes. Phenobarbital 44-51 erb-b2 receptor tyrosine kinase 2 Mus musculus 129-133 35245513-5 2022 At about one year after the postnatal treatment with PD0325901, Pax6Sey-Neu/+ mice showed robust improvements in retina size and visual acuity, and the elevated intraocular pressure (IOP) was also alleviated, compared to age-matched mice treated with vehicles only. mirdametinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 72-75 35461328-6 2022 Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Tricarboxylic Acids 130-148 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-80 35461328-6 2022 Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Tricarboxylic Acids 150-153 erb-b2 receptor tyrosine kinase 2 Mus musculus 76-80 35365900-6 2022 In combination with targeted delivery of the anticancer agent, doxorubicin (DOX), RPDC-HI significantly improved the tumor inhibition efficacy with 97.5% in treating HER2-positive breast cancer in the mouse model, comparing to 34.3% when using free DOX. rpdc-hi 82-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-170 35618478-9 2022 Conclusion: Combining rapidly internalizing, high-affinity HER2-targeted sdAbs with the iso-(211At)SAGMB residualizing prosthetic agent is a promising strategy for TAT of HER2-expressing cancers. sagmb 99-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 171-175 35477183-8 2022 Cells treated with Carcinosinum 200cH presented hyper-expression of HER-2 on the plasma membrane, identified by immunocytochemistry. carcinosinum 200ch 19-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 35631513-0 2022 Monoclonal Antibody Functionalized, and L-lysine alpha-Oxidase Loaded PEGylated-Chitosan Nanoparticle for HER2/Neu Targeted Breast Cancer Therapy. pegylated-chitosan 70-88 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-114 35631513-1 2022 Herein, we designed a nanocarrier to deliver the LO specifically to HER2+ breast cancer (BC) cells, where functionalization of mAb (anti-HER2+) with PEGylated chitosan enabled it to target the HER2+ BC cells. pegylated chitosan 149-167 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 35631513-1 2022 Herein, we designed a nanocarrier to deliver the LO specifically to HER2+ breast cancer (BC) cells, where functionalization of mAb (anti-HER2+) with PEGylated chitosan enabled it to target the HER2+ BC cells. pegylated chitosan 149-167 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-141 35631513-1 2022 Herein, we designed a nanocarrier to deliver the LO specifically to HER2+ breast cancer (BC) cells, where functionalization of mAb (anti-HER2+) with PEGylated chitosan enabled it to target the HER2+ BC cells. pegylated chitosan 149-167 erb-b2 receptor tyrosine kinase 2 Mus musculus 193-197 35434898-8 2022 RESULTS: Aspirin delayed time to metastasis in MDA-MB-231/LN/2-4/H2N xenografts and decreased growth of HER2+ /TNBC primary tumours. Aspirin 9-16 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-108 35434995-3 2022 Sortase A transpeptidation was used to install a desferrioxamine B (DFO) chelate bearing a reactive triglycine group to the C-terminal sortase tag of the G3-DARPin, and 89Zr-radiolabeling produced a novel 89ZrDFO-G3-DARPin radiotracer that can detect HER2/neu-positive tumors. Deferoxamine 49-66 erb-b2 receptor tyrosine kinase 2 Mus musculus 251-255 35434995-3 2022 Sortase A transpeptidation was used to install a desferrioxamine B (DFO) chelate bearing a reactive triglycine group to the C-terminal sortase tag of the G3-DARPin, and 89Zr-radiolabeling produced a novel 89ZrDFO-G3-DARPin radiotracer that can detect HER2/neu-positive tumors. Deferoxamine 68-71 erb-b2 receptor tyrosine kinase 2 Mus musculus 251-255 35434995-3 2022 Sortase A transpeptidation was used to install a desferrioxamine B (DFO) chelate bearing a reactive triglycine group to the C-terminal sortase tag of the G3-DARPin, and 89Zr-radiolabeling produced a novel 89ZrDFO-G3-DARPin radiotracer that can detect HER2/neu-positive tumors. glycyl-glycyl-glycine 100-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 251-255 35348729-11 2022 In summary, everolimus in combination with T-DM1 showed strong antitumor effects in HER2-positive breast cancer, both in vitro and in vivo. Everolimus 12-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 84-88 35431974-6 2022 Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 35368966-7 2022 The CMB-PTX-CRISPR/Cas9 increased the GSK-3, P21, P27, and Bad expression levels, while reduced the C-erbB-2 and mTOR expressions. Paclitaxel 8-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 100-108 35325006-11 2022 Inhibition of MET by Capmatinib increased p-EGFR in Tpl2-/- keratinocytes and papillomas, and inhibition of EGFR by Gefitinib increased HER2 and HER3 signaling in both genotypes. Gefitinib 116-125 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 35310062-0 2022 Resveratrol prevents hypoxia-induced retinal ganglion cell death related with ErbB2. Resveratrol 0-11 erb-b2 receptor tyrosine kinase 2 Mus musculus 78-83 34969858-8 2022 In addition, dual HER2 blockade using anti-HER2Ab LM008 NSCs and the tyrosine kinase inhibitor tucatinib significantly improved the survival of mice in a clinically relevant model of multiple HER2+ BCBM. Irbinitinib 95-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 18-22 35232969-0 2022 Loss of MIG-6 results in endometrial progesterone resistance via ERBB2. Progesterone 37-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-70 35232969-5 2022 To investigate the effect of ERBB2 targeting on endometrial progesterone resistance, fertility, and endometriosis, we introduce Erbb2 ablation in Mig-6d/d mice (Mig-6d/dErbb2d/d mice). Progesterone 60-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 29-34 35232969-8 2022 Together, our results demonstrate that ERBB2 overexpression in endometrium with MIG-6 deficiency causes endometrial progesterone resistance and a nonreceptive endometrium in endometriosis-related infertility, and ERBB2 targeting reverses these effects. Progesterone 116-128 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-44 35083840-0 2022 Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. taxane 58-64 erb-b2 receptor tyrosine kinase 2 Mus musculus 101-105 35104102-5 2022 Moreover, it demonstrated a strong efficacy in an HER2 xenograft tumor model in mice, superior to the clinically approved antibody-drug conjugate ado-trastuzumab emtansine, with a complete tumor regression observed both macroscopically and microscopically demonstrating its therapeutic potential. t-dm1 146-161 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 35104102-5 2022 Moreover, it demonstrated a strong efficacy in an HER2 xenograft tumor model in mice, superior to the clinically approved antibody-drug conjugate ado-trastuzumab emtansine, with a complete tumor regression observed both macroscopically and microscopically demonstrating its therapeutic potential. Maytansine 162-171 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-54 35203439-0 2022 Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. cdcc 23-27 erb-b2 receptor tyrosine kinase 2 Mus musculus 67-71 34969858-8 2022 In addition, dual HER2 blockade using anti-HER2Ab LM008 NSCs and the tyrosine kinase inhibitor tucatinib significantly improved the survival of mice in a clinically relevant model of multiple HER2+ BCBM. Irbinitinib 95-104 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-196